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Abstract 
Insulin-like growth factor-I receptor (IGF-IR) is integral to cancer cell proliferation, survival, 
migration, and invasion, and resistance to anti-cancer therapies in many human malignancies 
including breast cancer. Within the last few years several drugs targeting IGF-IR have entered 
clinical trials and are showing promising early results. One of the integral goals of my thesis 
is to identify patients who are most likely to benefit from therapy. The Lee Laboratory 
previously reported an IGF gene expression signature, based upon genes induced or repressed 
by IGF-I, which correlated with poor prognosis in breast cancer. Confirming that this 
signature can measure IGF activity, I report here that the signature is reversed in three 
different cancer models (cell lines or xenografts) treated with three different anti-IGF-IR 
therapies. The Lee laboratory originally reported that the IGF signature was present in triple-
negative human breast cancers (TNBC), and I found here that the signature is similarly 
present in TNBC cell lines. Supporting a role for IGF-IR signaling in this subtype of breast 
cancer, I found that TNBC cell lines were especially sensitive to an IGF-IR tyrosine kinase 
inhibitor (BMS-754807), and that sensitivity was significantly correlated to expression of the 
IGF gene signature. Consistent with this, comparative gene expression analysis among the 
most resistant and sensitive cell lines identified 114 differentially expressed genes which 
identified TNBC as being sensitive. To examine this association further we determined levels 
and activity of the IGF-IR in several recently developed primary human TNBC tumorgraft 
models. I found high activity in many models, and chose the TNBC model MC1, which had 
the highest levels of both IGF signature score and IGF-IR expression and activity, for testing 
an anti-IGF-IR tyrosine kinase inhibitor (BMS-754807) in vivo. MC1 tumorgrafts treated with 
BMS-754807 as a single agent showed growth inhibition, and in combination with 
chemotherapy tumor regression occurred until no tumor was palpable. This regression was 
associated with reduced proliferation, increased apoptosis, and mitotic catastrophe. These data 
provide a clear biological rationale to test anti-IGF-IR therapy in combination with 
chemotherapy in patients with TNBC. 
While IGF-IR activity is elevated in TNBC, in vitro cell culture evidence suggests an 
interaction between IGF-IR and ErbB2 (otherwise known as HER2).  To examine crosstalk 
between IGF-IR and ErbB2 in mammary tumorigenesis in vivo, I used two models of mouse 
mammary tumorigenesis, MMTV-CD8-IGF-IR (a constitutively active IGF-IR) and MMTV-
ErbB2. Bi-transgenic (bigenic) mice expressing both CD8-IGF-IR and ErbB2 developed 
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mammary tumors significantly faster than mice expressing either transgene alone. 
Histological analysis showed that ErbB2 tumors were predominantly adenocarcinomas, CD8-
IGF-IR tumors were mixed adenosquamous carcinomas, and interestingly, bigenic tumors 
showed a phenotype resembling both oncogenes. All tumor types contained CK8-positive 
luminal epithelial cells. Interestingly, markers of myoepithelial (CK14) and progenitor (CK6) 
cells were only detected in mammary tumors arising from MMTV-CD8-IGF-IR mice and 
bigenic mice. This data is consistent with the notion that expression of IGF-IR in the 
mammary gland of transgenic mice may results in expansion myoepithelial cells expressing 
CK14 and progenitor cells expressing CK6 thus resulting in a mixed lineage differentiation in 
the tumor. We hypothesized that the difference in tumor histology may relate to the 
transformation of different progenitor cell types by IGF-IR and ErbB2. To investigate this, we 
have developed a mouse model system using avian RCAS retrovirus as vehicle to deliver 
CD8-IGF-IR or ErbB2 into mammary glands of transgenic mice expressing the avian receptor 
TVA under the control of a MMTV promoter. This allows retroviral infection of specific 
mammary cell types in vivo. Mammary intraductal injection of RCAS-CD8-IGF-IR into 
MMTV-TVA transgenic mice resulted in expansion of CK14 cells and disruption of normal 
mammary gland architecture. We are currently investigating the differences between CD8-
IGF-IR and ErbB2-induced mammary tumorigenesis using this novel viral transduction 
system.  
In summary, I have shown that the IGF-IR pathway is active in TNBC and that 
inhibition of IGF-IR using a small molecule tyrosine kinase inhibitor in combination with 
chemotherapy results in tumor regression.  In addition, I have found that IGF-IR interact with 
ErbB2 to promote mammary cancer in vivo. These two studies provide a rationale for clinical 
studies of anti-IGF-IR therapy in TNBC and ErbB2-positive breast cancer. Future studies will 
examine tissue from patients treated with these inhibitors to identify biomarkers that predict 
response to therapy. It is anticipated that successful use of anti-IGF-IR therapy will improve 
breast cancer outcome. 
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Chapter 1 - Introduction and Background 
 
 
1.1 Breast Cancer 
1.1.1 Breast Cancer Facts 
Cancer is a major health problem not only in the United States, where one in four 
deaths results from cancer, but also in most other Western countries. Breast cancer is by far 
the most common cancer amongst women. It is estimated that over 190,000 women will be 
diagnosed with breast cancer in 2009, which accounts for 27% of all new estimated cancer 
cases. Among those cases, more than 40,000 women will die, resulting in the second leading 
cause of cancer-related deaths among women in the United States. Death related to breast 
cancer remained relatively unchanged until the early 1990s. Between 1991 and 2005, breast 
cancer death rates declined by 37%, which is attributed to advances in the prevention, 
detection, and targeted therapies of breast cancer. Although the mortality rate for breast 
cancer declined over the last two decades, breast cancer continues to be one of the most 
common fatal cancer (1). This highlights that there is still inadequate knowledge about breast 
cancer prevention, and better and more effective breast cancer therapies need to be developed. 
 
1.1.2 Risk Factors for Breast Cancer 
Breast cancer is influenced by several environmental and genetic factors. Some of the 
key factors affecting breast cancer risk are genetic predispositions such as the BRCA1 and 
BRCA2 genes (Breast Cancer Type 1/2 Susceptibility Gene) (2).  In addition, early age of 
menarche, late age of first pregnancy, late menopause, and a greater use of hormone 
replacement therapy increase the incidence of breast cancer (1, 3, 4). It has been reported that 
endogenous hormone level and life-style related factors including alcohol consumption, 
obesity, and lack of physical activity are associated with the risk of breast cancer. In contrast, 
two of the strongest protective factors against breast cancer are early age of pregnancy and 
lactation (4).   
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1.1.3 Breast Cancer Subtypes 
Gene expression profiling has significantly advanced the understanding of the 
heterogeneity of breast cancer. Perou et al used cDNA microarrays to classify breast cancer 
based on the similarities in gene expression patterns which identified breast cancer subtypes 
with divergent histopathological features, clinical outcomes, and therapeutic implications (5). 
Breast cancer is classified into two main subgroups: estrogen-receptor alpha (ER)-positive 
and ER-negative breast cancer (6, 7).   
ER-positive tumors, commonly called luminal breast cancer, are divided into luminal 
A and B subtypes based on the relative expression of ER. The luminal subtype makes up to 
75% of breast tumors and thus is the most common breast cancer diagnosed. ER positive 
tumors express ER, and ER-regulated genes such as PR and ER activated genes such as 
CycD1. Furthermore, they express luminal markers such as CK8, and GATA3 (6-8). Since 
estrogen is a key driver in this subtype of breast cancer, hormonal therapy targeting ER has 
proven to be very successful which resulted in increased disease-free survival in breast cancer 
patients (9).  
ER-negative tumors are separated into three subtypes: normal breast-like, HER2 
(ErbB2)-positive and basal-like tumors (6, 7). The normal breast-like group resembles normal 
breast tissue samples enriched with genes commonly found in adipose cells and other non-
epithelial cell types (6). HER2 positive tumors express high levels of genes located in the 
HER2 amplicon on chromosome 17q21, including HER2 and GRB7. HER2-positive tumors 
are further characterized by low to absent expression of ER, GATA3 and other luminal 
subtype specific genes (10).  HER2, which is overexpressed in about 20-30% of breast cancer, 
can be targeted with the monoclonal antibody trastuzumab and more recently lapatinib, which 
resulted in a marked improvement in both response and survival (11-13). Unfortunately, only 
30-60% of women with HER2-positive breast cancer benefit from trastuzumab (13-15). 
Recent studies have shown that aberrations in the phosphatidylinositol-3 kinase (PI3K) 
pathway limits the response to trastuzumab (16). Similarly, overexpression of the IGF-IR in 
HER2 positive breast cancer may confer to trastuzumab resistance (17). 
Triple-negative breast cancers (TNBC) are characterized by low to absent expression 
of ER, PR and HER2 (18-20) and account for up to 20-25% of all breast cancers. 60-90% of 
TNBC consist of basal-like breast cancers expressing genes characteristic for basal epithelial  
cells such as cytokeratins CK5 and CK14 (21). Currently, no targeted therapies are available, 
and patients with TNBC often respond poorly to chemotherapy (22). TNBC is commonly 
diagnosed in younger women and African-American women, and is associated with high 
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histological grade and aggressive clinical behavior (23). It is this subtype of breast cancer, 
which has great-unmet clinical need to develop novel agents as a basis for successful systemic 
therapy. 
 
1.2 Insulin-like Growth Factor – I Receptor (IGF-IR) 
 
1.2.1 IGF-IR Structure, Function, and Signaling 
The insulin-like growth factor (IGF) system involves a complex network of two 
ligands (IGF-I and IGF-II), cell surface receptors that mediate the signaling (IGF-IR and IGF-
IIR, insulin receptor (InsR)) and six high-affinity binding proteins (IGFBP 1-6), and several 
IGFBP-related proteins (IGFBPrP) (24). IGF-I and II, formerly known as somatomedins, are 
single chain polypeptides which share 50% homology to proinsulin and thus were named 
insulin-like growth factors (25). These factors are circulating hormones and are produced 
continuously through life in various human tissues such as kidney, lung and bone. Most IGF-I 
found in the circulation is produced in the liver and regulated by growth hormone (GH). In 
contrast, IGF-II is also expressed in the liver but is minimally GH responsive (25, 26). Both, 
IGF-I and II are currently known to affect cell survival and proliferation, regulate cell size, 
increase cell number, induce differentiation, and regulate cell death via apoptosis (27-29).  
IGF-I elicits downstream signaling by binding to the IGF-IR. IGF-IR is a classical 
tyrosine kinase receptor consisting of a glycoprotein tetramer of two extracellular alpha 
subunits and two transmembrane beta subunits, which are linked by disulfide bonds (30). 
Upon binding of the ligand to the alpha subunit, the receptor undergoes conformational 
changes resulting in stimulation of the beta subunit. The intrinsic tyrosine kinase domain 
autophosphorylates in the catalytic domain (Y1131, Y1135, and Y1136) and ensures 
multisided transphosphorylation in the C-terminal domain of the receptor (24). The activation 
of IGF-IR results in the recruitment of a variety of adapter proteins. Although several adapter 
proteins such as Src-Homology-Collagen (SHC), Growth Factor Receptor Bound-2/Son of 
Sevenless (GRB2/SOS), and p85 interact with the activated IGF-IR, it is primarily the insulin 
receptor substrates (IRS-1, IRS-2) that activate a cascade of pleiotropic downstream signaling 
events (24, 29, 31). The best characterized of those are the mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol-3‘-kinase (PI3K) pathways. The MAPK pathway effects 
proliferation by IGF-IR mediated phosphorylation of IRS1 and SHC whereas activation of the 
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PI3K pathway mediated through p85 protects cells from apoptosis and promotes cell survival 
(31) (Figure 1).  
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A. Schematic representation of the IGF-I receptor and its activation. The IGF-IR consists of an 
extracellular alpha subunit and two transmembrane beta-subunits linked together by disulfide 
bonds. The alpha subunit serves as binding sites for the IGF-I ligand and transmits the signal to 
the beta subunit which has an intrinsic autophosphorylation site (Tryrosine (Tyr) 1131, 1134, 
1135). This leads to phosphorylation of the Juxtamembrane domain and the C-Terminus. B. Upon 
binding of IGF-I to the receptor the beta subunit becomes phosphorylated in multiple sites and 
downstream signals are activated. Tyrosine950 serves as docking site for IRS and Shc. The major 
signaling pathways activated by IGF are the PI3K pathway and the MAPK pathway. Adapted from 
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Figure 1. Schematic represe ta ion of the IGF-I recep or and it activa ion  
A. IGF-IR consists of an extracellular alpha subunit and two transmembrane beta-subunits linked 
together by disulfide bonds. The alpha subuni  serves as binding sites for th  IGF-I ligand and 
transmits the signal to the beta subunit which has an intrinsic autophosphorylation site Tyrosine (Tyr) 
1131, 1134, 1135. This leads to phosphorylation of the juxtamembrane domain and the C-terminus. B. 
Upon binding of IGF-I to the receptor the beta subunit becomes phosphorylated in multiple sites and 
downstream signals are activated. Tyrosine 950 serves as docking site for IRS and Shc. The major 
signaling pathways activated by IGF are the PI3K pathway and the MAPK pathway.  
Chapter 1 – Introduction and Background 
 
23 
 
1.2.2 IGF-IR in Malignant Transformation 
The role of IGF-IR in transformation has mainly been studied in mouse fibroblasts. 
The first evidence was first reported by Kaleko in 1990 in which overexpression of the human 
IGF-IR transformed NIH-3T3, or mouse embryonic fibroblasts (32). In fact, IGF-IR is 
actually required for transformation (33). For example, oncogenes such as HA-ras, c-src, the 
human papilloma virus E7, overexpressed IRS-1, SV40 large T antigen and other 
overexpressed growth factors failed to transform mouse embryonic fibroblasts with a targeted 
disruption of IGF-IR (33-35). Conversely, re-introducing the IGF-IR into these cells reversed 
the protection against transformation (34). Several tyrosine residues of the IGF-IR are 
associated with transformation. A truncated IGF-IR lacking either residue 1229 or 1245 lost 
the ability to transform fibroblasts and breast cancer cells. However, the mitogenic and 
survival functions of the IGF-IR are still intact, indicating that specific signal transduction 
pathways are associated with transformation (36). These data suggest that IGF-IR is critically 
involved in malignant transformation, and that IGF-IR is necessary to maintain a transformed 
phenotype. 
 Recently, we showed that constitutive active IGF-IR is able to transform immortalized 
mammary epithelial cells (MCF10A) (37). More importantly, constitutive IGF-IR enabled 
cells to grow in vivo in immuncompromised mice. Conversely, growth of IGF-IR transformed 
mammary epithelial cells can be blocked in vitro and in vivo (38). These data indicate that 
overexpression of a single oncogene in MCF10A cells is sufficient to cause transformation.  
 
1.2.3 IGF-IR Signaling in Breast Cancer 
The IGF-pathway plays a major role in cancer promoting proliferation, survival, and 
resistance to anti-cancer therapies in many human malignancies including breast cancer. The 
presence of high IGF content in various types of tumors such as lung, colon and breast 
indicates a major role of IGF in tumor growth (27, 31, 39). Furthermore, transgenic mice 
expressing amino-terminally truncated IGF-I, des(1-3) IGF-I, develop mammary tumors (40). 
The association between higher IGF levels and increased cancer risk is thought to result in 
increased proliferation by activation of the IGF-IR and increased somatic cell turnover (26). 
This may result in acceleration of carcinogenesis which requires a stepwise accumulation of 
genetic alterations (26). Clinical studies support the importance of IGFs in breast cancer. 
Epidemiological studies have shown that high serum IGF-I levels predict increased breast 
cancer risk (26). On the other hand, downregulation of IGF-I levels reduces cancer incidence 
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[27, 33]. Dietary restriction is an effective strategy for the prevention of breast cancer which 
leads to significant reduction in circulating IGF-I levels (41). Liver specific deletion of IGF-I 
in mice showed a 25% reduction of circulating IGF-I, and exhibited delayed mammary tumor 
development in response to carcinogens (41). Similarly, dwarf animals, deficient in GH and 
IGF-I production, showed resistance to DMBA-induced carcinogenesis (42). However, 
application of GH to these animals was sufficient to raise IGF-I levels and increased tumor 
incidence (43).  
IGF-IR is frequently overexpressed in tumors compared to normal breast and confers 
to enhanced proliferation, survival, migration and invasion (31). Experimental studies in vitro 
and in vivo have provided substantial evidence for a role of IGF-IR in human breast cancer. 
Overexpression of a constitutively active IGF-IR or inducible overexpression of wild-type 
IGF-IR in the mouse mammary gland resulted in rapid mammary tumorigenesis (44, 45). In 
breast cancer patients IGF-IR was found to be nearly 14-fold higher compared to normal 
breast tissue (46). In addition, increased IGF-IR kinase activity (2-4 fold) in these tumors 
accounts for up to 40-fold hyperactivation of IGF-IR in breast cancer (46).  
 
1.2.4 IGF-IR in Triple Negative Breast Cancer 
Many groups focused on the strong positive interaction between the IGF-IR pathway  
and ER in breast cancer since both IGF-IR and its downstream adaptor IRS1 are estrogen-
regulated genes (47). However, there is also evidence for a role for IGF-IR in TN-breast 
cancer. IGF-IR gene expression can be downregulated by tumor suppressor genes such as p53 
and BRCA1 (Breast Cancer Type 1 Susceptibility Gene). Loss of p53 function by mutations 
in the p53 gene increases IGF-IR levels (48). BRCA1 binds to the transcription factor Sp1 
thereby blocking its binding and activation of the IGF-IR promoter (49). Mutations in BRCA1 
and p53 are frequently found in TN-breast cancer, which results in elevated IGF-IR. 
Furthermore, IGF-IR is selectively amplified in basal breast cancer (50), and high levels of 
IGF-IR protein are seen in 36% of basal breast cancers (51). The Lee laboratory recently 
defined an ‗IGF-I gene signature‘ pattern of genes up- or down-regulated by IGF-I in MCF7 
breast cancer cells and examined the presence of the IGF signature in human breast tumor 
(52). The IGF-I gene signature was manifested in virtually all ER-negative tumors (and a 
small fraction of ER+ tumors with low levels of ER).  Highly similar associations were found 
when studying other publicly available datasets (Wang et al.(53), and Miller et al. (54)).  
Kaplan-Meier curves and univariate Cox analysis showed that patients whose tumors showed 
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the presence of the IGF-I gene signature had reduced disease-specific survival (52). In a 
multivariate Cox model the IGF-I gene signature provided significant predictive power that 
was independent of the other clinical variables (p<0.001). This data suggests that the IGF 
pathway is highly active in triple-negative breast cancers. 
 
1.2.5 IGF Signaling and Tumor Initiating/Cancer Stem Cell Renewal 
IGF ligands and IGF-IR impact several developmental stages of the mammary gland 
that are critical for lineage determination or expansion. Therefore, it is likely that IGF 
signaling is involved in many aspects of stem cells (55).  
 The majority of mammary gland development occurs postnatally (56). At birth only 
rudimentary branches exist occupying only a small portion of the fat pad and growth occurs 
according to the normal growth of the animal. In mice, mammary development starts during 
puberty (3-6 weeks), when branching and ductal outgrowth into the fat pad develop. 
Branching of the ductal structures is caused by the estrous cycle. At around 4 weeks terminal 
end buds (TEB) are formed. The TEB consists of an enriched population of epithelial 
progenitors called cap cells and body cells which give rise to myoepithelial cells and luminal 
epithelial cells.  Growth of the epithelial cells in the TEBs result in ductal outgrowth and 
branching which occurs from puberty up to 10-12 weeks of age (56, 57).  
Loss of IGF-I prevents formation of TEBs (55), and IGF-IR deficiency in mammary 
epithelial cells (MECs) decreases proliferation and development of TEBs (58, 59). 
Furthermore, IGF-IR is required for proliferation the myoepithelial progenitor cells called cap 
cells. In contrast, lack of IGF-IR had no effect on growth of luminal progenitors of TEBs 
called the body cells (58, 60). Myoepithelial cells direct luminal polarization, and inhibit 
deregulated luminal cell growth (61, 62). Therefore, IGF may be important for myoepithelial 
cell survival as well as stem cell renewal during early development.  
Accumulating data in other cell types support the hypothesis that IGFs promote stem 
cell renewal (63-66). Savarese et al. demonstrated a strong correlation between umbilical cord 
blood plasma levels of IGF-I and estradiol, and the number of hematopoietic stem and 
progenitor cells (67). Furthermore, microarray studies of human stem-derived mammosphere 
cultures showed that IGF signaling is up-regulated in these stem- and progenitor-amplified 
cultures (68). Additionally, IGF-I signaling regulates cell fate determination of neural stem 
cells (63, 69).  
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Given the recent re-appreciation of the cancer stem cell hypothesis, it is possible that 
the pathways involved in normal IGF regulation of embryonic and hematopoietic stem cell 
renewal and expansion may become perturbed in cancer (70). PTEN/Akt/β-catenin pathway 
plays a role in regulation of mammary stem/progenitor cells (71). Given that the IGF-IR is a 
major upstream regulator of this pathway, suggests a role of IGF-IR in controlling embryonic, 
hematopoietic stem cell renewal, which may be conserved and retained during tumorigenesis.  
This provides a role for IGF-IR in cancer stem cell/tumor initiating cell number. It will be 
interesting to uncover the lineage specific responses of the mammary gland to IGF signaling, 
and to better understand this cellular signaling network. Likely, these efforts will contribute 
greatly to understanding the mechanisms of initiation and progression in breast cancers where 
deregulated IGF signaling plays a major role. 
 
1.3 Human Epidermal Growth Factor Receptor 2 (HER2) 
The human epidermal growth factor receptor (EGFR/ErbB) family comprises four  
tyrosine kinase type I receptors (ErbB1-4, also known as Her1-4) and 13 extracellular ligands 
(72). Two of these receptors are frequently deregulated in breast cancer and associated with 
poor prognosis: the epidermal growth factor receptor (EGFR or ErbB1) and the human 
epidermal growth factor receptor 2 (HER2 or ErbB2) (73). Upon binding of EGF-like or 
neuregulin (NRG) ligands the ErbBs form homo- and heterodimers, followed by activating 
the intracellular kinase domains. HER2 does not have a known ligand, thus it is transactivated 
by heterodimerization through its preferred partner the EGFR. Two major pathways are 
activated, the Ras and Shc-activated MAPK pathway is activated by all ErbB receptor 
combinations and the PI(3)K pathway is downstream of most active ErbB dimers (74, 75).  
 Both, EGFR and HER2 have been extensively studied in breast cancer, and both have 
been therapeutically targeted. Herceptin (trastuzumab) is a humanized monoclonal antibody 
(mAb) against the extracellular domain of HER2 that has significant therapeutic benefit in the 
treatment of patients with HER2-overexpressing breast cancer (76-79). Although trastuzumab 
significantly increased the response rate to chemotherapy as a first-line treatment of 
metastatic breast cancer, a majority of patients‘ tumors progressed, indicating the existence of 
de novo resistance to trastuzumab (76, 80). In addition, the majority of patients who initially 
responded developed disease progression within 1 year, suggesting the existence of an 
emerging acquired resistance. Because of de novo resistance and acquired resistance, 
alternative strategies have been developed which include targeting the EGFR with EGFR-
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inhibitors such as gefitinib and erlotinib and the dual EGFR/HER2 inhibitor Lapatinib (80, 
81). 
 
1.3.1 Cross Talk between HER2 and IGF-IR 
Accumulating data suggests that crosstalk pathways between HER2 (also known as 
ErbB2) and IGF-IR exist which might be responsible for resistance to HER2 therapy. For 
example, in SKBR3 breast cancer cells that overexpress HER2, trastuzumab inhibited 
proliferation. However, when SKBR3 cells were made to overexpress IGF-IR, trastuzumab 
lost its efficacy. Importantly, treatment with anti-IGF-IR agents sensitizes cells to trastuzumab 
and decreased cell growth (82). The underlying mechanism of how IGF-IR causes resistance 
to trastuzumab is not clear. However, it has been reported that IGF-IR heterodimerizes with 
HER2, and thus activates alternative signaling pathways in trastuzumab-resistant breast 
cancer. Furthermore, trastuzumab resistance can be mediated by downregulation of p27kip1. 
Low levels of p27kip1 in the nucleus and upregulation of CycE/Cdk2 complex lead to cell 
proliferation of tumor cells. The decrease in p27kip1 is possibly regulated through activation 
of IGF-IR pathway as inhibition of IGF-IR in these cells could overcome trastuzumab 
resistance (83).  
 Another study investigated the interaction between different tyrosine kinase receptors 
in medroxyprogesterone acetate (MPA) induced mammary carcinoma in mice. IGF-IR was 
required to activate ErbB2 and its blockage resulted in inhibition of MPA‘s capacity to 
activate ErbB2. Conversely, blocking of ErbB2 does not alter IGF-IR activation indicating a 
hierarchical interaction between IGF-IR and ErbB2 in which IGF-IR directs ErbB2 activation 
in this model. Furthermore, these authors found a physical interaction between IGF-IR and 
ErbB2 by formation of heterodimers (84). In summary, these data indicates cross talk between 
IGF-IR and ErbB2, however it is currently still unknown how IGF-IR influences ErbB2 
induced tumorigenesis in vivo.  
1.4 Development of IGF-IR Targeted Therapies for Breast Cancer 
Starting about 10 year ago, drug development programs were launched to design novel 
agents to block IGF signaling. Two different strategies were developed to inhibit IGF-IR 
signaling. Ligand targeting strategies involve reduction of the ligand levels, and inhibition of 
the IGF-IR itself.  Two different classes of anti-IGF-IR inhibitors are in development: 
monoclonal antibodies which are highly specific for IGF-IR and cause downregulation of the 
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receptor, and tyrosine kinase inhibitors which often cross-react and block insulin receptor 
(InsR) as well as IGF-IR action (85). Approaches of targeting IGF-I signaling are summarized 
in Figure 2. 
Many drug candidates showed impressive antineoplastic activity in preclinical studies 
and in 2007 the first phase I study of IGF-IR specific antibodies were reported. By 2008 data 
were convincing enough to expand to a phase II clinical trial program and large phase III 
clinical trials. Over these years progress has been substantial and many different drug 
candidates developed by different companies are evaluated in dozens of ongoing clinical trials 
(39).  
 
 
Tyrosine kinase 
inhibitors
IGF-IR targeting strategies: A. Ligand targeting strategies attempt to lower ligand
concentration by using ligand binding proteins or ligand-specific antibodies. B. 
Receptor-specific antibodies effectively block the IGF1 receptor (IGF1R) but have no 
effect on insulin receptors. C. The tyrosine kinase inhibitors have more general 
activity against IGF-IR and InsR. 
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Figure 2. IGF-IR targeting strategies 
A. On the extracellular level lig  targeting strategies attempt to lower ligand concentration by using 
ligand binding proteins or ligand-specific antibodies. B. Receptor-specific antibodies effectively block 
the IGF-I receptor (IGF-IR) and downregulate IGF-IR level. C. On the intracellular level, the tyrosine 
kinase inhibitors have activity against IGF-IR and InsR. These tyrosine kinase inhibitors compete with 
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ATP for the Tyr 1131, 1135, 1136 residues in the tyrosine kinase domain, which blocks the activity of 
the receptor. However, the receptor levels cannot be down regulated from the cell surface.  
 
 
1.4.1 Ligand Targeting Strategies 
Approaches to inhibit the ligand IGF-I are based on growth – hormone antagonists, or 
ligand neutralization.  
The IGF signaling is regulated by growth hormone (GH) and disruption of the 
GH/IGF axis with a GH-antagonist such as Pegvisomant inhibits IGF signaling by lowering 
serum IGF-I levels (86). Ligand neutralization by IGFBPs shows promising results. IGFBPs 
have higher affinity for IGF-I and IGF-II than the receptors. Administration of IGFBPs on 
MCF7 resulted in inhibition of monolayer growth and reduction of cell motility (87).  
Somatostatin analogues such as octreoide reduces circulating IGF-I by about 33% and 
the combination with Tamoxifen, a selective estrogen receptor modulator (SERMS), resulted 
in 39% reduction of  blood IGF-I level (88). However, one of the largest clinical trials using 
somatostatin analogues to reduce circulating IGF levels failed because the desired suppression 
of ligand levels was not achieved (39).  
  
1.4.2 Receptor Blockade 
One important feature of the IGF system is that it is almost ubiquitously present in 
breast cancer. The expression of IGF-IR itself is present in all subtypes of breast cancer (89). 
Despite the broad potential use of IGF-IR therapy, side effects of therapy remain a major 
concern. The ubiquitous expression of the IGF pathway can lead to severe adverse systemic 
side effects. During childhood, IGF plays an important role in development and growth 
making IGF-IR blockade in children not a suitable strategy. Blocking IGF signaling could 
have toxic effects on the central and peripheral nervous systems. In addition, disruption of the 
IGF-IR signaling in the heart may affect cardiac myocyte survival (90). A major concern is 
the cross-reactivity with the insulin receptor (InsR) because the two receptors share a 70% 
homology (24). Interference with the insulin signaling causes hyper- or hypoglycemia and 
hyperinsulinemia (39). Therefore, glucose metabolism and insulin levels must be carefully 
analyzed during IGF-IR blockade when treating patients.  
 
Chapter 1 – Introduction and Background 
 
30 
 
1.4.2.1 IGF-IR Blocking Antibodies   
The monoclonal antibodies have shown the most rapid clinical development. The 
largest clinical experience has been with the Pfizer antibody Figitumumab (CP-751,871, 
Pfizer) (91-93). Phase 1 studies showed minimal toxicity and revealed major responses in 
several types of sarcoma with a complete response in a case of chemo-refractory Ewing‘s 
sarcoma (94). Several Phase 2 trials are ongoing and the first has just been reported - a 
randomized trial in a non-small cell lung cancer, which compared standard chemotherapy to 
chemotherapy plus anti-IGF-IR antibody Figitumumab. In this trial, the addition of the anti-
IGF-IR antibody significantly increased object response rate from 41 to 54% and resulted in a 
doubling of relapse-free survival (95). Figitumumab entered Phase 3 trials in non-small cell 
lung cancer, however, sadly enough, the trial was suspended in December 2009 due to excess 
deaths. However, other phase I and II trials are still underway. Phase II clinical trials with 
Figitumumab in breast cancer are currently evaluated in combination with the chemotherapy 
agent Docetaxel or in combination with the aromatase inhibitor Exemestane (96).  
 
Additional antibodies have been developed. Early clinical phase I trial data have been 
reported for AMG479 (Amgen) (97), AVE1642 (Sanofi-Aventis), A12 (Imclone), MK0646 
(Merck) and R1507 (Roche) (39). They all share in common a generally favorable toxicity 
and disease stabilization, which are now being evaluated in Phase II clinical trials in many 
oncological indications in various combinations with approved therapies. Antibodies against 
IGF-IR that are currently in the clinical development are summarized in table 1.  
 
1.4.2.2 IGF-IR Tyrosine Kinase Inhibitors  
Tyrosine kinase inhibitors (TKI) function as ATP-competitive inhibitors of the IGF-IR kinase 
domain. These compounds are expected to inhibit the function of the insulin receptor (InsR) 
because the kinase domains of the IGF-IR and InsR are highly similar and the ATP binding 
cleft of IGF-IR and InsR share 100% homology (98). The exception to this are two inhibitors 
developed by Novartis (NVP-AEW541 and NVP-ADW742), which has 15–30 fold increased 
potency for IGF-IR kinase inhibition compared to InsR kinase inhibition in vitro (98, 99). 
Additionally, cyclolignan picropodophyllin (PPP) successfully inhibited IGF-IR but not InsR 
phosphorylation (100). While the pharmaceutical industry has put a lot of effort in identifying 
compounds that do not target the InsR tyrosine kinase domain, the potential advantage of 
tyrosine kinase inhibitors over antibody therapies may be in their ability to block InsR. It is 
possible that TKIs are more potent anti-cancer agents since InsR has been found on malignant 
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cells (39). Supporting this, specific downregulation of IGF-IR alone sensitizes breast cancer 
cells to insulin and targeting both receptors might be necessary to block cancer growth (101). 
Although this approach has a lot of advantages, blocking InsR, represent a significant 
metabolic liability (102). The major concern is insulin resistance when TKIs are given in high 
doses. Insulin resistance is characterized by hyperglycemia; too much circulating glucose in 
the blood (39). However, it should be emphasized that hyperglycemia and evidence of insulin 
resistance are observed clinically with the IGF-IR monoclonal antibody therapies (96).  
There are several receptor kinase inhibitors in the preclinical and clinical development, 
which are summarized in table 1. However, safety data from phase I are not yet published, 
although compounds are evaluated in phase II clinical trials. The relative advantages and 
disadvantages of receptor specific antibodies and tyrosine kinase inhibitors remain unclear. 
 
 
 
Monoclonal Antibodies   
Figitumumab (CP 751,871) Pfizer Phase 1, 2 
IMC-A12 Imclone Phase 1, 2 
AVE1642 Sanofi-Aventis 
Discontinued AVE1642 development 
program 
MK 0646 Merck Phase 1, 2 
AMG 479 Amgen Phase 1, 2 
R1507 Roche Phase 1, 2 
SCH-717454 (19D12) Schering-Plough Phase 1, 2 
BIIB022 Biogen Idec Phase 1 
 
Tyrosine Kinase Inhibitors 
Insm-18 (NDGA) Insmed Phase 1 
BMS-754807 Bristol Myers Squibb Phase 1, 2 
XL-228 Exelixis Phase 1 
OSI-906 OSI Phase 1 
GSK 621659A Glaxo Smith Kline Preclinical 
 
Table 1. Monoclonal antibodies and tyrosine kinase inhibitors in clinical development  
Table 1 summarizes agents targeting IGF-IR that are either at the end of preclinical development or in 
clinical trials. Several companies are in the clinical development of the IGF-IR. The monoclonal 
antibodies have shown the most rapid clinical development compared to tyrosine kinase inhibitors. 
The largest clinical experience has been with the Pfizer antibody Figitumumab (CP-751,871, Pfizer).  
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1.5 IGF-IR-Mediated Resistance to Anti-Cancer Therapies 
As a single agent therapy, IGF-IR inhibition has not uniformly displayed in vivo 
antitumor activity. However, the critical role in proliferation and survival and resistance to 
anti-cancer therapies makes IGF-IR targeting a promising strategy to combine it with other 
therapies including anti-estrogen therapy, or in combination with other targeted therapies such 
as trastuzumab, or conventional chemotherapy (39).  
 
1.5.1 Anti-Estrogen Therapy 
Many patients experience resistance to endocrine therapy and this may be partially 
explained by crosstalk between the ER and the IGF systems. Estrogen is a potent mitogen for 
breast cancer cell growth and survival. As mentioned earlier, the majority of patients are 
diagnosed with hormone responsive breast cancer (9), which can be successfully treated with  
selective estrogen receptor modulators (SERMs) like tamoxifen, aromatase inhibitors (AIs) 
like letrozole, anastrozole, and exemestane, and selective estrogen receptor down-regulators 
like fulvestrant (103-105). Unfortunately, many patients experience resistance to endocrine 
therapy.  
Growth of tamoxifen resistant MCF7 cells show increased cell growth upon 
stimulation with IGFs (106). Similarly, proliferation of HBL100 cells is inhibited by 
tamoxifen but concomitant treatment with IGF-I increases survival (107). One possible 
mechanism of tamoxifen resistance is through IGF-IR phosphorylation and  activation of ER 
(108). For example, exposure of tamoxifen resistant breast cancer cells to an IGF-IR antibody 
AG1024 reduces ER phosphorylation and significantly inhibits cell growth (106). 
Furthermore, in ER-positive breast cancer xenografts, the IGF-IR monoclonal antibody, 
Figitumumab, enhances the anti-tumor activity of tamoxifen in vivo (109). Currently, 
combination anti-ER and anti-IGF-IR therapy is being tested in phase II clinical trials. 
 
1.5.2 HER2/ErbB2 Receptor Therapy 
As summarized in Section 1.3.1 crosstalk exists between HER2 and IGF-IR. While 
IGF-IR contributes to HER2 signaling, both activated EGFR and HER2 are sufficient to cause 
resistance to anti-IGF-IR therapy (110). These data support the concept of simultaneously co-
targeting IGF-IR in combination with anti-HER2 therapy. This concept is being investigated 
in a phase II clinical trial in HER2 positive breast cancer patients comparing the efficacy of 
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lapatinib and capecitabine in combination with the monoclonal antibody IMC-A12. Another 
ongoing phase II clinical trial evaluates the combination of small molecule inhibitor BMS-
754807 with trastuzumab. 
 
1.5.3 Chemotherapy  
De novo or acquired chemotherapy resistance commonly occurs in breast cancer 
patients. When tumors are exposed to cytotoxic chemotherapy, susceptible cancer cells die 
through apoptosis, whereas a subset of resistant cells continue to proliferate and survive. 
Stimulation of the IGF pathway showed a protective effect against chemotherapy by either 
promoting cell proliferation or inhibiting apoptosis. HBL100 breast cancer cells treated with 
IGF-I become resistant to 5-fluorouracil, methotrexate, and camptothecin (107). Consistent 
with this, MCF7 cells treated with IGF-I are protected from doxorubicin and paclitaxel 
treatment (111). In contrast, blockade of IGF-IR sensitizes cells to chemotherapy (112), 
supporting the role for combination of IGF-IR inhibitor and chemotherapy. A randomized 
phase II trial is currently investigating Docetaxel in combination with Figitumumab. This is 
for particular interest in patients with triple negative breast cancer where no targeted therapies 
are available, and patients often respond poorly to chemotherapy (22). 
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1.6 Summary and Significance  
 Breast cancer is one of the leading causes of death among women in westernized 
countries. Despite many advances in the prevention, detection, and targeted therapy of breast 
cancer, it is clear that better and more effective breast cancer therapies need to be developed. 
Recent molecular classification of breast cancer identified breast cancer subtypes with 
divergent histopathological features, clinical outcomes, and therapeutic implications. Breast 
cancer subtypes that express either ER/PR or HER2 have targeted therapies, which 
significantly reduce the recurrence and mortality from this disease. However, TNBC, lacking 
the expression of ER, PR and HER2, are very aggressive, have no targeted therapies and often 
respond poorly to chemotherapy.   
Experimental studies have provided substantial evidence for a role of IGF-IR in 
human breast cancer, which lead to the development of anti-IGF-IR therapies. An important 
discovery in the clinical development of targeted therapies against cancer is to identify 
appropriate patient populations in which tumors show addiction to a particular pathway for 
continued survival and proliferation and in which these tumors are susceptible to the drug. 
Therefore, the goal of the first part of my study is to define a breast cancer subtype that 
has an active IGF-pathway, and that is most responsive to the IGF-IR inhibitor BMS-
754807. Literature pointed out a role of IGF-IR in TNBC. IGF-IR is selectively amplified in 
basal breast cancer, and high IGF-IR protein levels are seen in 36% of basal breast cancers, 
which would make this subtype of breast cancer an ideal candidate for anti-IGF-IR therapy.  
 
We hypothesized, that the IGF-I signaling pathway is highly active in triple-
negative breast cancer, and that the new anti-IGF-IR tyrosine kinase inhibitor BMS-
754807 will be effective in this subtype of disease.   
 
To address this hypothesis 4 aims were developed:  
i) Perform bioinformatic studies using an IGF-gene signature to identify breast 
cancer subtypes with an active IGF pathway 
ii) Test whether response of breast cancer cells to the IGF-IR inhibitor BMS-754807 
is correlated with markers identified in Aim I 
iii) Use transcriptomic profiling of a large panel of breast cancer cell lines to identify a 
subtype of breast cancer that is sensitive to BMS-754807 
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iv) Test the efficacy of BMS-754807 with and without chemotherapy in breast 
tumorgrafts in vivo 
 
Furthermore, data suggest bi-directional crosstalk pathways between ErbB2 and IGF-
IR. While IGF-IR contributes to HER2 therapy, both activated EGFR and HER2 are sufficient 
to cause resistance to anti-IGF-IR therapy. However, little is known whether crosstalk occurs 
between IGF-IR and HER2 in mammary cancer development and cancer progression. The 
goal of the second part of my thesis is to examine crosstalk between HER2 and IGF-IR 
during tumorigenesis in vivo. I believe that this study will increase our understanding and 
provide further insides of ErbB2 and IGF-IR in cancer development and progression. 
 
We hypothesized that IGF-IR modulates ErbB2 induced tumorigenesis in vivo.  
  
 To address this hypothesis 3 aims were developed:  
i) Examine the tumor rate by Kaplan-Meier survival curves of mice with elevated 
ErbB2 (MMTV-ErbB2) and elevated IGF-IR (MMTV-CD8-IGF-IR) and mice 
expressing both ErbB2 and IGF-IR (MMTV-ErbB2/CD8-IGF-IR) 
ii) Compare the histology of tumors arising from either transgene alone and tumors 
expressing both transgenes  
iii) Examine whether IGF-IR and ErbB2 transform different progenitor cells 
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Chapter 2 - Materials and Methods 
 
 
2 Introduction 
The materials and methods described in this chapter pertain to experiments performed across 
several of the chapters throughout this thesis. 
 
2.1 BMS-754807 
 The structure of BMS-754807 and its activity against IGF-IR has been recently 
described (113). For in vitro studies, BMS-754807 was dissolved in DMSO to 10mM. For in 
vivo studies, BMS-754807 was formulated in PEG400:H2O (80:20). 
 
2.2 Docetaxel  
Docetaxel was obtained from Sigma. Docetaxel was prepared as a stock solution of 45 
mg/ml in Tween80 the day prior to treatment by stirring the solution over night. The working 
solution of 11.25 mg/ml was made by adding 16.25% v/v ethanol/water. Working solution 
was used within 8 hours or otherwise disposed.  
 
2.3 Cell Culture  
The human breast cancer cell lines were obtained from American Type Culture 
Collection (Manassas,VA) except H3396, which was obtained from the Pacific Northwest 
Institute (Seattle, WA). Cell lines were maintained as outlined in Table 2. Also listed in Table 
2 are the characteristics of the cell lines used in the experiments throughout the thesis. 
MCF7/HER2 cell line was generated by stable transfection of the HER2 gene into MCF7 
cells. Cells were grown using recommended culture condition as indicated in Table 2.  
MCF10A cells were cultured in DMEM/F12 medium (Invitrogen) supplemented with 
5% horse serum (Sigma, St. Louis, MO), 20ng/ml epidermal growth factor (Sigma), 10µg/ml 
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insulin (Sigma), 0.5µg/ml hydrocortisone (Sigma), 100ng/ml cholera toxin (Sigma), and 100 
units/ml penicillin-streptomycin (Invitrogen, Carlsbad, CA) as previously described [63]. 
SUM149PT, SUM185PE, SUM225CWN are maintained in Ham‘s F12 (Gibco) supplemented 
with 5µg/ml insulin (Sigma), 1µg/ml hydrocortisone (Sigma), 10mM HEPES (Gibco) and 
10% FBS (CellGro). SUM190PT was cultured in Ham‘s F12 (Gibco) supplemented with 
5µg/ml insulin (Sigma), 1µg/ml hydrocortisone (Sigma), 5mM Ethanolamine (Sigma), 10mM 
HEPES (Gibco), 5µg/ml Transferrin (Sigma), 10nM (6.6ng/ml) Triiodo Thyronine (T3) 
(Sigma), 50nM (8.7ng/ml) Sodium Selenite (Se, Sigma) and 0.5g/L bovine serum albumin 
(BSA, JRH Bioscience). All cell line media contained 1% (v/v) penicillin-streptomycin 
(Invitrogen, Carlsbad, CA).  
 
Cell line ER PR HER2 Culture conditions 
600MPE Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
AU565a Lu − [−] RPMI, 10% FBS 37°C, 5% CO2 
BT20 BaA − [−] DMEM, 10% FBS 37°C, 5% CO2 
BT474 Lu + [+] RPMI, 10% FBS 37°C, 5% CO2 
BT549 BaB − [−] RPMI, 10% FBS 37°C, 5% CO2 
CAMA1 Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
HCC1143 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC1187 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC1419 N/A N/A N/A RPMI, 10% FBS 37°C, 5% CO2 
HCC1428 Lu + [+] RPMI, 10% FBS 37°C, 5% CO2 
HCC1395 N/A N/A N/A RPMI, 10% FBS 37°C, 5% CO2 
HCC1500 BaB − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC1569 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC1937 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC1806 N/A N/A N/A RPMI, 10% FBS 37°C, 5% CO2 
HCC1954 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC202 Lu − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC2218 N/A N/A N/A RPMI, 10% FBS 37°C, 5% CO2 
HCC38 BaB − [−] RPMI, 10% FBS 37°C, 5% CO2 
HCC70 BaA − [−] RPMI, 10% FBS 37°C, 5% CO2 
HS578T BaB − [−] DMEM, 10% FBS 37°C, 5% CO2 
KPL4 N/A N/A N/A RPMI, 10% FBS 37°C, 5% CO2 
MCF10A BaB − [−] DMEM/F12 * 37°C, 5% CO2 
MCF7 Lu + [+] DMEM, 10% FBS 37°C, 5% CO2 
MCF7-HER2 Lu + [+] DMEM, 10% FBS 37°C, 5% CO2 
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MDAMB134VI Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB157 BaB − [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB175VII Lu + [−] Leibovitz’s L15 Media, 10% FBS 37°C, no CO2 
MDAMB231 BaB − [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB361 Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB415 Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB435 BaB − [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB436 BaB [−] [−] L15, 10% FBS 37°C, no CO2 
MDAMB453 Lu − [−] DMEM, 10% FBS 37°C, 5% CO2 
MDAMB468 BaA [−] [−] Leibovitz’s L15 Media, 10% FBS 37°C, no CO2 
SKBR3 Lu − [−] DMEM, 10% FBS 37°C, 5% CO2 
SUM149PT BaB [−] [−] Ham's F12, 5% FBS * 37°C, 5% CO2 
SUM185PE Lu [−] [−] Ham's F12, 5% FBS * 37°C, 5% CO2 
SUM190PT BaA − [−] Ham's F12, BSA* 37°C, 5% CO2 
SUM225CWN BaA − [−] Ham's F12, 5% FBS * 37°C, 5% CO2 
T47D Lu + [+] RPMI, 10% FBS 37°C, 5% CO2 
UACC812 Lu + [−] DMEM, 10% FBS 37°C, 5% CO2 
ZR75-1 Lu + [−] RPMI, 10% FBS 37°C, 5% CO2 
ZR7530 Lu + [−] RPMI, 10% FBS 37°C, 5% CO2 
ZR75B Lu + [−] RPMI, 10% FBS 37°C, 5% CO2 
DF1 N/A N/A N/A DMEM, 10% FBS 37°C, 5% CO2 
Table 2. Cell lines used during the work of this thesis 
This table is modified from R. Neve (114). The ER, PR and HER2 status are derived from mRNA and 
protein levels presented in Neve’s study. Square brackets indicate that the ER/PR/HER2 status is 
derived from mRNA levels alone where protein data was not available. * indicates that media is 
supplemented as listed in the text at 2.3. Lu = Luminal subtype; BaA = Basal A Subtype; BaB = Basal 
B subtype. Since basal A/B subtypes do not exist in human breast cancer, I refer to basal/triple 
negative breast cancer cell lines throughout this thesis.  
 
 
2.4 Monolayer Growth Assay 
For breast cancer cell line studies, cells were plated in complete media at 1000 to 
12,000 cells per well depending on the growth properties of each cell line in 96 well 
microtiter plates and incubated overnight. The next day, the start absorbance (cell number at 
the beginning of the experiment, i.e. at time of drug treatment) was measured in which no 
compound was added and the plate immediately developed using the CellTiter 96
®
 AQueous 
Cell Proliferation Assay (MTS assay, Promega) according to the manufacturer‘s instructions. 
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Briefly, a solution containing 20:1 ratio of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and PMS (phenazine 
methosulfate) was added to the cells. Plates were incubated at 37°C for 1.5 hours and 
absorption was measured at 490nm. BMS-754807 was serially diluted and added to the test 
plate with the following concentrations 0, 0.01µM, 0.1µM, 1µM, 5µM, 10µM and 20µM. 
After 72h exposure, cell number and viability was estimated by MTS assay. Each data point 
was performed in 12 replicates. Percentage of cell growth inhibition was calculated as percent 
(%) of control = end absorbance – start absorbance x 100%. The growth curves (expressed as 
percentage of growth observed in untreated controls) were used to determine the IC50. The 
IC50 value is the drug concentration at which 50% of maximal growth inhibition was 
observed.   
 
2.5 Comparative Gene Expression Analysis  
 Comparative gene expression analysis was performed by determining genes with 
significantly different expression between sensitive cell lines with an IC50<4µM (n=10) and 
resistant cell lines with an IC50>14µM (n=9) using dChip software (115, 116). We utilized 
publicly available gene expression data published by Neve et al (114). Differentially 
expressed genes were found using a t-test. False discovery rate (FDR) was estimated by 
permutation method. We used a p-value = 0.001, which resulted in 136 differentially 
expressed probe sets representing 114 genes, with FDR < 5%. Hierarchical clustering and 
expression values
 
were visualized as heat-maps using TreeView (117). 
 
2.6 RNA Extraction 
To validate the comparative gene expression analysis, seven sensitive (MCF7, BT20, 
MDA-MB-468, HS758T, MDA-MB-231, HCC38, MDA-MB-436) and six resistant cell lines 
(ZR75-1, SKBR3, BT474, CAMA-1, MDA-MB-134, UACC812) were cultured in triplicates.. 
Total RNA was isolated using the QIAshredder and RNeasy isolation kits (Qiagen, Valencia 
CA) according to the user manual. Triplicate RNA samples were prepared for each cell line. 
The RNA concentration and quality of the RNA samples was assessed using the Beckman 
Coulter DU 800 Spectrophotometer and an OD 260/280 ratio.  
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2.7 qRT-PCR 
Isolated mRNA was converted to cDNA in a final volume of 100µl using 0.5µg RNA, 
0.5µl random primers (Invitrogen), and 25mM desoxynucleotide triphosphate (Invitrogen). 
After the samples were heated for 5 min at 65°C, 20µl of 5x first strand buffer (Invitrogen), 
5µl 0.1M dithiothreitol (Invitrogen) and 0.5µl of Superscript II RNase H reverse transcriptase 
(Invitrogen) were added. Reverse transcription was performed at 25°C for 5min, 48°C for 
30min and 70°C for 10min.  
Quantitative reverse transcription-PCR (qRT-PCR) assays were performed using gene-
specific primers in an ABI Prism 7900 sequence detector using the power SYBR green PCR 
master mix (Applied Biosystems). Primer Express 2.0 software (Applied Biosystems) was 
used to design all primers. Quantitative reverse transcription-PCR analysis was performed 
with the following primers: Cav2-fwd: 5‘ ATCCCCACCGGCTCAACT, Cav2-rev: 
5‘CCGGCTCTGCGATCACAT, Cav1-fwd: 5‘GGTCAACCGCGACCCTAAA, Cav1-rev: 5‘ 
CCTTCCAAATGCCGTCAAA, Spdef-fwd: 5‘ TGGATGAAAGAGCGGACTTCA, Spdef-
rev: 5‘ TCGGTCCAGCTCTCCTCACT, ErbB3-fwd: 5‘ CGGTTATGTCATGCCAGATAC, 
ErbB3-rev: 5‘GAACTGAGACCCACTGAAGAAAGG, beta actin-fwd: CCTGGCACC 
CAGCAC, beta actin-rev: GCCGATCCACACGGAGTAC. For each sample, qRT-PCR was 
performed in triplicates for each gene of interest. Each reaction contained 5µl of template 
cDNA, a final concentration of 0.15µM forward and reverse primer, 12.50µl of 2X SYBR 
Green Buffer and RNAse free H2O to make a final volume of 25µl. The PCR was performed 
at 50°C for 2 minutes, denaturing at 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds 
and 60°C for 30 seconds. Analysis was done using the ΔΔCT method normalizing first to the 
average of the housekeeping β-actin (118). The expression values were log10 transformed, 
graphs were represented as the mean, and error bars represent the SEM. Data points were 
compared by the two-tailed t-test. 
 
2.8 Gene Expression Data Sets  
 In this thesis many of the analyses was performed using publicly available datasets for 
gene expression analysis and response to therapy. A brief description of all the data sets used 
in this thesis is below. 
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2.8.1 IGF-Gene Signature Data Set 
 The IGF-gene signature was developed in a study entitled ―Insulin-like Growth 
Factor-I Activates Gene Transcription Programs Strongly Associated with Poor Breast Cancer 
Prognosis‖ by Chad Creighton et al (52). MCF7 cells were stimulated for 3 or 24 hours with 
IGF-I. RNA was isolated and microarray analysis was performed using Affymetrix U133A 
2.0 gene chips. 2154 RNA transcripts were up or downregulated by IGF-I at 3 or 24 hours 
with a p-value <0.01, fold change >1.5. Around 800 genes commonly up- or downregulated at 
both time points defines the IGF signature. Proliferation- associated genes annotated by GO 
analysis (http://www.geneontology.org/) were extracted from the IGF-gene signature. Array 
data has been deposited in Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo), accession GSE7561. 
 
2.8.2 Desmedt Data Set 
 This data set originated from a study entitled ―Strong Time Dependence of the 76-
Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG 
Multicenter Independent Validation Series‖ by Desmedt et al (119). Patients were eligible for 
inclusion if they were younger than 61 years old at diagnosis with systemically untreated 
node-negative, T1-T2 (≤ 5 cm) tumors that have been diagnosed between 1980 and 1998. 
Patients with previous malignancies (except basal cell carcinoma) and bilateral synchronous 
breast tumors were excluded. The corresponding paraffin-embedded tumor samples of these 
patients were sent to the Department of Pathology at the European Institute of Oncology, 
Milan, Italy, where the same pathologist determined ER status (using immunohistochemistry) 
and histologic grade (using the Elston and Ellis method) blinded to the genomic data. RNA 
from frozen samples was isolated and the quality of the RNA was validated. Gene expression 
profiling was performed using the Affymetrix U133A GeneChip blinded to the clinical data. 
The raw and normalized gene expression data, together with the patient's characteristics are 
publicly available on GEO (http://www.ncbi.nlm.nih.gov/geo), with accession number GSE 
7390. 
 
2.8.3 Hoadley Data Set 
 This data set originated from the study ―EGFR associated expression profiles vary 
with breast tumor subtype‖ by Hoadley et al (120). 248 breast tissue samples represented by 
241 fresh frozen breast tumor samples and 7 normal breast tissue samples were obtained from 
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four different sources and are publically available (121-124). In addition, 117 tumors with 
diverse breast cancer subtypes were profiled. The patients were heterogeneously treated in 
accordance with the standard of care dictated by their disease, stage, ER, and HER2 status. 
Microarray raw data together with the patient clinical data were uploaded into the UNC 
Microarray Database and is publically available on Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE6128.  
 
2.8.4 Neuroblastoma Xenograft Treated with h10H5 
 This gene expression data set was published in ―Anti-IGF-IR antibody h10H5 induces 
a unique transcriptional profile in SK-N-AS human neuroblastoma xenograft tumor‖ (125). 
Female nu/nu and C.B-17 SCID beige mice were inoculated with 10 × 10
6
 SK-N-AS 
neuroblastoma cells. Once tumors reached a mean volume of 130 to 260 mm
3
, mice were 
randomized to receive vehicle, weekly 5mg/kg h10H5 anti-IGF-IR therapy and/or 
chemotherapy. Total RNA was isolated from SK-N-AS xenograft tumors 24 hours after 
treatment with h10H5. Four independent tumors representing either vehicle or 24h treated 
with h10H5 were profiled using the Affymetrix human genome U133 Plus 2.0 arrays. Gene 
expression data set is publically available on Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo) under the accession number GSE11959. 
 
2.8.5 IGF-IR Transfected NIH3T3 Cells 
 This data set originated from a study with the title ―Reversal of oncogene 
transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-
928605‖ (126). The tyrosine kinase inhibitor A-928605 abrogates activation of the IGF 
pathway by effectively inhibiting the proliferation of an oncogene addicted tumor model cell 
line (CD8-IGF-IR NIH3T3) both in vitro and in vivo. NIH3T3 mouse fibroblast cells infected 
with a constitutive active IGF-IR (CD8-IGF-IR), were treated with 1μM of A-928605 or 
DMSO, and grown under normal conditions for 24 hours. RNA was isolated and profiled 
using an Affymetrix Mouse Genome 430A 2.0 array. Array data has been deposited in the 
public Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo), accession 
GSE14024. 
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2.8.6 Colon Cancer Xenografts Treated with BMS-754807 
This gene expression data set was generously provided by Bristol-Myers Squibb and is 
unpublished. Female SCID beige mice were inoculated subcutaneously with 10 × 10
6
 GEO 
colon cancer cells. Once tumors reached a mean volume of 150 to 250 mm
3
, mice were 
randomized to receive vehicle, 12.5mg/kg BMS-754807 anti-IGF-IR therapy one daily for 15 
days or 1 mg/kg Erbitux anti-EGFR therapy once every three days for 15 days. Total RNA 
was isolated from GEO xenograft tumors 1 hour, 6 hours, 24 hours and 15 days after 
treatment with vehicle, BMS-754807 and Erbitux. Two independent tumors representing each 
treatment time point were profiled using the Affymetrix human genome U133 Plus 2.0 arrays.   
 
2.8.7 Breast Cancer Cell Line Collection 
 Richard Neve et al. published gene expression profiles of breast cancer cell lines in ―A 
collection of breast cancer cell lines for the study of functionally distinct cancer subtypes‖ 
(114). Breast cancer cell lines used in this study were obtained from ATTC or from 
collections developed in the laboratories from Dr. Steve Ethier and Adi Gazdar. Total RNA 
was isolated from sub-confluent cells in the exponential phase of growth in full media. Gene 
expression profiling was performed using Affymetrix high-density oligonucleotide array 
human HG-U133A chip. All expression data are available at 
http://cancer.lbl.gov/breastcancer/data.php. The raw data for expression profiling are available 
at ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) with accession number E-TABM-157. 
 
2.8.8 Ovarian Cancer Cells 36M2 Treated with Chemotherapy 
 Data sets were published in a paper entitled ―Carboplatin-induced gene expression 
changes in vitro are prognostic of survival in epithelial ovarian cancer‖ (127). Briefly, 36M2 
ovarian cancer cell lines were treated with 100μM carboplatin or vehicle-control for 24hrs and 
cells were harvested in duplicates and processed for RNA isolation at 24, 30 and 36 hours 
after treatment. All raw microarray data are provided in GEO 
(http://www.ncbi.nlm.nih.gov/geo), accession number: GSE13525. 
 
2.9 IGF Signature T-score 
 Bioinformatic analysis was performed by Chad Creighton at Baylor College of 
Medicine. In order to score each breast cancer cell line within a set for similarity to the IGF-
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gene signature, a ―t-score‖ for each breast cancer cell line in relation to the IGF-gene 
signature was derived, similar to previously published analyses (52). The t-score was defined 
as the two-sided t-statistic comparing the average of the IGF-induced genes with that of the 
IGF-repressed genes within each breast cancer cell line. The gene expression values in the 
breast cancer cell line dataset were first normalized to the median before computing the t-
score. For each gene transcription profile dataset, we assigned intrinsic molecular subtypes to 
the cell lines, essentially as previously described (128), using the human tumor dataset from 
Hoadley et al. (120) to define the subtype-specific expression patterns.   
 
2.10 Statistical Analysis  
Statistical analysis of the tumor curves was performed by Susan Hilsenbeck at the 
Statistical Core of the Sue and Lester Smith Breast Center. To compare the tumor growth 
pattern among the treatment groups in the tumorgraft study, data were analyzed by a mixed 
model with treatment group, polynomial terms of day up to the third order, and their 
interaction term as the fixed-effect factors; subject as the random-effect factor. The overall 
growth curves were compared by examining the interaction terms in the model. ANOVA 
analyses and pairwise comparisons with holm adjustment were performed for comparisons of 
glucose and insulin levels, BrdU, Ki67 and CC3 between the 4 groups: vehicle, BMS-754807, 
Docetaxel, and combination. To achieve normality, log-transformation was used for glucose 
and insulin data because data is skewed; Arcsine transformation was used for BrdU, Ki67, 
and CC3 data because data were expressed as proportion from 0 to 1. 
  
2.11 Protein Analysis  
 Overall protein and activated phosphorylated protein levels were determined by 
immunoblot analysis. Cell lines were washed in ice cold phosphate buffered saline (PBS) 
twice followed by lyses in the appropriate amount of 5% sodium dodecyl sulfate (SDS). The 
lysed cells were scraped-off, homogenized by sonication and quantified by BCA protein assay 
(Pierce, Rockford, IL, USA). Human tumorgraft tissues were lysed by electric homogenizer 
for 8 seconds in RPPA lysis buffer (1% Triton X-100, 50mM HEPES (pH 7.4), 150mM NaCl, 
1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM NaPPi, 10% glycerol, 1mM Na3VO4, and 
protease inhibitor (Roche Applied Science, Indianapolis, IN, USA) and incubated on ice with 
occasional shaking for 20 min. The supernatant was collected by centrifugation at 14,000rpm, 
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4°C for 10 min and quantified by BCA protein assay (Pierce, Rockford, IL, USA). Total 
protein extract (50–100µg) was mixed in 4x denaturing sample loading buffer (0.5 M Tris-
HCl (pH6.8), 8% sodium dodecyl sulfate, 0.2% bromophenol blue, 30% glycerol, 20% 
mercaptoethanol) and boiled for 5min followed by rapid cooling on ice. The proteins were 
separated by an 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 1x 
electrophoresis buffer using BioRad chamber system. First, the proteins were focused at 60V 
in the stacking gel followed by separation at 120V in the resolving gel. The membrane was 
blocked with PBS plus 0.05% Tween-20 (PBST) containing 5% bovine serum albumin for 1 
hour. The following antibodies were utilized: anti-phospho-IRS1 (Ser612, #2386, Cell 
Signaling, 1:500), anti-IRS1 (#sc-7200, Santa Cruz Biotechnology, 1:500) anti-phospho-IGF-
IRβ (Tyr1135/1136, #3024, Cell Signaling, 1:500), anti-IGF-IRß (#sc-713, Santa Cruz 
Biotechnology, 1:500), anti-phospho-Erk1/2 (#9101, Cell Signaling, 1:1000), anti-Erk1/2 
(#06-182, Upstate/Millipore 1:1000), anti-phospho-AKT (Ser473, #9271, Cell Signaling, 
1:1000), anti-AKT (#9272, Cell Signaling, 1:1000), and anti-β-actin (#A1978, Sigma, 
1:4000). Antibodies were incubated in blocking solution for 4 hours. Subsequently, the 
membrane was washed three times with PBST for 5min and then incubated with a horseradish 
peroxidase-linked secondary antibody (Amersham Pharmacia Biotech, Piscataway, NJ) at a 
dilution of 1:4000 in blocking solution. Bands were visualized by enhanced 
chemiluminescence (Pierce Biotechnology, Rockford, IL) and captured using an Alpha 
Innotech 7000 Imager (Alpha Innotech, San Leandro, CA). 
 
2.12 Immunohistochemistry and Histological Analysis 
For human tumorgraft analysis, the tissue microarray (TMA) technique was used for 
immunohistochemical analysis. To account for cancer tissue heterogeneity, 0.6mm diameter 
cores were punched that had been selected on the original tumor slides by H&E to include all 
patterns of differentiation. The paraformaldehyde-fixed, paraffin-embedded TMAs were 
sectioned at 5μm onto Superfost Plus slides (Fisher Scientific, Fair Lawn, NJ). TMAs were 
deparaffinized and rehydrated three times for 3 min in Xylene, three times for 2 min in 100% 
ethanol, ones for 2 min in 95%, 80% and 70% ethanol each followed by 5min in PBS.  
Subsequently, slides were stained with hematoxylin and eosin (H&E) and then examined 
microscopically. Immunohistochemistry was performed after heat-induced citrate based 
antigen retrieval for p-IGF-IR/Y1161 (Abcam, ab39398-100), total IGF-IR (Ventana), BrdU  
(5-bromo-2-deoxyuridine, 1:100 Zymed), cleaved caspase 3 (CC3, Covance, Berkeley, CA), 
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Ki67 (Dako) using a Vectastain ABC peroxidase immunodetection kit. Slides were 
counterstained with hematoxylin, dehydrated, and mounted using cytoseal. 
Immunohistochemistry on the TMA was performed by the Breast Center Pathology Core 
(Baylor College of Medicine).   
 For mouse tissues serial sections, 5μm thick, were placed on Super Frost Plus slides, 
deparaffinized and gradually rehydrated three times for 3min in Xylene, three times for 2min 
in 100% ethanol, ones for 2min in 95%, 80% and 70% ethanol each followed by 5min in PBS. 
Endogenous peroxidase was blocked with 5% H2O2 for 5min. Antigen retrieval was 
performed by boiling slides in 10mmol/L citrate buffer, pH6 for 15min in a pressure cooker. 
After cooling slides down for 30min, immunohistochemistry was performed for mouse 
cytokeratin 6 (CK6) (1:100, Covance, Berkeley CA), cytokeratin 14 (CK14) (1:200, Covance, 
Berkeley CA), cytokeratin 8 (CK8) (1:100, Developmental Studies Hybridoma Bank, Iowa 
City, IA), IGF-IR (1:150, #3027, Cell Signaling) and ErbB2 (1:200, Zymed). After incubation 
for 1hour with the primary antibody slides were washed and incubated with horseradish 
peroxidase (HRP)-labeled anti-rabbit antibody (1:500, Vector Laboratories) for 30min, 
washed again and then incubated with 3,3-diaminobenzidene (BioGenex, San Ramon, CA), 
followed by counterstaining and coverslipping. Staining with CK8, a rat-anti mouse antibody, 
was carried out using Vectrastain ABC peroxidase immunodetection kit (rat immunoglobulin 
G (IgG)) and a M.O.M. immunodetection kit, respectively (Vector Laboratories, Burlingame, 
CA) according to users instructions.  
. 
2.13 Tumorgraft Study 
 All procedures were conducted in accordance with the NIH Guide for the Care and 
Use Laboratory Animals and were approved by the IACUC of Baylor College of Medicine. 
Human breast tumors were collected as biopsy cores or pieces of tumors after surgery by Dr. 
Jenny Chang at Baylor College of Medicine and implanted in humanized cleared fat pads of 
NOD/scid mice for establishing human tumorgrafts. Tumorgraft lines are maintained by 
transplantation of small pieces (1mm
3
) of tumorgraft into 4 to 6-week-old female NOD/scid 
mice (Harlan Sprague-Dawley Inc., Madison, WI). When tumorgrafts reached 1cm
3
 they were 
then re-transplanted. For the testing the efficacy of BMS-754807 with and without 
chemotherapy 4 to 6-week-old female NOD/scid mice were transplanted with a 1mm
3
 piece 
of tumorgraft into a cleared number four mammary fat pad. A total of 22 mice with successful 
human tumor growth were included in this study. Tumor volume was measured weekly with a 
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digital caliper according to the formula for an ellipsoid sphere: (long dimension) x (short 
dimension)
2
/2 = mm
3
. When tumors reached a volume between 100-200 mm
3
, they were 
randomized to receive the following treatments: vehicle (Tween80/ethanol/saline (20:13:67) 
by IP weekly and polyethylen glycol (PEG400)/water (80:20) daily by oral gavauge, 50mg/kg 
BMS-754807 daily by oral gavauge, 20mg/kg docetaxel weekly by intraperitoneal injection or 
the combination of 50mg/kg BMS-754807 daily and 20mg/kg docetaxel weekly by 
intraperitoneal injection. Tumor volume and body weight was measured daily. All mice were 
sacrificed when control tumors reached 1000mm
3
. For Bromodeoxyuridine (BrdU) labeling 
cells, mice were injected with BrdU (100mg/kg, Amersham) two hours before sacrifice. Plots 
of tumor growth curves and body weight measurements were generated using Graphpad 
(Prism). Statistical analysis of the tumor curves was performed by Susan Hilsenbeck at the 
Statistical Core of the Sue and Lester Smith Breast Center and is outlined in 2.10.  
 
2.14 Mouse Serum Isolation and Metabolic Studies 
 Whole blood from mice was collected three hours after treatment with BMS-754807 
IGF-IR therapy and inserted into BD microtainer serum separator tubes (VWR, #VT365956) 
allowing to sit at room temperature for 1 hour for clotting. Then samples were centrifuged for 
7min at 12000rpm. The top layer containing the serum was collected from each tube and 
stored at -80°C. Serum samples were thawed on ice prior to being tested. Serum glucose was 
measured using a Glucose Assay Kit (BioVision - Mountain View, CA).  Samples (1µl) were 
diluted in supplied assay buffer and tested in duplicate using the protocol provided by the 
supplier.  Serum glucose was measured from the standard curve of the supplied glucose 
positive control. Standard deviation was calculated using the duplicate values in the assay. 
Serum insulin was measured using the Ultra Sensitive Mouse Insulin ELISA kit (Crystal 
Chem. Inc – Downers Grove, IL).  Samples (0.5 and 1 µl) were diluted in kit supplied assay 
diluent and tested in duplicate. Vendor supplied assay protocol was followed and insulin 
concentration was measured from the standard curve of the supplied insulin standard. 
Standard deviation was derived from the duplicate samples. 
 
2.15 MMTV-ErbB2 Mouse Model 
 ErbB2 is amplified and overexpressed in 20-30% of human breast tumors and is 
associated with a poor prognosis (129, 130). Consistent with this, mammary specific 
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overexpression of ErbB2 using the MMTV promoter conclusively showed a role for ErbB2 in 
breast cancer (131, 132). This model is ideal for studying ErbB2 induced tumorigenesis 
because it closely mimics the development and progression of human breast cancer, which is 
driven by the amplification and overexpression of the human homologue HER2. 
 The mouse mammary tumor virus (MMTV) is a retrovirus that targets the expression 
of transgenes specifically to the mammary epithelium. MMTV drives transgene expression in 
the ductal, alveolar luminal and myoepithelial cells during all stages of mammary gland 
differentiation (132-134).  
 The MMTV-ErbB2 mouse model overexpresses wild-type ErbB2 in the mammary 
gland. The long latency period suggests the requirement for additional events during 
tumorigenesis. One event induces activation and autophosphorylation of ErbB2 in the tumor 
as examined by in vitro kinase assays, whereas ErbB2 from the adjacent normal epithelium is 
not activated (135). In this case, tumors contain 10 ± 50-fold elevated levels of transgene 
mRNA compared to normal mammary tissue. In addition, many tumors from these mice, 
acquire mutations in the transgene such as in frame deletion or insertion of cystein residues 
which results in constitutive dimerization through disulphide bonds (132). Furthermore, 
elevated levels of endogenous ErbB3 are observed in ErbB2 induced mammary tumors. 
Therefore, heterodimerization with ERBB3 might represent an additional mechanism for 
activating ERBB2 (136). 
 
2.16 MMTV-CD8-IGF-IR Mouse Model 
 To better understand the biological function of the IGF-IR pathway in oncogenesis.  
Carboni et al. developed a transgenic mouse model in which overexpression of a 
constitutively active IGF-IR occurs in the mammary gland (44). The active IGF-IR consists of 
the human CD8α extracellular domain fused to the human IGF-IRβ subunit. Disulfide bonds 
in the CD8α domain brings the IGF-IRβ domain in close proximity which allows constitutive 
activation (Figure 4). This model was used to eliminate any confounding affects from ligand 
and binding protein interactions. Two different transgenic mouse lines were developed. 
Transgenic line 15 overexpressing the activated receptor showed disrupted mammary gland 
development and a rapid appearance of mammary gland tumors starting as early as 8 weeks of 
age. Transgenic line 19 showed disrupted mammary gland development but the correct tumor 
rate has not been determined yet. We chose transgenic line 19 because tumor development 
was observed at a similar rate as MMTV-ErbB2.  
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Schematic representation of the CD8-IGF-IR
Constitutive activityLigand-dependent 
activity
IGF
hIGF-IR
hIGF-IR hCD8
hIGF-IR
Disulfide bonds
CD8-IGF-IRMMTV
IGF-IR constitutively active mouse model A. Schematic representation of the transgenic 
construct, MMTV CD8-IGF-IR. B. The constitutively active receptor is composed of an 
extracellular CD8α domain and the IGF-IRβ subunit. Intramolecular disulfide bonds result 
in receptor homodimerization leading to constitutive activation
 
Figure 3. Schematic representation of a constitutive active IGF-IR under the control of the 
MMTV prom ter 
The IGF-IR is activated upon binding of the ligand IGF-I for downstream signaling. The constitutively 
active r t r is composed of a  xtracellular CD8α domain nd the IGF-IRβ subunit. Intramolecular 
disulfide bonds result in receptor homodimerization leading to constitutive activation. This chimeric 
receptor is placed under the control of an MMTV promoter for generating mammary tumors. 
 
2.17 CD8-IGF-IR x ErbB2 Mouse Study 
 To test the effect of cross-talk between IGF-IR and ErbB2 on mammary tumorigenesis 
in vivo we set up the following mouse study: Heterozygous MMTV-ErbB2 mice were bred 
with het rozygous MMTV-CD8-IGF-IR mice to produce 4 cohorts for study – wild type, 
heterozygous MMTV-ErbB2, heterozygous MMTV-CD8-IGF-IR, and bigenic heterozygous 
MMTV-ErbB2/MMTV-CD8-IGF-IR (Figure 4). FVB/N mice are used as the genetic 
background for the transgene expression. The median times to tumor formation (MMTF) of 
more than 20 females per group were analyzed by weekly palpation. Female mice were 
housed four per cage and palpated twice a week for tumor formation. Animals were 
euthanized when tumors reached 1000mm
3
. Time to tumor formation was analyzed using the 
method of Kaplan and Meier (using Prism software). Statistical comparison of survival curves 
was done in Prism using logrank tests. 
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4.
MMTV-CD8-IGF-IR/ ErbB2            
Bigenic (tg/tg)             
1.
Wild type 
(wt/wt)             
3. 
MMTV-ErbB2 
(tg/wt)             
2.
MMTV-CD8-IGF-IR 
(tg/wt)             
MMTV-CD8-IGF-IR (het) MMTV-ErbB2 (het)
The MMTV promoter drives transgenic expression in the mammary gland. FVB/N 
heterozygous MMTV-CD8-IGF-IR mice were crossed with MMTV-ErbB2 heterozygous FVB/N 
mice to create 4 phenotypes. Wild type (controls); CD8-IGF-IR only (constitutively active IGF-
IR causes mammary tumors); ErbB2 only (ErbB2 overexpression causes mammary specific 
tumors); Bigenic (IGF-IR + ErbB2). Virgin females were housed 4 per cage and palpated twice 
a week. Animals were harvested when tumors reached 1000mm3.
 
Figure 4. Schematic representation of the CD8-IGF-IR x ErbB2 mouse study 
The MMTV promoter drives transgenic expression in the mammary gland. FVB/N mice were used as 
genetic background. Heterozygous MMTV-CD8-IGF-IR mice were crossed with heterozygous MMTV-
ErbB2 mice to create 4 phenotypes: FVB/N Wild type (controls); CD8-IGF-IR only (constitutively active 
IGF-IR causes mammary tumors); ErbB2 only (ErbB2 overexpression causes mammary specific 
tumors); Bigenic (CD8-IGF-IR + ErbB2). Virgin females were housed 4 per cage and lpated twice a 
week. Animals were harvested when tumors reached 1000mm
3
. het = heterozygous 
 
 
2.18 Mammary Gland and Tumor Harvest  
 Tumors were harvested when they reached 1000mm
3
. Mammary glands and tumors 
were removed and either fixed in 4% paraformaldehyde (PFA) in PBS overnight at 4°C or 
snap-frozen in liquid nitrogen. Fixed tissues were paraffin-embedded and proceeded as in 
2.12.  
 
2.19 Whole Mounts 
 Whole inguinal mammary glands were dissected and placed on glass slides and fixed 
overnight in ethanol–acetic acid (v/v 75/25). The next day glands were washed in 70% 
ethanol for 30 min, washed twice in water for 10 min and stained overnight with carmine 
alum. Carmine was prepared by adding 2g Carmine, 5g AlK(SO4) to 1L of water. The 
solution was boiled for 15min, filtered and stored at 4ºC.  Glands were then destained in 70%, 
95% and 100% ethanol each for 30 min and then soaked in toluene until fat pat clears. Glands 
were then placed in methylsalicylate and photos were taken using a Nikon dissecting 
microscope.  
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2.20 RCAS-TVA Technology 
 The RCAS-TVA technology has been described before (137-140) and was used to 
study the role of IGF-IR and ErbB2 expression in different cell lineages during development. 
In addition, this system was used to identify whether IGF-IR and ErbB2 transform different 
progenitor cells.  
 RCAS(BP)(A) (Replication-Competent avian sarcoma-leucosis virus long terminal 
repeat with Splice acceptor, Bryan-Rous sarcoma virus polymerase subgroup A) referred to as 
RCAS in this thesis is a viral expression vector derived from the replication competent 
retrovirus avian leucosis virus A. Since a retrovirus has the ability to introduce new genetic 
information into the chromosomes of target cells, RCAS serves as vehicle for stable transfer 
of genes. RCAS has a multiple cloning site, which allows insertion of up to 2.5 kb of DNA. 
RCAS vector is able to infect avian cells, which express the cell surface receptor tumor virus 
A (TVA) for virus entry and infection. Thus, virus can be generated in high titer in chicken 
fibroblasts. However, RCAS does not infect mammalian cells because they do not encode the 
TVA-receptor unless they are genetically engineered to ectopically express the TVA receptor 
on their cell surface thus rendering the cells susceptible to infection with RCAS virus (Figure 
5) (137-140) .  
 In transgenic mice, the TVA receptor can be expressed under the control of a cell or 
tissue specific promoter in order to develop tissue specific targeting. After entry into TVA-
positive mammalian cells, the viral DNA integrates into the host DNA. The internal promoter 
promotes high levels of transcription of the integrated provirus. Importantly, RCAS infection 
in mammalian cells does not result in infectious progeny because mammalian cells do not 
produce viral proteins thus prevents cell-to-cell spreading. Previous publication showed that 
despite infection of only a few thousand mammary cells, introduction of an oncogene caused 
tumorigenesis (137-140).  
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The TVA system uses the retroviral vector RCAS, which is modified from the avian 
leukosis virus subgroup A (ALV-A).  A gene of interest such as the CD8-IGF-IR can be 
cloned into the vector and expressed under control of the viral LTR. RCAS can only infect 
cells expressing the TVA receptor, which is found exclusively in avian cells. Transgenic 
mice expressing TVA under the control of a mammary gland selective promoter are 
susceptible by infection with the rcas virus expressing the gene of interest allowing 
infection of a small number of cells in a developmentally-normal mammary gland
A. B.
 
 
 
 
Figure 5. Schematic representation of the TVA system 
A. The TVA system uses the retroviral vector RCAS, which is modified from the avian leukosis virus 
subgroup A (ALV-A). A gene of interest such as the CD8-IGF-IR can be cloned into the vector and 
expressed under control of the viral LTR. The RCAS vector is competent containing all genes for high 
titer proliferation. RCAS can only infect cells expressing the TVA receptor, which is found exclusively 
in avian cells such as DF1 cells but not on mammalian and mouse cells. Transgenic mice expressing 
TVA under the control of a mammary gland selective promoter are susceptible by infection with the 
RCAS virus expressing the gene of interest allowing infection of a small number of cells in a 
developmentally-normal mammary gland. B. Cancer initiation in humans evolve from a normal cell that 
has gained genetic changes. This cancer initiation can be recapitulated using the TVA-technology by 
introducing genetic changes into somatic cells. Transgenic mouse models have genetic changes in 
their germline, resulting in genetic changes in every epithelial cells. Picture was adapted from Z. Du et 
al, Cell Cycle 2007 (137). 
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2.20.1   Strategy to Monitor Introduction of CD8-IGF-IR in the Mammary 
Gland 
 To prove that an oncogene is successfully introduced in the mammary epithelial cells 
several steps during tumorigenesis were analyzed. The first step was to determine that TVA 
positive mammary epithelial cells were susceptible to infection by RCAS after intraductal 
injection. Because IGF-IR is a potent oncogene it is likely that tumors would result from 
infection of a relatively small number of cells. Therefore, mice were injected with RCAS-
CD8-IGF-IR virus and the response of normal mammary epithelial cells to the oncogene 
CD8-IGF-IR was monitored after 2 weeks and 6 weeks of injection by analyzing the histology 
for hyperplasia. In addition, mice were injected with RCAS-CD8-IGF-IR virus to monitor 
tumor formation. To study the role of IGF-IR and ErbB2 expression in different cell lineages 
during development, we will compare the histology from CD8-IGF-IR infected mice to ErbB2 
infected mice at the same time points after infection. Our collaborator Prof. Dr. Yi Li has 
successfully infected mammary epithelial cells with ErbB2 which resulted in lesion and tumor 
formation. A schematic representation of the strategy is depicted in figure 6.  
 
2.20.2   MMTV-TVA Mouse Model  
 In this study we used the MMTV-TVA mouse model which was developed in the lab 
of our collaborator Professor Dr. Yi Li (139). Transgenic mice express TVA in mammary 
epithelial cells under the control of the mouse mammary tumor virus (MMTV) LTR. MMTV 
targets the expression of the TVA specifically to the mammary epithelium in luminal and 
myoepithelial cells during all stages of mammary gland differentiation (134). Only mouse 
cells that express the TVA receptor can be infected with RCAS virus while mouse cells that 
do not harbor the tva gene are resistant to RCAS infection 
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RCAS-CD8-IGF-IR infection
MMTV-TVA (target cells at different 
developmental stages )
Staining of hyperplasia and tumors with IGF-IR, and 
differentiation marker (K6, K8, K14)
RCAS-ErbB2 infection
MMTV-TVA (target cells at different 
developmental stages )
Staining of hyperplasia and tumors with ErbB2, and 
differentiation marker (K6, K8, K14)
B.   Determine if IGF-IR and ErbB2 transform different progenitor cell types
RCAS-CD8-IGF-IR infection
MMTV-TVA (target cells at different 
developmental stages )
Determine the effect of clonal
expansion of CD8-IGF-IR infected 
mammary epithelial cells
1.
5 days after infection:
detect CD8-IGF-IR in 
infected mammary epithelial 
cells by FACS 
Determine if RCAS-CD8-IGF-IR 
infects mammary epithelial cells
2.
2 and 6 weeks after infection:                     
detect CD8-IGF-IR expression in infected 
mammary epithelial cells and hyperplasia 
by IHC for IGF-IR and lineage specific 
markers K6, K8, K14
3.
Determine tumor formation by 
CD8-IGF-IR 
Perform IHC on tumors for IGF-IR, 
and differentiation marker (K6, K8, 
K14)
If IGF-IR and ErbB2 transform different progenitor cell types, major differences in the tumor 
histology and differentiation markers are identified.
A.   Strategy to monitor CD8-IGF-IR infection in mammary glands
 
 
Figure 6.  Strategy to monitor CD8-IGF-IR infection in the mammary gland 
A. RCAS-CD8-IGF-IR virus is injected in MMTV-TVA mice and monitored for successful infection of 
mammary epithelial cells, development of lesions/hyperplasia and tumor formation. B. Strategy to 
determine if IGF-IR and ErbB2 transform different progenitor cell types. Once tumors are formed by 
infection with RCAS-CD8-IGF-IR hyperplasia and tumor histology of IGF-IR and ErbB2 infected 
mammary epithelial cells are analyzed and compared.  
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2.20.3   Cloning Strategy of RCAS-CD8-IGF-IR 
 RCAS(BP)(A) was linearized using the restriction enzyme pme1. The chimeric CD8-
IGF-IR cDNA was excised from pcDNA3.1-CD8-IGF-IR with EcoR1 and NehI and ligated 
into RCAS(BP)(A) vector. RCAS-CD8-IGF-IR was verified by sequencing in both directions. 
 
2.20.4   Transformation of Competent Cells 
DH5α bacteria were thawed on ice. 48μl DH5α bacteria and 10ng of plasmid were 
mixed together and incubated for 20-30min on ice followed by a heat shock for 90sec at 
42°C. After incubating on ice, 950μl SOC Media (Invitrogen) were added and the cells were 
incubated for 1h at 37°C shaking. 50 - 100μl of transformed bacteria were plated on LB-plates 
containing ampicillin (100µg/ml) and incubated over night at 37°C. 
 
2.20.5   Isolation of Plasmid DNA 
Single colonies of the transformed DH5α cells were picked and cultured in 2 ml LB-
Media containing Ampicillin (100µg/ml). After incubation at 37°C for 5-6 hours 200µl of 
seed culture were added in 200ml LB broth containing ampicillin (100µg/ml) and grown over 
night at 37°C with shaking. Plasmid isolation was performed as described in QIAGEN 
Plasmid Purification Handbook. DNAs were dissolved in 100μl of ddH2O, and concentration 
was measured. 
 
2.20.6   Enzymatic Manipulation of DNA 
 DNA restriction was performed according to the manufacturer‘s guidelines for buffers 
and temperatures for each restriction enzyme. For cutting 1μg DNA 2-10U of enzyme was 
used. The restriction enzyme reaction was incubated for 2 - 12 hours at 37°C. RCAS-Plasmid 
and the CD8-IGF-IR fragment were purified via QIAGEN Purification handbook. The 
products were electrophoresed on a 1 % standard agarose gel and detected via EtBr staining 
and UV light. The concentration of the digested DNA was estimated to determine the optimal 
ratio between CD8-IGF-IR and RCAS vector for the ligation. Ligation was performed with 
T4-DNA-Ligase (Invitrogen) in recommended buffers in a total volume of 20μl. 
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2.20.7   Testing Transfection and Infection Efficiency in DF1 Cells 
 Before producing high virus titer, RCAS-CD8-IGF-IR vector was tested for effective 
transfection and infection efficiency. Untransfected DF1 chicken fibroblasts (141, 142) were 
passaged into several 60mm dishes with 20-50% confluency and subsequently transfected 
with 2µg of RCAS-CD8-IGF-IR using Lipofectamine transfection reagent (Invitrogen). 
48hours post-transfection, protein levels were analyzed by harvesting cells for 
immunofluorescence analysis as described in 2.20.5 and immunoblot analysis using phospho 
and total IGF-IR as described in 2.11. Five days post-transfection supernatant containing virus 
was used to infect new DF1 cells. Infection efficiency was analyzed 5 days later by FACS 
analysis as described in 2.20.9.  
 
2.20.8   Immunofluorescence  
 For immunofluorescence cells were fixed in 4% PFA (vPFA/vPBS) for 10 min on ice 
and subsequently washed twice with PBS for 10 min. Cells were treated with 0.1% Triton X-
100 (0.1% Triton X-100 in PBS) for 10 min followed by washing twice with PBS for 10min. 
After blocking with 5% BSA in PBST for 1 hour cells were incubated with CD8-PE (1:100 in 
blocking solution, eBioscience). The nuclei were stained with 15µM ToPro3 (Invitrogen) in 
PBS for 10min. After washing twice for 10min the slides are mounted (Mounting medium, 
Vectrashield), sealed and analyzed by fluorescence microscopy.  
 
2.20.9   Virus Preparation 
 To achieve high titer viral production we followed methods described before (138). 
Briefly, to produce RCAS-CD8-IGF-IR virus, DF1 chicken fibroblasts (141, 142) were 
transfected with RCAS-CD8-IGF-IR vector by using Lipofectamine transfection reagent 
(Invitrogen) and maintained in DMEM media supplemented with 10% FBS in humidified 
37°C incubators with 5% CO2. 48 hours after transfection the supernatant was harvested and 
used to infect DF1 cells that were plated the day before infection on 60mm dishes. After 
several passages the DF1 cells achieved 100% infection. The infected DF1 cells were grown 
into 15-18 15cm dishes. The supernatant containing virus was collected every day for 12 days 
from confluent plates and pooled together. Cell debris was removed by centrifugation at 
1000rpm for 5 min at 4°C. Each day the virus in the culture supernatant was concentrated 
100-fold by ultracentrifugation at 125,000 x g for 90min, resuspended in 1ml DMEM media 
containing 10% FBS and frozen in aliquots at -80°C for titer determination and infection of 
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cells and animals. The virus titer may have variability between daily preparations. Therefore, 
one aliquot from each day was mixed together for maintaining a consistent virus titer 
throughout experiments. Virus titer was determined on DF1 cells plated in 60mm dishes by 
limiting dilution from 10
-2
 to 10
-12
. Cells were passed once they reached confluency and 5 
days after infection cells were harvested for protein analysis. Protein analysis was performed 
as described in 2.11 with phospho-and total IGF-IR.  
 
2.20.10  Infection of the Mammary Gland 
 In vivo infection of mammary epithelial cells with RCAS virus has been described 
before (138). For injection of virus in one mammary gland, 10µl of virus was used in 
combination with a tracking dye (0.1% bromophenol blue). To infect mammary glands, 9-12 
week old MMTV-TVA female mice were anesthetized, the nipple of the mammary gland was 
cut and virus was injected through intraductal injection with concentrated RCAS-viruses. 
Throughout multiple experiments, MMTV-TVA mice were injected in all three left mammary 
glands and in the right number four mammary gland. The other two mammary glands, which 
were not infected were used as negative controls. Michael J. Toneff, a graduate student in 
Prof. Dr. Yi Li‘s lab, performed all intraductal injections.  
 
2.20.11  Mammary Epithelial Cell Isolation 
 To document that TVA positive mammary epithelial cells are susceptible to infection 
by RCAS-CD8-IGF-IR virus, cells from mammary glands of MMTV-TVA mice were 
isolated 5 days after infection and analyzed by fluorescent activated cell sorting (FACS) 
analysis. To isolate mammary epithelial cells, mammary glands were removed from each 
mouse and placed into a 50ml conical tube with 30ml wash buffer (DMEM/F12 media 
(Invitrogen) containing 5% FBS (Cellgro) and 2% antibiotic-antimycotic solution (Cellgro)). 
Tissue was minced into small pieces with a scalpel and 1mg of tissue is placed into 10ml of 
digestion buffer (DMEM/F12 (Invitrogen) buffered with HEPES (Cellgro), 1% antibiotic-
antimycotic solution (Cellgro), 1mg/ml collagenase (Roche), 100 units/ml hyaluronidase 
(Sigma). The digestion was incubated over night at 110-125 rpm (rounds per minute) at 37 C. 
After digestion tubes were filled with wash buffer cells were collected by centrifugation at 
1000rpm for 5 min. The supernatant was removed and the cell pellet was resuspended and 
washed three times with 10ml of wash buffer. The cell pellet was trypsinized with 10ml 
0.25% Trypsin – EDTA (Invitrogen) for maximal 5min until the epithelial organoids were 
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separating. Cells were filtered with a 40µm cell strainer (BD Falcon) and then centrifuged at 
1000 rpm for 5 min to remove the trypsin. Cells were reconstituted in 1ml of HBSS + (Hanks' 
balanced salt solution (GIBCO/BRL), 2% FBS, and 10mM Hepes). Cells were counted and 
approximately 100,000 cells/100µl were transferred into each 15 conical tube and analyzed by 
FACS.  
 
2.20.12  FACS Analysis 
 Cells isolated in 2.20.8 were blocked for 30 min with 20% mouse serum in HBSS + 
(Hanks' balanced salt solution (GIBCO/BRL), 2% FBS, and 10mM HEPES). After incubation 
cells were washed with ten times the volume with wash buffer (Hanks' balanced salt solution 
(GIBCO/BRL), and 10mM HEPES). Cells were centrifuged at 1000rpm for 5 min, 
supernatant was removed and the cell pellet was resuspended in 100µl HBSS + 0.5µg CD8-
PE primary (#12-0088, eBioscience) antibody was added and incubated for 30 min on ice. A 
final concentration of 5nM CYTOX Red was added to all tubes except control tubes, which 
exclude dead cells during FACS analysis. After 20min incubation, cells were washed, 
centrifuged and the cell pellet was resuspended in 100µl HBBS+ and 500µl 0.2% 
paraformaldehyde in PBS (PFA/PBS). Cells were filtered into FACS analysis tubes and 
analyzed on a BD™ LSR II FACS machine.  
 
2.21 Genotyping 
 Mouse tails were digested in 180 l H2O, 20 l 10x PCR buffer with 15mM MgCl2, 
10 l Proteinase K and 1 l IGEPAL (NP40, Sigma). The mix was added to each tail and 
incubated over night at 55 C. The tails were boiled for 10min and centrifuged at 14000rpm 
for 2 min. The supernatant was used to perform genotyping of CD8-IGF-IR and ErbB2. The 
following primers were used to genotype ErbB2 and CD8-IGF-IR: ErbB2 rev genotype: 
5‘TTTCCTGCAGCAGCCTACGC, ErbB2 fwd genotype: 5‘CGGAACCCACATCAGGCC, 
IGFR-geno: 5‘CGTCCGAGTAAGTGGTGAAGA, CD8-geno: 5‘AGGGTGTGGTGAAAGA 
TGAAC. The PCR was set up as listed in table 3. The PCR was performed at 94°C for 5 
minutes, 39 cycles of denaturing at 94°C for 20sec, annealing of primers at 60°C for 20 
seconds and elongation at 72°C for 1min followed by 72°C for 5 min and cooling at 4°C.  
 To genotype MMTV-TVA mice, the supernatant was transferred to a new tube and 
DNA was isolated by mixing 1:1 with Phenol:Chloroform. The DNA phase was separated by 
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centrifugation at 14000rpm for 15 min. The upper phase containing DNA was transferred to a 
new tube and 10% 3M Sodium Acetate and 5 volume 100% Ethanol was added. If the DNA 
did not precipitate immediately, the solution was incubated for 1 hour at -80 C. DNA was 
centrifuged at 14,000rpm for 30 min at 4 C. DNA pellet was washed with 70% ethanol and 
dried. The DNA was dissolved in 50 l H2O. To genotype for the TVA transgene the 
following primers were used: Forward primer: 5' TCC GGT AAC GGT TCT TTG 3', Reverse 
primer: 5' AGG TCC TGC CCT ATT TTG 3'. The PCR reaction was set up as listed in table 
3. The PCR was performed at 94°C for 4 minutes, 30 cycles denaturing at 94°C for 30 sec, 
annealing of primers at 55°C, elongation at 72°C for 30 seconds and 72°C for 10min. PCR 
products were separated on a 2% Gel at 120V for 60 min. 
 
 
Table 3. Genotyping PCR for CD8-IGF-IR, ErbB2 and TVA was set up as listed in this table   
 
 
 
 
 
CD8-IGF-IR 
genotyping 
ErbB2 
genotyping 
TVA genotyping 
1x reaction ( l)    
10x PCR buffer  2,5 3,5 10x PCR buffer 5 
MgCl2 (50mM) 0,75 0,75 MgCl2 (25mM) 5,5 
10mM dNTPs 0,5 0,5 DMSO 3 
20 µM Fwd. primer 0,5 0,5 25mM dNTPs 0,5 
20 µM Rev. primer 0,5 0,5 100  µM Fwd primer 0,5 
dH2O 18 16.75 100  µM Rev primer 0,5 
Recombinant Taq 
(Invitrogen) 0,25 0,5 
Taq (5U/µl) (5’Prime, cat#: 
2200020) 0,3 
DNA 2 2 dH2O 29 
total 25 25 DNA 2 
 total 44,3 
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Chapter 3 – Defining a breast cancer subtype with an active IGF 
pathway that is responsive to the IGF-IR inhibitor BMS-754807  
 
 
3 Rationale 
In the last few years, drugs targeting the IGF-IR have entered clinical trials and are 
showing promising early results. One of the integral goals in developing cancer therapeutics is 
the identification of a patient population that is most likely to benefit from therapy. Therefore, 
it is necessary to find a subtype of breast tumors that show addiction to the IGF pathway and 
that are susceptible to BMS-754807.  
 
3.1 Results 
3.1.1 The IGF signature is present in triple negative human breast cancer 
 The Lee laboratory previously reported the development of an ‗IGF-I gene signature‘ 
pattern of genes up- or down-regulated by IGF-I. This IGF-gene signature was derived from 
MCF7 cells stimulated for 3 or 24 hours with IGF-I. After isolation of RNA, microarray 
analysis was performed. More than 2000 RNA transcripts were up or downregulated by IGF-I 
at 3 or 24 hours. The IGF signature is defined by around 800 genes commonly up- or 
downregulated at both time points. In addition, proliferation-associated genes annotated by 
GO analysis (http://www.geneontology.org/) were extracted from the IGF-gene signature. We 
found that this IGF signature was present in human breast cancers, specifically the subtypes 
luminal B and TNBC (52).  
 To independently validate these results we analyzed the IGF gene signature in a 
recently published data set of 198 node negative breast cancers (Desmedt (119)) and 
confirmed the presence of the IGF signature in the majority of ER-negative tumors (Figure 
7A). Most of the ER-negative breast tumors showed high expression of the genes induced in 
vitro by IGF-I and low expression of genes repressed in vitro by IGF-I. We went on to apply 
the IGF signature to a more recent profile dataset from Hoadley et al. (120). This independent 
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cohort of 248 tumors has previously been classified into breast cancer subtypes using an 
intrinsic gene expression signature. The IGF gene signature was present in most basal tumors, 
luminal B tumors and a subset of HER2-positive tumors (Figure 7B). This data suggests that 
the IGF pathway is highly active in TNBC, and that these tumors may be excellent candidates 
for anti-IGF-IR therapy. 
 
Figure 1
A.
B.
 
 
 
Figure 7. IGF-I-induced gene expression signature is present in triple-negative breast cancer 
A. and B. Genes in the IGF gene signature were examined in two published data sets of clinical 
breast tumors from Desmedt and Hoadley. Within the ER-positive and ER-negative as well as the 
distinct breast cancer subtype tumors are ordered from those with the least similarity to the IGF 
signature pattern to those with the highest similarity to the IGF signature. Relative gene expression is 
represented using a yellow–blue color scale. Patterns for genes that are upregulated (yellow) in the 
IGF gene signature are separate from the patterns for genes that are downregulated (blue).  
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3.1.2 The IGF-signature is reversed by anti-IGF-IR inhibitors 
 We next set out to examine the effect of inhibitor of IGF signaling on the IGF 
signature. We reasoned that regulation of genes by IGF-I that made up the IGF gene signature 
should be reversed by anti-IGF-IR inhibitors.  
 Thus, we examined the levels of genes that are induced or repressed by IGF-I in 
neuroblastoma xenografts treated with an anti-IGF-IR (h10H5, Genentech) antibody (125). 
Mice growing a mean tumor volume of 130 to 260 mm
3 
SK-N-AS neuroblastoma xenografts 
were randomized to receive vehicle, weekly 5mg/kg h10H5 anti-IGF-IR therapy and/or 
chemotherapy. Four independent tumors representing either vehicle or 24h treated h10H5 
were microarray profiled and used for this analysis (125). Genes induced by IGF-I in MCF7 
cells were repressed by h10H5, and genes repressed by IGF-I were now induced thus there 
was a striking reversion of the IGF-I signature (Figure 8A). This result was highly significant 
(Fig 8D, p~0). Highly similar results were obtained with an IGF-IR tyrosine kinase inhibitor 
(A-928605, Abbott) (126) that was administered in vitro to NIH3T3 fibroblasts transfected 
with the IGF-IR (Figure 8B). Treatment with the tyrosine kinase inhibitor A-928605 resulted 
in reversion of the IGF-I gene signature. Finally, we generated gene expression data from 
colon cancer xenografts (GEO) treated in duplicates with the anti-IGF-IR tyrosine kinase 
inhibitor BMS-754807 (12.5mg/kg/day) for various time-points of 1, 6 and 24 hours and 15 
days. Treatment of these GEO xenografts resulted in gene expression values that were again 
reversed compared to the IGF-signature (Figure 8C). Note that there was no change in the 
IGF signature after 1 hour as previous studies showed that the drug has not reached its target 
at this point. However, after 6 hours of exposure to the drug a strong reversion of the IGF 
signature was seen, which is entirely consistent with the pharmacodynamics and 
pharmacokinetics of BMS-754807. This data gives us confidence that our signature can 
measure IGF activity, and furthermore, suggests that the IGF signature might be a predictor of 
cells that have an active IGF pathway and thus may response to an IGF-IR inhibitor.  
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Figure 3
 
 
Figure 8. An IGF-I gene signature is reversed by treatment of cancer xenografts and IGF-IR 
overexpressed NIH3T3 cells with anti-IGF-IR therapies 
Genes in the IGF-I gene signature derived from MCF7 cells stimulated with IGF-I (52) were examined 
in A. a gene expression profile of neuroblastoma (SK-N-AS) xenografts treated with vehicle or an anti-
IGF-R antibody and in B. IGF-IR transfected NIH3T3 fibroblasts treated with an IGF-IR small molecule 
inhibitor and in C. colon cancer xenografts treated with the small molecule inhibitor BMS-754807. For 
A-C, relative gene expression is represented using a yellow–blue color scale; patterns for genes that 
are upregulated (yellow) in the IGF gene signature are separate from the patterns for genes that are 
downregulated (blue). D. Statistical enrichment of the MCF7 IGF-I signature gene sets within each of 
the indicated IGF-I inhibitor treatment expression profile datasets. All genes represented in the IGF-I 
inhibitor dataset were first ranked by expression in inhibitor/control (using two-sided t-test), then the 
overall positions of the MCF7 gene sets within the ranked lists was assessed by Spearman’s rank sum 
(positive rank sum, associated with inhibitor group; negative rank sum, associated with control group). 
In all three datasets, treatment with IGF-IR inhibitors reversed expression of the IGF regulated genes.   
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 When the Lee laboratory originally developed the IGF signature, the importance of 
proliferative genes was reduced by 1) including genes modulated by IGF-I at both 3 and 24hrs 
(as genes induced at only 3 or 24 hrs were often found to be cell cycle genes), 2) removing 
genes annotated as being associated with proliferation in Gene Ontology (GO), and 3) 
removing genes that were found to be induced in fibroblasts stimulated to proliferate by 
serum (52). Thus, this reversal of the signature by IGF-IR inhibitors (Figure 8) presumably 
doesn‘t simply reflect changes in cell growth but rather highlights changes in metabolism and 
DNA repair (the major GO terms of the IGF gene signature). To further examine the 
specificity of the IGF signature, and its reversion, we examined the levels of genes in the IGF 
signature on a data set of ovarian cancer cells (36M2) treated with carboplatin (127). 
Importantly, chemotherapy had no discernable effect upon the IGF gene signature. Indeed, it 
weakly induced the IGF signature perhaps due to a DNA damage response (Figure 9).  
 
Figure 2
 
Figure 9. Chemotherapy has no discernable effect upon the IGF-I gene signature 
Genes in the IGF-I signature were examined in a gene expression profile of ovarian cancer cells 36M2 
treated with the chemotherapy agent carboplatin. Chemotherapy treatment does not result in reversion 
of the IGF gene signature. Patterns for genes that are upregulated (yellow) in the IGF gene signature 
are separate from the patterns for genes that are downregulated (blue).  
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 A recent study comparing genes regulated by growth factors (IGF-I, insulin, EGF and 
heregulin) in MCF7 cells showed that there was significant overlap (correlation coefficient 
0.6) (143), consistent with highly redundant nature of growth factor downstream signaling 
(e.g.. PI3K, ERK1/2 etc). We therefore next examined whether the IGF-I signature would be 
modulated by inhibitor of other growth factor receptors. We developed gene expression 
profiles from colon cancer (GEO) xenografts treated in duplicates for various time-points of 
1, 6 and 24 hours and 15 days with the EGFR inhibitor Erbitux. Interestingly, the IGF 
signature was reversed by Erbitux indicating the IGF signature is likely a marker of active 
growth factor signaling and highlights pathways downstream of receptor tyrosine kinase 
inhibitors (Figure 10). 
Figure 2
 
Figure 10.  The IGF-I gene signature is a marker of active growth factor signaling  
Genes in the IGF-I signature were examined in a gene expression profile of colon cancer xenografts 
treated with the IGF-IR small molecule inhibitor BMS-754807 (12.5mg/kg/daily) and the EGFR small 
molecule inhibitor Erbitux (1mg/kg/every 3 days) for 1h, 6h, 24h and 15 days. Patterns for genes that 
are upregulated (yellow) in the IGF gene signature are separate from the patterns for genes that are 
downregulated (blue). Treatment with IGF-IR and EGFR inhibitors reversed expression of the IGF 
regulated genes.  
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3.1.3 Triple-negative/basal-like breast cancer cell lines show activation of 
the IGF gene signature 
To examine the usefulness of the IGF gene signature in predicting patients who may 
respond to anti-IGF-IR therapy, we studied cell lines grown in culture where we could rapidly 
assess response. Therefore, we examined the IGF-I gene signature in a publicly available 
dataset of gene expression profiles from a large panel of breast cancer cell lines. 51 breast 
cancer cell lines were grown in complete medium, RNA was isolated and microarray analysis 
was performed (114). Figure 11A shows a panel of breast cancer cell lines arranged according 
to their subtype based upon the similarity of their gene expression profile to the ―intrinsic 
gene set‖ (120). In addition, we indicate subtype as defined in the original gene expression 
study by Neve et al. (114). The IGF signature is present in the majority of basal-like (and 
TNBC) cell lines (Figure 11A). We assigned each cell line a T-score based upon the similarity 
of its gene expression profile to the IGF signature and the positive T-score in the majority of 
TNBC cell lines highlights the presence of the signature in this subtype (Figure 11B). This 
data is entirely consistent with Figure 7 and our previous report of the IGF signature in TNBC 
(52) suggesting that the IGF-IR pathway is highly active in the triple-negative/basal-like 
subtype of breast cancer. 
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Figure 11. The IGF-I gene signature is present in triple-negative/basal-like breast cancer cell 
lines 
Breast cancer cell line profiles were classified using the Hoadley dataset, where intrinsic subtypes 
were previously defined by hierarchical clustering. The correlation was computed between a given cell 
line gene expression profile and the mean centroid of each subtype; cell lines were then assigned to a 
subtype with the highest correlation. A. The heatmap represents the IGF gene signature in the cell 
lines according to subtype. ER, PR, and HER2 mRNA levels are shown. Within the distinct breast 
cancer subtypes cell lines are ordered from those with the least similarity to the IGF signature pattern 
to those with the highest similarity to the IGF signature. In addition, the breast cancer subtype is 
indicated as defined in the original gene expression study by Neve et al. (114). Relative gene 
expression is represented using a yellow–blue color scale.  Patterns for genes that are upregulated 
(yellow) in the IGF gene signature are separate from the patterns for genes that are downregulated 
(blue). B. The graph represents the T-score for each cell line based on the similarity to the IGF 
signature. 
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3.1.4 An IGF-IR tyrosine kinase inhibitor BMS-754807 shows selective 
activity in triple-negative breast cancer cell lines 
 To test whether the presence of the IGF signature in basal-like/TNBC cell lines was an 
indicator of response to an IGF-IR inhibitor, we examined the sensitivity of a panel of 30 
breast cancer cell lines to a new IGF-IR tyrosine kinase inhibitor currently in Phase 1/2 
clinical trials (BMS-754807). Among the different tumor
 
cell lines, sensitivity presented as 
IC50 to BMS-754807 varied widely from 0.1µM to 25µM (Figure 12A). When defining cell 
lines as sensitive or resistant based on the median IC50 (6.4µM), we found a clear correlation 
between the sensitive/resistant classification to BMS-754807 and specific breast cancer 
subtypes. The greatest response to BMS-754807 was in basal-like/TNBC cell lines (10/15), 
while luminal breast cancer cell lines and HER2 overexpressing cell lines were relatively 
resistant (13/15) (Figure 12A). The TNBC group was enriched for cell lines with low IC50 
(p<0.01, Spearman‘s rank sum, two-sided). Importantly, when the IC50 is plotted alongside 
the T-score for the IGF signature for each cell line there is a significant inverse correlation 
(r=-0.41, p=0.014), with a higher T-score (indicating an active IGF pathway) being associated 
with a greater response (lower IC50) to BMS-754807 (Figure 12B).  This data strongly 
suggests that BMS-754807 is specifically active in TNBC.  
 
3.1.5 114 differentially expressed genes identify TNBC cell lines as most 
responsive to BMS-754807 
 To examine genes and pathways associated with response to BMS-754807, we used an 
unbiased approach in which we performed comparative gene expression analysis between the 
ten most sensitive cell lines with an IC50 below 4µM and the 9 most resistant cell lines with an 
IC50 above 14µM BMS-754807 using gene expression data published by Neve et al (114). 
This analysis identified 136 probe sets corresponding to 114 genes (p < 0.001 and false 
discovery rate (FDR) < 5 %) that were differentially expressed between sensitive and resistant 
cell lines. The top 10 differentially expressed genes were validated in a panel of seven 
sensitive (MCF7, BT20, MDA-MB-468, HS758T, MDA-MB-231, HCC38, MDA-MB-436 
with an IC50<4µM) and six resistant breast cancer cell lines (ZR75-1, SKBR3, BT474, 
CAMA-1, MDA-MB-134, UACC812 with an IC50>14µM) by qRT-PCR. We identified that 
most of these 114 genes were actually markers of the basal or luminal subtype. The genes 
overlap significantly with the ―intrinsic gene‖ list distinguishing luminal and basal tumors (p-
value < 0.001, respectively). Sensitive cell lines express basal markers such as CAV1 and 
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CAV2 and resistant cell lines expressed luminal markers such as ErbB3 and SPDEF (Figure 
13A). Consistent with this, protein levels validated mRNA levels in these four genes (Figure 
13B). 
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Figure 12. BMS-754807 is active in basal-like/triple-negative breast cancer cell lines 
A. The concentration of BMS-754807 required to reduce growth by 50% (IC50) was calculated for each 
cell line using monolayer proliferation and MTS assay. Breast cancer cells were seeded at 1,000 to 
12,000 cells per well depending on the cell line in 96 well microtiter plates and incubated overnight. 
BMS-754807 was serially diluted and added. After 72 hr exposure, MTS assay was performed. Bars 
represent the average IC50 (µM) of each breast cancer cell line. For seven cell lines the IC50 was not 
reached (>16.48µM and >25µM, respectively). Sensitive cell lines have an IC50 below the mean of the 
group of cells (6.4µM); resistant cell lines are above the mean. The graph shows cell lines ranked 
according to its IC50. Black bars represent cell lines that have a basal-like gene expression signature 
(TNBC) based upon the studies of Neve et al. and grey bars represent luminal or HER2 positive cell 
lines. B. IC50 is plotted alongside the T-score for the IGF signature for each cell line. Pearson 
correlation shows there is a significant correlation (r=-0.41, p=0.014), with a higher T-score (indicating 
an active IGF-IR pathway) being associated with a greater response (lower IC50) to BMS-754807.  
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Figure 13. Sensitive cell lines express basal markers whereas resistant cell lines express 
luminal markers 
A. The expression of differentially expressed genes were validated by qRT-PCR in a panel of seven 
sensitive cell lines (MCF7, BT20, MDA-MB-468, HS758T, MDA-MB-231, HCC38, MDA-MB-436) and 
six resistant cell lines (ZR75-1, SKBR3, BT474, CAMA-1, MDA-MB-134, UACC812). Analysis was 
done using the ΔΔCT method (118), normalizing first to the average of the housekeeping β-actin. The 
results are presented as log10 transformed transcript levels. Graphs represent the mean and error 
bars represent the SEM. Data points were compared by the two-tailed t-test. B. Protein quantification 
values for each cell line in A were taken from Neve et al. (114). Bars represent the mean and error 
bars represent the SEM. Data values were compared by the two-tailed t-test. 
 
 
 
 
We next analyzed the 114 genes in a panel of 51 breast cancer cell line profiles with known 
and unknown IC50 to BMS-754807 (114). Hierarchical clustering separated the cells lines into 
two major bins: ER-negative cell lines that were sensitive and ER-positive cell lines that were 
mostly resistant (Figure 14). To validate this clustering data, we determined the sensitivity to 
BMS-754807 of breast cancer cell lines with an unknown IC50. Breast cancer cell lines were 
exposed for 72 hours to 0, 0.01, 0.1, 1, 5, 10 and 20µM BMS-754807 and analyzed by MTS 
assay. Among the cell lines tested the TNBC cell lines SUM149PT and MCF10A showed the 
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greatest response to BMS-754807 whereas cell lines that are ER negative but overexpress 
HER2 (SUM225 and SUM190PT) are less sensitive to BMS-754807 (Figure 15, Table 4). 
Luminal breast cancer cell lines such as ZR75B, MDA-MB-175VII and MDA-MB-316 
showed the least response to BMS-754807. This unbiased approach supports our previous 
findings that BMS-754807 is especially active in TNBC cell lines. 
Figure 6
 
 
Figure 14. 114 differentially expressed genes identify triple negative breast cancer cell lines as 
most responsive to BMS-754807 
136 differentially expressed probe sets, representing 114 genes, were analyzed in 51 breast cancer 
cell line profiles published by Neve et.al. with known and unknown IC50. S=sensitive (IC50<4µM), 
M=Medium IC50: (4µM<14µM), R=Resistant (IC50>14µM). In addition, the ER, PR and Her2 status is 
indicated (P = positive, N = negative). Gene-cluster indicates the breast cancer subtype as defined in 
the original gene expression study by Neve et al. (A = basal A, B = basal B, L = Luminal).   
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Figure 15. BMS-754807 is especially active in TNBC cell lines 
Breast cancer cells with unknown IC50s to BMS-754807 were plated in 96 well microtiter plates and 
incubated overnight. BMS-754807 was serially diluted and added. After 72 hr exposure, MTS assay 
was performed. Sensitive cell lines have an IC50<4µM, moderate IC50 between 4µM and 14µM, 
resistant: IC50>14µM 
 
Table 4. Summary of the effect of BMS-754807 on cells lines with an unknown IC50 
Cell lines Response  to BMS-754807 ER status Breast Cancer subtype 
SUM149PT sensitive - TN 
MCF10A Sensitive - TN 
SUM225CWN Moderate - (HER2+) 
Sum190PT Moderate - (HER2+)  
SUM185PE Moderate Low + Luminal 
ZR75B Moderate + Luminal  
MDA-MB-175VII Moderate + Luminal  
MDA-MB-361 Moderate + Luminal  
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3.1.6 Novel tumorgraft models of triple-negative breast cancer show 
strong IGF-IR activation 
 Preclinical cancer research has relied heavily upon cell lines grown in culture and then 
xenografted for growth in mice. However, recent work has shown that human cancers placed 
directly into the mouse (tumorgrafts) maybe a more appropriate model that is better at 
predicting response to drugs in humans (144). Drs Jenny Chang and Mike Lewis have 
recently developed several new tumorgraft models of human TNBC. We screened three of 
these for activity of the IGF-IR by both immunohistochemistry (IHC) and immunoblotting 
(IB). Figure 16A shows that all tumorgrafts expressed various levels of IGF-IR and had 
divergent levels of active phosphorylated pY-IGF-IR. Protein lysates from the same 
tumorgrafts as in Figure 16A confirmed that MC1 had the highest activation of IGF-IR 
(Figure 16B). Activation of downstream signaling molecules varied among the tumorgraft 
models. MC1 had high levels of IRS1 and activated AKT whereas the tumorgraft 2665A 
showed activation of MAPK.  We isolated RNA, generated gene expression data from all of 
the tumorgrafts, and calculated an IGF signature t-score for each tumorgraft. Analysis of these 
profiles showed that tumorgraft MC1 (145) had the highest level of IGF-IR, pY-IGF-IR, and 
in addition had a high IGF signature T-score.  
 
3.1.7 BMS-754807 inhibits growth of MC1 TNBC tumorgrafts, and when 
combined with chemotherapy causes complete regression 
 Our studies identified TNBC and TNBC cell lines as having an active IGF pathway. 
Supporting this, we discovered high levels and activity of the IGF-IR in several recently 
developed TNBC tumorgraft models. As we previously showed that BMS-754807 is most 
active in TNBC cell lines in vitro (Figure 12), we directly examined the effectiveness of the 
IGF-IR inhibitor BMS-754807 in the recently developed MC1 tumorgraft model of TNBC 
breast cancer alone as a single agent or in the presence of chemotherapy (docetaxel). We 
chose the tumorgraft MC1 for this preclinical study as it had the highest levels of active and 
total IGF-IR and also had a high IGF T-score. A recent study examining timing of anti-IGF-
IR therapy and chemotherapy in cells in culture showed that most efficacious combination 
was chemotherapy followed by anti-IGF-IR therapy (112). We thus administered docetaxel 
followed by BMS-754807 the next day. Control mice received docetaxel vehicle and BMS-
754807 vehicle following the same dose and schedule as treatment groups. Single agent 
therapy with BMS-754807 achieved a statistically significant (p<0.001) reduction in tumor  
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Figure 16. TNBC human tumorgrafts express high levels of IGF-IR 
A. Three different TNBC human tumorgraft lines (2147, 2665A, MC1) were harvested and processed 
in paraffin. Immunohistochemistry was performed on five-micrometer sections for anti-pY-IGF-IR 
(Phospho-IGF-IR) and total IGF-IR. Microarray analysis was performed on these tumorgrafts. Based 
on the gene expression data an IGF signature t-score was calculated for each tumorgraft as indicated 
underneath the representative picture. B. The same three tumorgraft lines were lysed and analyzed by 
immunoblot and probed using IGF-IR specific antibodies as well as total/phospho-specific antibodies 
for IRS1, AKT, ERK1/2. ß-actin was used as a loading control. Tumorgraft lines that were not relevant 
to this study were cropped out between 2665A and MC1. 
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growth when compared with the control group (Figure 17A). Docetaxel stabilized MC1 tumor 
growth and after 12 days of treatment with chemotherapy. Strikingly, combined treatment 
with BMS-754807 and docetaxel showed superior tumor growth inhibition to either single 
agent alone. Four out of six mice receiving the combined agents had tumors regress until no 
tumor was palpable and the overall growth rates of combined treatment showed superior 
growth inhibition to that of docetaxel alone (p<0.001). 
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Figure 17. BMS-754807 inhibits growth of TNBC tumorgrafts and causes regression in 
combination with chemotherapy  
A. 4 to 6-week-old female NOD/scid mice were transplanted with a 1mm
3
 piece of tumorgraft into a 
cleared number four mammary fat pad. When tumors reached a volume between 100-200mm
3
 they 
were randomized to receive the following treatments: vehicle, 50mg/kg BMS-754807 daily by oral 
gavauge, 20mg/kg Docetaxel weekly by intraperitoneal injection or the combination of 50mg/kg BMS-
754807 daily and 20mg/kg docetaxel weekly by intraperitoneal injection. Tumor volume and body 
weight was measured daily. All mice were sacrificed when control tumors reached 1000mm
3
. B. 
Untreated and treated tumors were processed in a tissue microarray (TMA) for immunohistochemical 
analysis. Immunohistochemistry was performed for Phospho and total IGF-IR. Representative IHC 
staining of the treatment groups is taken at 40x magnification.  
To confirm the ability of BMS-754807 to inhibit IGF-IR activity in triple negative breast 
cancer, tyrosine phosphorylation and total level of IGF-IR was examined in the various 
treatment groups. Both p-IGF-IR and IGF-IR showed membrane staining with a small amount 
Combination Vehicle Docetaxel BMS-754807 B. 
pY-IGF-IR 
IGF-IR 
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of cytoplasmic staining. There was no change in the levels of pY-IGF-IR between tumors 
treated with docetaxel or vehicle (Figure 17B). In contrast, BMS-754807 completely blocked 
IGF-IR phosphorylation. There was no change in levels of total IGF-IR between the different 
treatment groups. 
  
3.1.8 Toxicity associated with BMS-754807 
 Despite the potent inhibitory activity of BMS-754807 on MC1 TNBC tumorgrafts, 
minimal toxicity was observed in animals at doses that show significant antitumor activity. 
Mice treated with docetaxel or BMS-754807 as single agents lost a maximum of 5% body 
weight. This weight loss remained steady at an average 94% to 95% after 14 days of treatment 
(Figure 18A). Combination therapy with BMS-754807 plus
 
docetaxel resulted in a body 
weight loss of 15%.   
 BMS-754807 is a dual IGF-IR/InsR small molecule inhibitor that inhibits IGF-IR but 
also cross-reacts with the insulin receptor (InsR). Because glucose homeostasis in vivo is 
maintained through the insulin-mediated uptake of glucose in skeletal muscle and suppression 
of glucose production in the liver (146), the biological effect of BMS-754807 on InsR 
inhibition was determined. As expected, blood glucose levels remained unaltered in mice 
treated with chemotherapy. However, mice treated once daily with BMS-754807 alone 
showed a significant two-fold increase in glucose levels when compared with vehicle-treated 
mice (p-value < 0.05, Figure 18B). Interestingly, mice treated with the combination of BMS-
754807 and docetaxel showed a lower elevation of glucose levels, which was not significantly 
different compared to vehicle or docetaxel-treated mice (p-value > 0.05).  
 Blood insulin levels were also monitored in mice after 14 days of treatment. No 
changes in insulin were observed in chemotherapy treated mice compared to vehicle treated 
mice. However, insulin levels increased from 0.5 to 110ng/ml after 14 days of treatment with  
BMS-754807 alone (p-value<0.05; Figure 18C). Consistent with the reduction of elevated 
glucose in the combination treatment group, BMS-754807 and chemotherapy induced insulin 
levels (57ng/ml) to a level lower than BMS-754807 alone (114ng/ml) but this was still 
significantly elevated compared to vehicle or chemotherapy (p-value < 0.05).  
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Figure 18. Minimal toxicity is observed in animals at doses that show significant antitumor 
activity 
A. Body weight was measured daily. Graph represents the percentage of body weight compared to 
treatment initiation. Control mice weigh 104% compared to treatment initiation. Docetaxel and BMS-
754807 treated mice weigh 95% and 94%, respectively. Combination treated mice weigh 85% 
compared to treatment initiation. B. Blood glucose levels were measured on mice of all groups after 14 
days treatment. C. Plasma insulin levels were measured by ELISA after 14 days of treatment.  
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3.1.9 BMS-754807 blocks growth and induces apoptosis, and sensitizes 
MC1 tumorgrafts to docetaxel - induced mitotic catastrophe 
 Several reports have shown that chemotherapy agents such as docetaxel affect the 
stability of the microtubules and in doing so induce mitotic catastrophe (147, 148). Mitotic 
catastrophe results from aberrant mitosis, or missegregation of chromosomes followed by cell 
division which results in the formation of multinucleated giant cells leading to cell death. Cell 
death through mitotic catastrophe may occur through apoptosis as well as necrosis (148). 
MC1 tumorgrafts treated with Docetaxel showed relatively few multinucleated giant cells 
(Figure 19A). However, the addition of BMS-754807 dramatically increased docetaxel-
induced mitotic catastrophe (Figure 19A). Analysis of H&E staining showed that normal 
breast cancer cells were still present in Docetaxel treated tumors whereas only multinucleated 
cells were present in the combination treated tumors.  
 Since multinucleated cells may be temporarily viable and mitotic catastrophe may be a 
process leading to death (148), we analyzed the treated tumors for replication, proliferation, 
and apoptosis. All treatment groups showed a reduction in replication as indicated by less 
BrdU incorporation into DNA compared to untreated tumor cells (Figure 19B).  BMS-754807 
alone reduced replication by 36% (22% BrdU positive cells in vehicle tumors versus 15% in 
treated tumors).  Chemotherapy significantly reduced replication by 55% and the combination 
by 59% compared to vehicle (p-values < 0.05). We next analyzed proliferation as assessed by 
Ki67 positive cells (Figure 19C and E). Whereas single agents alone were able to significantly 
reduce proliferation by 30-32% (p-values < 0.05), combination treatment resulted in only a 
17% reduction in proliferation (p-value < 0.05 compared to vehicle). We then investigated 
whether single agents alone or the combination of BMS-754807 and Docetaxel induces cell 
death. BMS-754807 caused a 4-fold elevation in apoptosis as measured by cleaved caspase 3 
(CC3) from 3% apoptotic cells in vehicle treated tumors to 11% in BMS-754807 treated 
tumors (Figure 19D and E). Chemotherapy resulted in a 6.7-fold induction of apoptosis, 
whereas the combination caused striking 12-fold induction of apoptosis (Figure 19D and E). 
In addition, combination therapy resulted in massive cell destruction through necrosis as 
shown in Figure 19A.  
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Figure 19.  BMS-754807 sensitizes MC1 tumorgrafts to docetaxel induced mitotic catastrophe 
A. Representative tumor sections of the treatment groups stained with hematoxylin and eosin are 
taken at 40x magnification. B. Quantification of BrdU incorporation per cell was done by image 
analysis. Data represents means ± SE of 12 representative pictures per treatment group. C and D. 
The percentage of Ki67/CC3-positive cells within the tumor was scored. Values represent the means ± 
SE of 12 representative pictures per treatment group. E. Representative tumor sections of the 
treatment groups stained with Ki67 and CC3 (cleaved caspase 3) are taken at 40x magnification. 
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3.2 Summary and Discussion 
  An important component in the clinical development of targeted therapies against 
cancer is to identify appropriate patient populations in which tumors show addiction to a 
particular pathway for continued survival and proliferation, and in which these tumors are 
susceptible to the drug.  In this study, we confirmed that an IGF-gene signature can measure 
IGF activity, as based on reversion of the signature in three different cancer models treated 
with different anti-IGF-IR therapies. We found that the majority of human TNBC and TNBC 
cell lines have an active IGF signature. Consistent with this, TNBC cells lines are most 
sensitive to anti-IGF-IR tyrosine kinase inhibitor BMS-754807, and sensitivity correlates with 
expression of the IGF signature.  Finally, new tumorgraft models of TNBC show activation of 
IGF-IR and treatment with BMS-754807 in combination with chemotherapy results in 
complete tumor regression.  This preclinical study provides a strong clear biological rationale 
to test anti-IGF-IR therapy in combination with chemotherapy in patients with TNBC. 
 Although many studies identified ER-positive breast cancer as an important target for 
anti-IGF-IR therapy, the significance of IGF-IR as a target in triple-negative breast cancer has 
been poorly addressed. However, there is a growing literature indicating a role for IGF-IR in 
the aggressive subtype of breast cancer. IGF-IR is specifically amplified (albeit in a small 
number of tumors) in TNBC (50) and high levels of IGF-IR protein are detected in triple 
negative breast cancer (51). Moreover, activated (phosphorylated) IGF-IR and IR are 
associated with poor survival in TNBC (89). Growth inhibition of the TNBC cell line 
SUM149 in vitro with BMS-536924 suggests that this subtype of breast cancer may be 
inhibited by targeting IGF-IR/InsR (89). 
 There has been recent considerable interest in the identification of biomarkers for anti-
IGF-IR therapies.  Several in vitro cell culture studies have recently been reported.  Studies of 
an IGF-IR tyrosine kinase inhibitor, NVP-AEW541, reported high levels of IGF-IR in all 
breast cancer cell lines (149). IGF-IR expression alone provided insufficient information to 
select cell lines sensitive to NVP-AEW541 but sensitivity was limited to those that express 
both IGF-IR and IRS1 (149). Huang et al examined response to a panel of neuroblastoma and 
sarcoma cells lines to BMS-536924 and identified genes differentially expressed between 
sensitive and resistant cell lines.  Interestingly, IGF-IR mRNA was a weak predictive marker 
of response to BMS-536924, but that prediction improved when the levels of IGF-IR, IGF-I, 
and IGF-II were also considered (150). We found IGF-IR mRNA levels didn‘t predict 
response to BMS-536924, but in contrast that IGF-IR protein was weakly associated with 
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response (38). Similarly, a study in lung cancer cells also showed that IGF-IR protein predicts 
response to a monoclonal antibody R1507 (151). A study of a large panel of breast cancer cell 
lines in response to the monoclonal antibody h10H5 showed that IGF-IR mRNA levels 
correlate with response, with IGF-IR mRNA being an excellent negative predictive factor 
(low levels being associated with resistance) but mRNA levels being a relatively poor positive 
predictive factor.  Importantly, inclusion of IGF-II, IRS1 and IRS2 mRNA levels increase the 
potential to predict which cells respond to h10H5 (152). We recently performed the first 
analysis in human NSCLC tumors treated in a Phase 2 clinical trial with the anti-IGF-IR 
antibody Figitumumab (Pfizer) and found that IGF-IR was a weak predictor of response only 
in squamous cell NSCLC (153). To date, the majority of data suggest that IGF-IR may be a 
relatively strong negative predictive factor, similar to the estrogen receptor for hormone 
therapy and HER2 for anti-HER2 therapy, but that IGF-IR alone is a weak positive predictive 
factor.   
 We developed the IGF signature to learn more about transcriptional events 
downstream of IGF-IR, and to examine the role of IGF-IR regulated genes in breast cancer. 
However, the obvious question as to the potential role of the IGF signature in predicting 
response to anti-IGF-IR therapy alone. We show here that the IGF signature can measure IGF 
activity in tumors, however it also measures other related growth factor pathways.  Not 
surprisingly, the IGF signature is only weakly correlated (r=0.41) with response of cells to an 
IGF-IR inhibitor.  However, the strength of the signature may come when used in 
combination with IGF-IR protein levels and activity. Thus IGF-IR alone, or the IGF signature 
alone maybe insufficient to indicate an active IGF pathway, but the combination may yield 
better prediction. To this end, we used this strategy to select a TNBC tumorgraft for study and 
found dramatic effects of an IGF-IR inhibitor. Further comprehensive studies are required to 
definitively prove whether the combination of IGF-IR levels and downstream gene transcripts 
is a useful method for identify patients who may respond to anti-IGF-IR therapy. 
 Standard xenografts using permanent cell lines poorly predict how a drug works in 
patients with the same type of tumor (144). A study showed that tumorgrafts correctly predict 
response in 90% of patients (19 of 21 tumors) and resistance in 97% (57 of 59) tumors (154). 
A clinical trial in pediatric neuroblastoma testing the drug topotecan was consistent with that 
reported in preclinical tumorgraft models of neuroblastoma (155). Therefore, we chose to 
study recently developed tumorgrafts, in which tumors taken from patients and small pieces 
directly implanted into immunodeficient mice. We found a dramatic effect of BMS-754807 
against MC1 tumorgrafts, with complete regression when the drug was combined with 
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chemotherapy.  Complete regression of standard cell line xenografts has been rarely reported, 
and we found that BMS-754807 shows only minimal activity against a range of breast cancer 
cell lines grown as xenografts (data not shown), again indicating that the tumorgraft model 
maybe more appropriate for determining response. 
 IGF-IR has been linked to resistance to hormone therapy, anti-HER2 therapy, 
chemotherapy, and radiation therapy (156).  As such, there is great interest in combing anti-
IGF-IR therapies with current anti-cancer agents. IGF-IR signals to potent survival pathways, 
and has been shown to confer resistance to chemotherapy-induced death (157, 158)  and 
inhibition of the IGF-IR sensitizes breast cancer cells to chemotherapy (159, 160).  In this 
study we combined BMS-754807 with docetaxel as it has previously been shown that IGF-IR 
is a mediator of survival to taxanes, and the combination of an IGF-IR antibody (A12) and 
docetaxel showed excellent anti-tumor activity in prostate cancer (161).  We found a similar 
effect with the combination therapy. Why anti-IGF-IR therapy is so active in combination 
with an anti-microtubule therapy is intriguing.  As anti-IGF therapy mainly acts as a G1 
block, and docetaxel causes a G2/M block, it is possible that the double blockade is especially 
effective.  Indeed, in our analysis of the IGF signature, ingenuity pathway analysis identified 
G2/M checkpoint as the major IGF regulated process after 24 hours, with IGF upregulating 
numerous genes involved in G2/M transition including AURKA, AURKB, BUB1, CCNB, 
CENPE, CENPA and CDCA8.  Thus, is it possible that IGF-IR normally confers G2/M 
progression and that in combination with docetaxel this leads to mitotic catastrophe.  
However, further intrigue is provided by the finding that BMS-754807 actually inhibits 
AURKA (113), albeit with lower affinity than IGF-IR. It is thus possible that BMS-754807 
and docetaxel synergize due to a concomitant action on the G2M checkpoint. 
 In summary, this preclinical study shows that IGF-IR is active in TNBC and provides 
substantial support and rationale for a clinical trial using BMS-754807 in ER-negative and 
HER2-negative breast cancer. 
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Chapter 4 – Crosstalk between IGF-IR and ErbB2-induced 
tumorigenesis in vivo  
 
4 Rationale 
Both IGF-IR and ErbB2/HER2 play an important role in breast cancer and several 
studies indicate that crosstalk occurs between these two receptors. In breast cancer cells, the 
formation of HER2/IGF-IR heterodimers has been observed (84). While IGF-IR contributes 
to HER2 therapy, both activated EGFR and HER2 are sufficient to cause resistance to anti-
IGF-IR therapy (110, 162). Similar observations were made in the previous chapter 3.  The 
MCF7 breast cancer cell line was sensitive to the IGF-IR inhibitor BMS-754807, whereas 
MCF7 cells overexpressing HER2 are resistant to IGF-IR therapy (Figure 12A).  However, 
the expression of
 
IGF-IR per se does not predict trastuzumab resistance in ErbB2-
overexpressing
 
breast cancer patients (163). More importantly, activated HER2 and IGF-IR 
share common downstream signaling pathways such as the MAPK pathway and PI3K 
pathway. To date, little is known with regards to crosstalk between IGF-IR and HER2 in 
cancer development and cancer progression. Therefore, a better understanding of crosstalk 
between HER2 and IGF-IR during tumorigenesis in vivo is important to increase our 
understanding and provide further insides of ErbB2 and IGF-IR in cancer development and 
progression. 
 
4.1 Results 
4.1.1 CD8-IGF-IR does not alter branching morphogenesis in adult ErbB2 
overexpressing mice  
 The Lee laboratory recently reported the generation of a chimeric and constitutively 
activated IGF-IR consisting of a human CD8α extracellular domain fused to the IGF-IRβ 
subunit.  Constitutive dimerization and activation was used to eliminate any confounding 
effects from ligand and binding protein interactions. Overexpression of the CD8-IGF-IR in 
the mouse mammary gland under the control of an MMTV promoter resulted in mammary 
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tumor formation (44). Similarly, expression of ErbB2 in the mammary gland results in tumor 
formation. To determine whether elevated (MMTV-CD8-IGF-IR) IGF-IR levels modulate 
ErbB2-induced tumorigenesis in vivo we set up the following mouse study: Heterozygous 
MMTV-ErbB2 mice were bred with heterozygous MMTV-CD8-IGF-IR mice to produce four 
cohorts for study – wild type (wt), heterozygous MMTV-ErbB2, heterozygous MMTV-CD8-
IGF-IR, and bigenic heterozygous MMTV-ErbB2/MMTV-CD8-IGF-IR. The day tumors 
were first palpated was recorded and tumors and mammary glands were harvested when they 
reached a tumor volume of 1000mm
3
.  
 We first examined the effect of CD8-IGF-IR and ErbB2 overexpression on normal 
mammary ductal outgrowth in adult transgenic mice (CD8-IGF-IR and ErbB2, respectively) 
and bigenic MMTV-CD8-IGF-IR/ErbB2 mice.  
Mammary gland branching occurs at the terminal end buds (TEBs) and within the 
mammary gland two types of branching patterns can be distinguished. The dichotomous 
branching occurs with an angle of 60 degree, which is also called primary branching. 
Dichotomous branching occurs through ductal elongation filling first the entire fat pat before 
secondary branching occurs. Secondary branches develop from already pre-existing branches 
by side branching of 90 degree (164).  Several studies support the importance of the GH/IGF-
I axis and respective receptors in mammary gland branching. Full differentiation and 
development of the mammary gland depends on a combination of hormones including the 
pituitary hormones (growth hormone and prolactin), the ovarian hormones (estrogen and 
progesterone) and glucocorticoids (165, 166). Growth hormone mediates via growth hormone 
receptor the local production of IGF-I which stimulates duct formation (167). IGF-I causes 
outgrowth of primary branches during development. In addition, evidence also indicates that 
the transmembrane tyrosine kinase and potential EGFR partner ErbB2 influences ductal 
morphogenesis (56). Moreover, genetic studies have shown that gene targeted deletion of 
IGF-I, IGF-IR, or growth hormone receptor, have retarded ductal development (55). Finally, 
any effect on normal development would likely alter subsequent tumorigenesis, thus we felt it 
important to first examine the normal mammary gland. 
 Primary branches as well as secondary side-branches were counted manually in 11 
trangenic MMTV-CD8-IGF-IR, 12 transgenic MMTV-ErbB2 and 19 MMTV-CD8-IGF-
IR/ErbB2 whole mounts, which is summarized in figure 20 and table 5. MMTV-CD8-IGF-IR 
and MMTV-ErbB2 transgenic mice developed 40% and 46% primary branches, respectively, 
whereas bigenic mice developed 42% primary ducts (Figure 20A). Representative whole 
mounts showed no difference in the ductal morphogenesis (Figure 20B). We observed no 
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significant difference in secondary side branching between transgenic and bigenic mice with 
60% and 54% of ductal outgrowth in MMTV-CD8-IGF-IR and MMTV-ErbB2 transgenic 
mice, respectively, compared to 58% secondary ductal outgrowth in bigenic mice (Figure 
20A). Two recent publications reported that ductal development is impaired in mice 
overexpressing the IGF-IR. The elongation of the ductal structure was delayed and in some 
cases remained behind the lymph node (44, 45). However, by the time we harvested the mice, 
ducts completely filled the fat pad and we didn‘t observe a difference in branching or alveolar 
development. Thus, we concluded that CD8-IGF-IR does not alter branching morphogenesis 
in adult mature ErbB2 overexpressing mice.   
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Figure 20. CD8-IGF-IR and ErbB2 have no effect on normal ductal development at time of tumor 
harvest  
A. Quantification of manually counted mammary primary and secondary branch points in whole 
mounts of adult transgenic and bigenic mice. B. Representative whole mounts of mammary glands 
from adult CD8-IGF-IR transgenic mice, ErbB2 transgenic mice, ErbB2/CD8-IGF-IR bigenic mice and 
wild type (wt) FVB/N mice. Pictures were taken at 2x magnification. 
 
Table 5. Summary of whole mount analysis and primary and secondary branch points 
Primary and secondary branches were counted manually in representative whole mount pictures taken 
at 4x magnification  
  Number of whole mounts Primary (%) 90˚ Secondary (%) 60˚  Total 
CD8-IGF-IR 11 
13 ± 2.58 18.36± 2.0 
31.36± 3.32 
40% 60% 
ErbB2 12 
15.91 ± 2.24 17.08 ± 1.18 
33 ± 2.15 
46% 54% 
Bigenic 19 
13.68 ± 1.39 19 ± 1.88 
32.68 ± 2.53 
42% 58% 
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4.1.2 Bigenic mice developed tumors significantly faster than either of the 
transgenic mice alone 
 Given that there was no major difference in normal mammary gland development in 
transgenic versus bigenic mice, we next compared the median time to tumor formation 
(MMTF) by Kaplan-Meier plots in the same sets of mice. Kaplan-Meier tumor curve 
illustrates the percent of animals without mammary gland tumors versus the day tumors were 
first palpated. We determined the penetrance of mammary tumor formation using palpation to 
measure the MMTF in transgenic and bigenic mice. MMTV-CD8-IGF-IR transgenic female 
mice showed palpable tumors beginning at 103 days and with a MMTF of 10.4 months. 
MMTV-ErbB2 transgenic mice developed tumors as early as 201 days with a MTTF of 9.6 
months. Overall, comparison of survival curves between CD8-IGF-IR and ErbB2 by log rank 
test showed no significant difference with a p-value of 0.302. However, bigenic mice 
(MMTV-CD8-IGF-IR/ErbB2) showed a more rapid tumor formation developing tumors as 
early as 78 days of age with a MMTF of 7.2 months (Figure 21 and Table 6). Bigenic mice 
developed tumors significantly faster (MMTF = 7.2 months) than CD8-IGF-IR transgenic 
mice (MMTF = 10.5 months; p-value < 0.05). Moreover, bigenic tumors appeared more 
rapidly compared to ErbB2 overexpressing tumors (MMTF = 9.6; p-value < 0.05). Table 6 
illustrates the percent of animals without mammary gland tumors versus the day tumors were 
first palpated. In each group more than 20 female mice developed mammary tumors. 66% 
(22/33) of females with CD8-IGF-IR overexpression, 96% (28/29) of females in the ErbbB2 
group and 93% (40/43) of bigenic mice developed tumors. When tumors reached 
approximately 1000mm
3
, they were harvested and a representative part was cut for 
histological analysis. At the time of harvest, we observed macro-metastasis in all groups.    
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Kaplan-Meier tumor curve illustrating the percent of animals without mammary gland 
tumors vs. the day tumors were first palpated. Bigenic mice initiated mammary 
tumorigenesis significantly faster than either trangene alone. Table 1. 66% of femals with 
CD8-IGF-IR overexpression, 96% of the females in the ErbB2  group and 93% of the 
bigenic mice got tumors. Bigenic mice developed tumors significantly faster than either 
of the transgenic mice alone with a mean time to tumor formation (MMTF) of 218 days 
compared to CD8-IGF-IR (MMTF = 314 days, p = 0.0173) and to ErbB2 (MMTF = 288 
days, p =  0.0219). Wt = wild type (FVB/N)
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Figure 21. Bigenic mice initiate mammary tumorigenesis significantly faster than either 
transgene alone 
Kaplan-Meier tumor curve illustrates the percent of animals without mammary gland tumors versus the 
day tumors were first pal ated comparing MMTV-CD8-IGF-IR transgenic mice to MMTV-ErbB2 
transgenic mice to bigenic MMTV-CD8-IGF-IR/ErbB2 mice. Bigenic mice initiated mammary 
tumorigenesis at a faster rate than MMTV-CD8-IGF-IR and MMTV-ErbB2 transgenic mice alone. 
 
  
Wt MMTV-CD8-IGF-IR MMTV-ErbB2 
MMTV-CD8-IGF-IR 
/ErbB2 
Number of tumors 0 (33) 22 (33) 28 (29) 40 (43) 
Lung metastasis No Yes Yes Yes 
Mean Time to Tumor 
Formation (MTTF) N/A 
314 days 
(10.4 month) 
288 days 
(9.6 month) 
218 days 
(7.2 months) 
 
Table 6. Comparing Groups: End of Tumor Study Summary 
66% (22/33) of females with CD8-IGF-IR overexpression, 96% (28/29) of the females in the ErbB2 
group and 93% (40/43) of the bigenic mice developed tumors. Bigenic mice developed tumors 
significantly faster than either of the transgenic mice alone with a mean time to tumor formation 
(MMTF) of 218 days compared to MMTV-CD8-IGF-IR (MMTF = 314 days, p-value < 0.05) and to 
MMTV-ErbB2 (MMTF = 288 days, p-value <0.05). Wt = wild type (FVB/N) 
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4.1.3 Bigenic tumors show a time-dependent difference in tumor histology 
We next examined the histology of CD8-IGF-IR and ErbB2 overexpressing tumors 
and compared them with mammary tumors overexpressing both oncogenes. Histological 
analysis was performed by H&E staining of 20 MMTV-CD8-IGF-IR mammary tumors, 22 
MMTV-ErbB2 mammary tumors and 34 bigenic MMTV-CD8-IGF-IR/ErbB2 mammary 
tumors.  
MMTV-ErBB2 tumors were predominantly adenocarcinoma (Figure 22 A-D), which 
lack myoepithelium, keratinization or squamous metaplasia. Some of the ErbB2 tumors had 
dense stroma with lymphocytic infiltrates. Only two tumors displayed squamous carcinomas.  
 In contrast to ErbB2 tumors, which are predominantly adenocarcinoma, MMTV-CD8-
IGF-IR induced tumors exhibited only a few solid nodular adenocarcinomas. Most of the 
CD8-IGF-IR transgenic tumors had distinguishing shaft-like neoplastic ducts consisting of 
keratin swirls. Other tumors were highly differentiated characterized by ductal architectures 
or less-differentiated tumors without ductal structure. Highly-differentiated tumors display 
extensive squamous differentiation, dense stroma with lymphocytic infiltrates, keratinization, 
and/or glandular acini formation with lactating properties (Figure 22 E-H).  
 We found that MMTV-CD8-IGF-IR/ErbB2 bigenic tumors show a time-dependent 
difference in tumor histology. We separated tumors into two groups based on the mean time 
to tumor formation of 218 days. Tumors that developed faster than the MMTF of 218 days 
were predominantly differentiated tumors displaying squamous differentiation and stromal 
infiltration, other tumors showed characteristics of a papillary tumor with defined cords of 
branched ductal architecture or glandular acini formation with lactation (Figure 22 I-K). 
Tumors of this group displayed similar tumor histology to CD8-IGF-IR tumors (Table 7). In 
contrast to this group, bigenic mice that developed tumors later than the mean time to tumor 
formation of 218 days showed undifferentiated solid nodular mammary tumors with sparse 
stroma being absent of myoepithelial cells and squamous metaplasia. Interestingly, these 
tumors had a similar histology to ErbB2 overexpression tumors (Figure 22L and Table 7). 
 In conclusion, tumors with overexpression of CD8-IGF-IR are highly differentiated 
whereas tumors overexpressing ErbB2 are predominantly undifferentiated. Bigenic mice 
showed a phenotype resembling both oncogenes. Tumors that appeared rapidly are highly 
differentiated, whereas tumors that developed with a long latency are undifferentiated.  
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MMTF < 218 days MMTF > 218 days
Representative H&E staining of mammary tumors promoted by ErbB2, CD8-
IGF-IR and bigenic (ErbB2/CD8-IGF-IR) overexpression. Histological analysis 
showed that ErBB2 tumors were predominantly adenocarcinoma, CD8-IGF-IR 
tumors were mixed adenosquamous carcinoma, and interestingly, bigenic 
tumors showed a phenotype resembling both oncogenes. Magnification: 20x 
E
A B C D
F G H
I J K L
MMTV-
ErbB2
MMTV-
CD8-IGF-IR
MMTV-
CD8-IGF-IR/      
ErbB2
 
Figure 22. Representative H&E images highlight the characteristics of mammary tumors 
promoted by ErbB2, CD8-IGF-IR and both (ErbB2/CD8-IGF-IR) oncogenes 
A to D. Four different ErbB2 undifferentiated solid nodular mammary tumor with sparse stroma and 
lack of myoepithelial ells and squamous metaplasia. E. CD8-IGF-IR mamm ry tumor with branched 
ductal architecture and keratin swirls. F. Highly differentiated CD8-IGF-IR tumor with dense stroma 
containing lymphocytic infiltrates. G. CD8-IGF-IR mammary tumor with squamous metaplasia and 
keratin swirls. H. CD8-IGF-IR tumor defined by glandular acinus formation with lactation. I-K. Bigenic 
tumors show characteristics similar to CD8-IGF-IR tumors where cells undergo squamous 
differentiation, stromal infiltration and glandular acinus formation. L. Bigenic undifferentiated solid 
nodular mammary tumor similar to mammary tumors promoted by ErbB2. Representative pictures 
were taken at 20x magnification. 
 
Table 7. Histologies of bigenic tumors 
  MMTF < 218 days MMTF > 218 days 
Histology of 
Bigenic tumors 
 Keratinization,  
 Squamous differentiation,  
 similar to CD8-IGF-IR 
overexpressing tumors  
 Undifferentiated,  
 predominantly adenocarcinoma,  
 less squamous differentiation,  
 similar to ErbB2 overexpressing tumors 
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4.1.4 Expression of IGF-IR in the mammary gland of transgenic mice may 
results in expansion of myoepithelial cells and progenitor cells 
Overexpression of CD8-IGF-IR resulted in tumors with various histological 
phenotypes. Previous studies have shown that tumor phenotype can be predicted by the 
transgene that is overexpressed (168). Consistent with this, tumors that overexpress CD8-IGF-
IR were similar to tumors generated by overexpression of activators of the canonical 
Wnt/Beta-Catenin signaling pathway (169, 170), which often show multiple differentiated cell 
lineages. To further characterize the spectrum of tumors observed in transgenic and bigenic 
mice immunohistochemistry was performed for lineage specific markers. Breast cancers are 
thought to arise from multi potent stem cell/progenitor cell populations (171). Stem cells 
differentiate into progenitor cells which can be stained with cytokeratin 6 (CK6). Cytokeratin 
6 has been identified as marker of early mammary gland development and has been proposed 
to be a marker of mammary gland progenitor cells (172). Mammary progenitor cells then 
differentiate into the two cell types of the mammary duct, luminal and myoepithelial cells. 
Luminal epithelial cells can be stained with cytokeratin 8 (CK8) whereas CK14 is typically 
associated with basal myoepithelial cells surrounding the epithelial cells (171). In normal 
ducts of transgenic and bigenic mice, luminal epithelial cells stain positive for CK8 (Figure 23 
A - C). In the normal mammary duct CK14 stained the myoepithelial cells between the 
luminal epithelial cells and the basement membrane (Figure 23, D - F). The progenitor cell 
marker CK6 was rarely expressed in mature mammary gland (Figure 23, G - I) of transgenic 
and bigenic mice, which is consistent with the literature (172-174). 
Tumors arising from MMTV-Erbb2, MMTV-CD8-IGF-IR, or both oncogenes stained 
positive for CK8 (Figure 24, A - C). Particularly tumors with solid sheet of cells, such as 
ErbB2 tumors, stained positive for CK8 but were generally negative for CK14 and CK6. 
Oncogenes like ErbB2/Neu or Ras appear to develop tumors that arise from more 
differentiated mammary epithelial cells. They transform cells that are more developmentally 
advanced or drive cells to a more mature epithelial character during oncogenesis (175). 
ErbB2/Neu or PyMT antigen pathways seem to act on progenitor cells committed to the 
ductal epithelial lineage resulting in poorly differentiated tumors with specific staining for the 
luminal epithelial markers CK8 (Figure 24).  
 As shown in Figure 22 tumors driven by CD8-IGF-IR are highly differentiated. As 
illustrated in Figure 24, highly differentiated CD8-IGF-IR tumors stained positive for the 
luminal epithelial marker CK8 (Figure 24B) and the myoepithelial marker CK14 (Figure 
24E). Likewise, differentiated bigenic tumors were positive for the same epithelial markers 
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CK8 and CK14 (Figure 24 C and F). Positive CK14 staining in tumors likely represents 
expansion of the myoepithelial cell population within the tumor. In contrast, adenocarcinomas 
arising in bigenic mice were only CK8 positive (data not shown) and didn‘t express CK14 and 
CK6 similar to ErbB2 tumors. In addition, highly differentiated CD8-IGF-IR and bigenic 
tumors stained positive for the mammary progenitor cell marker CK6 (Figure 24 H and I). 
This staining represents an expansion of the progenitor cell population, as normal mammary 
glands expressed very few CK6-positive cells (Figure 23 G – I). This observation is consistent 
with reports in the literature (175). Tumors arising from stem or progenitor cells show a 
mixed lineage differentiation. For example, the Wnt/B-Catenin pathways act directly on either 
self-renewing progenitor or self-renewing stem cells leading to the expansion of myoepithelial 
and luminal epithelial cell populations in the tumor. This results in highly differentiated 
tumors, containing markers for progenitors as well as both epithelial lineages (175). 
CK8
CK14
CK6
Normal  duct
A. Immunostaining of normal mammary gland and tumors was performed with 
antibodies against keratin 14 (K14), keratin 8 (K8) and keratin K6 (K6) to assess 
the cells or origin and their identity in the tumor. All tumors were stained for ErbB2 
and IGF-IR. Representative pictures of normal mammary glands and tumors of 
transgenic mice were taken at 40x magnification. B. All bigenic tumors were 
evaluated for ErbB2 overexpression and summarized in table 2. Representative 
pictures were taken at 40x magnification.
MMTV-ErbB2 MMTV-CD8-IGF-IR MMTV-CD8-IGF-IR/ErbB2
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Figure 23. Expression of lineage specific markers in normal mammary glands of transgenic 
and bigenic mice 
To assess the cells or origin and their identity in the mammary gland immun staining of normal 
mammary gl nds was performed with antibodies against the myoepithelial marker CK8 (A – C), the 
luminal marker CK14 (D – F) and progenitor marker CK6 (G – I). Representative pictures of normal 
mammary ducts of transgenic mice were taken at 40x magnification.  
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Figure 24. Expression of luminal and basal cytokeratins in ErbB2 and IGF-IR tumors and 
bigenic (CD8-IGF-IR/ErbB2) tumors 
MMTV-CD8-IGF-IR and MMTV-CD8-IGF-IR/ErbB2 tumors contain luminal and myoepithelial cells and 
express markers of mammary progenitor cells. A – C. Representative pictures for the luminal epithelial 
marker CK8 in tumors from transgenic and bigenic mice. D – F. Staining of myoepithelial cells with an 
antibody against CK14. G – I.  Anti-CK6 IHC for detection of progenitor cells. Pictures were taken at 
20x magnification. 
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4.1.5 Different tumor histology in the bigenic group might be the result of 
time dependent expression of IGF-IR and ErbB2 
We next used IHC to determine the localization of transgene expression in the 
mammary gland and tumors of transgenic and bigenic mice. Therefore, we stained all 
mammary glands and tumors with antibodies against IGF-IR and ErbB2. In mice 
overexpressing CD8-IGF-IR, normal mammary ducts stained positive for IGF-IR whereas 
staining was absent in mammary glands overexpressing ErbB2 (Figure 25A and B). On the 
other hand, mammary glands with ErbB2 overexpression displayed intense ErbB2 staining 
which was absent in CD8-IGF-IR overexpressing glands (Figure 25D and E). As expected in 
bigenic mammary glands we detected positive ErbB2 and IGF-IR staining (Figure 25C and 
F). Tumors were cut in serial sections to determine IGF-IR and ErbB2 expression. Consistent 
with the staining pattern in the normal mammary gland, CD8-IGF-IR tumors were highly 
positive for IGF-IR and lacked ErbB2 staining (Figure 25H and K). In contrast, ErbB2 tumors 
showed intense staining of ErbB2 but not IGF-IR (Figure 25G and J). Bigenic tumors 
displayed a unique pattern of staining. Most tumors stained positive for IGF-IR as determined 
by IHC (Figure 25I). However, tumors that developed earlier than the mean time to tumor 
formation of 218 days showed intense IGF-IR staining, but only 16% of these tumors were 
positive for ErbB2 (Table 8, Figure 25L and M). In contrast, in tumors that formed after the 
MMTF of 218 days, 63% of bigenic tumors overexpress ErbB2 with less intense IGF-IR 
staining (Table 8, Figure 25L and M). We concluded that the different tumor histology 
(Figure 22) observed in bigenic mice might be the result of time dependent expression of IGF-
IR and ErbB2.   
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Figure 25. IGF-IR and ErbB2 expression in mammary glands and tumors.  
Immunohistochemistry was performed with antibodies against ErbB2 and IGF-IR on serial sections to 
determine the localization of transgene expression in the mammary gland and tumors of transgenic 
and bigenic mice. Representative pictures of normal mammary glands and tumors were taken at 40x 
magnification.  
Table 8. Summary of differential ErbB2 expression in bigenic tumors 
  Differential ErbB2 expression in bigenic tumors 
   MMTF < 218 days MMTF > 218 days 
ErbB2 status 
16% ErbB2 + 
47% ErbB2 – 
37% N/A 
63% ErbB2+ 
19% ErbB2 – 
19% N/A 
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4.1.6 Development of a new model to test whether CD8-IGF-IR and ErbB2 
transform different progenitor cell types 
 Evidence showed that bigenic tumors could be categorized into two different groups 
based on their pathology, which might rely on the expression pattern of IGF-IR and ErbB2 in 
these tumors. One group of tumors with tumor formation of less than the MMTF of 218 days 
contained squamous and myoepithelial components, as well as stoma with significant 
lymphocytic infiltration, and keratinization. Most likely, these tumors are driven by IGF-IR 
expression resulting in expansion of myoepithelial cells and progenitor cells in the tumor. The 
other group of tumors with a MMTF of more than 218 days, were solid undifferentiated 
adenocarcinomas predominantly driven by ErbB2 transgene expression. Since there were only 
two tumors with both strong positive IGF-IR and strong ErbB2 expression we hypothesized 
that IGF-IR transforms a different progenitor cell type than ErbB2.  
 Conventional germ-line mouse models are limited for understanding the initiation and 
progression of breast cancer because most human cancers evolve from genetic changes in a 
few cells of a normal mammary duct. Therefore, we used the RCAS-TVA based gene 
delivery system to study oncogenesis in the mouse. This alternative strategy uses an avian 
retroviral vector RCAS to introduce the oncogene CD8-IGF-IR and ErbB2 into a subset of 
somatic breast cells. In this case, we introduced CD8-IGF-IR or ErbB2 into MMTV-TVA 
mice. Ectopic expression of the TVA receptor under the control of the MMTV promoter 
allows genes of interest to be introduced into both progenitor cells and more differentiated 
cells of the mammary gland. Thus, this allows infection of CD8-IGF-IR or ErB2 in several 
cell lineages. Our collaborator Prof. Dr.Yi Li has successfully infected mammary epithelial 
cells with ErbB2, which resulted in mammary lesions and tumor formation. Therefore, we 
focused on introducing RCAS-CD8-IGF-IR into mammary glands. Once we successfully 
generated lesions and tumors by CD8-IGF-IR we compared the histology of CD8-IGF-IR 
induced lesions and tumors to ErbB2 lesions and tumors at the same time point after infection. 
  
4.1.7 RCAS-CD8-IGF-IR effectively infects DF1 chicken cells and produce 
high virus titer 
 RCAS-CD8-IGF-IR was generated by subcloning the CD8-IGF-IR into the RCAS 
vector. We screened several of these clones for activity of the IGF-IR by immunoblotting. 
CD8-IGF-IR has a size of 75kDa and can be distinguished from endogenous IGF-IR with a 
size of 95kDa. Stably transfected MCF10A with CD8-IGF-IR (MCF10A-CD8-IGF-IR) as 
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Clone 157 for making virus
well as transfected pcDNA3.1-CD8-IGF-IR in 293T cells served as positive control. Figure 
26 showed that all clones expressed various levels of IGF-IR and had different levels of 
activated phosphorylated pY-IGF-IR.  
  
Figure 26. Screening RCAS-CD8-
IGF-IR clones 
Different RCAS-CD8-IGF-IR clones 
(CL48, 58, 61, 115, 157, 170) were 
transfected into 293T cells. Stably 
transfected CD8-IGF-IR into 
MCF10A cells serve as positive 
control. 48 hours after transfection 
clones were screened for 
expression of activated IGF-IR by 
immunoblot using antibodies against 
p-Y-IGF-IR and total IGF-IR. 
 
We chose clone 157 which when transfected showed the highest activation of the IGF-
IR. We next transfected DF1 cells (chicken cells that are susceptible to infection with RCAS) 
with RCAS-CD8-IGF-IR to determine the transfection and infection efficiency. 48 hours after 
transfection, DF1 cells were analyzed by immunofluorescence and immunoblotting of CD8-
IGF-IR expression. Immunofluorescence was performed with a CD8 conjugated PE antibody 
to rule out endogenous IGF-IR. CD8-IGF-IR-MCF10A cells were used as positive control. 
After 48 hours of transfection DF1 cells expressed CD8-IGF-IR as shown by positive CD8-
PE staining by immunofluorescence whereas MCF7B cells which express high levels of 
endogenous IGF-IR are negative for CD8-PE (Figure 27A). In addition, immunoblot 
confirmed activation of CD8-IGF-IR in DF1 cells (Figure 27B). Untransfected DF1 cells as 
well as transfected DF1 cells with an RCAS-GFP control vector showed low levels to absent 
levels of endogenous activated IGF-IR. DF1 cells transfected with RCAS-CD8-IGF-IR 
showed strong IGF-IR activation. To document that DF1 cells are susceptible to RCAS-CD8-
IGF-IR infection, media from transfected DF1 cells containing viable competent virus was 
used to infect freshly plated DF1 cells. Five days after infection, DF1 cells were analyzed by 
FACS analysis. Figure 27C showed that 82.7% of DF1 cells were infected by RCAS-CD8-
IGF-IR compared to uninfected DF1 cells. After several passages, 100% infection was 
achieved. These producer cells were used to generate virus as described in materials and 
methods. Viral titer was determined by adding serial diluted viral stock to DF1 cells (Figure 
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27D). Immunoblot analysis showed a virus titer of 10
9
 was able to express activated CD8-
IGF-IR.  
 In conclusion, we created a RCAS-CD8-IGF-IR virus that expresses activated IGF-IR 
in DF1 cells, which successfully infects DF1 cells and produce a high virus titer.  
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Figure 27. Transfected DF1 cells produce viable and infectious RCAS-CD8-IGF-IR virus.  
A and B. 48 hours after transfection with RCAS-CD8-IGF-IR, DF1 cells were analyzed by 
immunofluorescence with a CD8-PE specific antibody or analyzed by immunoblot. C. Media containing 
virus was used to infect DF1 cells. Infected DF1 cells were analyzed by FACS 5 days after infection. 
D. Virus was serial diluted from 10
-5
 – 10
-10
 and added to freshly plated DF1 cells. After 5 days 
incubation, viral titer was determined by immunoblot analysis with antibodies against pY-IGF-IR and 
total IGF-IR. Endogenous IGF-IR has a size of 95 kDa whereas CD8-IGF-IR is smaller with 75kDa.  
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4.1.8 RCAS-CD8-IGF-IR infects mammary epithelial cells expressing TVA 
five days after infection 
 To document that TVA positive mammary epithelial cells are susceptible to infection 
by RCAS virus in vivo, we exposed them to RCAS-CD8-IGF-IR virus via intraductal 
injection (176) of MMTV-TVA female mice at 9 weeks of age. At this stage, female mice 
have finished puberty and a fully developed mammary duct is susceptible to infection. 
Intraducatal injection was performed on three glands in each MMTV-TVA mice, the other 
glands were used as negative controls. Mammary glands were harvested five days after 
injection to ensure adequate time for virus entry, synthesis, integration of viral DNA into the 
genome, and expression of CD8-IGF-IR from the provirus. We harvested all mammary 
glands, isolated the mammary epithelial cells, and examined them for CD8-IGF-IR expression 
using flow cytometry analysis with a CD8-PE antibody. In addition, we used wild type (wt) 
mammary glands from FVB/N female mice as negative control, and transgenic mammary 
glands and tumors as positive control for CD8-IGF-IR (MMTV-CD8-IGF-IR) expression. 
Single mammary epithelial cell suspensions were made from five pooled infected, wild type, 
or transgenic mammary glands, respectively, or from each tumor of CD8-IGF-IR mice. We 
determined that 3.3% (Figure 28B) of the mammary epithelial cells expressed the transgene 
CD8-IGF-IR whereas only 2% and 1.1% of CD8-IGF-IR transgenic tumors, respectively, 
expressed CD8-IGF-IR (Figure 28 D and E, Table 9). We expected to detect a high number of 
CD8-IGF-IR positive cells in the tumor, however, we used two frozen tumors for this analysis 
and when thawed, many cells died and were excluded by CytoxRed dye. This may account in 
part for the low level of CD8-IGF-IR positive cells in the tumor. As expected, no CD8-IGF-
IR expression was observed in wild type mammary glands (Figure 28A). Five control or 
infected mammary glands of MMTV-TVA mice were pooled together, respectively, to make 
a single cell suspension. We determined that 0.7-1.1% mammary epithelial cells were infected 
by RCAS-CD8-IGF-IR (Figure 28 G and H, Table 9) whereas uninfected mammary glands 
showed no expression of CD8-IGF-IR (Figure 28 F). In conclusion, RCAS-CD8-IGF-IR is 
able to infect MMTV-TVA mice in vivo.  
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Figure 28. RCAS-CD8-IGF-IR infects mammary epithelial cells expressing TVA 5 days after 
infection   
10µl of RCAS-CD8-IGF-IR was injected via the nipple duct into the left No 2-4 mammary glands in 9 
week-old MMTV-TVA female mice. The infected mammary glands were analyzed after 5 days of 
infection for CD8-IGF-IR expression via FACS. FACS analysis was performed using a PE-conjugated 
CD8 antibody. Uninfected mammary glands of MMTV-TVA females were used as negative control. 
Transgenic MMTV-CD8-IGF-IR mammary glands and tumors were used as positive controls. Mg = 
Mammary Gland; PE= CD8-PE, PI = CytoxRed, Wt = wild Type; inf. = infected  
 
Table 9. Summary of FACS analysis  
Table shows the percentage of positive CD8-IGF-IR cells in mammary glands and tumors of 
transgenic females and the percentage of infected mammary epithelial cells expressing CD8-IGF-IR. 
  % positive CD8-IGF-IR cells (CD8-PE) 
Wt Mg  0 
CD8-IGF-IR transgenic Mg 3.3 
CD8-IGF-IR transgenic tumor 2.0 
CD8-IGF-IR transgenic tumor 1.1 
MMTV-TVA non infected 0 
MMTV-TVA infected with RCAS-CD8-IGF-IR 1.1 
MMTV-TVA infected with RCAS-CD8-IGF-IR 0.7 
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4.1.9 Infection of mammary glands of MMTV-TVA transgenic mice with   
RCAS-CD8-IGF-IR induces hyperplastic lesions 
To test the response of normal mammary epithelial cells to oncogenes delivered by 
intraductal infection, we injected RCAS-CD8-IGF-IR virus via the nipple duct into three 
glands in each of 20 MMTV-TVA mice at the age of 9-12 weeks. Because IGF-IR is 
oncogenic, we expected that tumors would result from infection of a relatively small number 
of cells. We collected mammary glands from four mice after 2 weeks and from four mice after 
6 weeks of infection to analyze early response of the CD8-IGF-IR oncogene on mammary 
epithelial cells. All other 12 mice were left to examine tumor formation. Mammary glands 
were prepared for paraffin sections and whole mounts for detection of lesions. Figure 29A 
shows a representative normal duct of MMTV-TVA female mouse harvested at the same time 
as infected mammary glands. After 14 days of injection, bridging of cells were readily 
detectable in H&E-stained sections (Figure 29 E) and after 6 weeks of infection many ducts 
showed hyperplastic lesions with complete ductal filling (Figure 29 I). Immunohistochemical 
staining was used to examine the hyperplastic lesions for expression of CD8-IGF-IR. CD8-
IGF-IR expression was detected in lesions of infected mice but not in mammary glands of 
control mice (Figure 29B, 28F, 28 J). Furthermore, CD8-IGF-IR expression expanded after 6 
weeks of infection compared to 2 weeks of infection. This expansion is likely due to the small 
number of infected cells at 2 weeks having a proliferative advantage and growing out as a 
clonally infected cell population. 
CK14 is typically associated with basal myoepithelial cells surrounding the epithelial 
cells (171). It was previously shown that IGF-IR is required for proliferation of myoepithelial 
progenitor cells. In contrast, genetic deletion of IGF-IR had no effect on growth of luminal 
progenitors (58, 60). Myoepithelial cells direct luminal polarization, and inhibit deregulated 
luminal cell growth (61, 62). Therefore, IGF could be important for myoepithelial cell 
survival. In addition, overexpression of IGF-IR in the mammary gland of MMTV-CD8-IGF-
IR results in expansion of myoepithelial cells expressing CK14. Therefore, we next examined 
the expression pattern of CK14 in lesions caused by RCAS-CD8-IGF-IR in MMTV-TVA 
mice. Figure 29C shows myoepithelial cells stained with CK14 surrounding luminal epithelial 
cells. However, after 2 weeks of infection, the myoepithelial cell layer disrupts (Figure 29G) 
and after 6 weeks of infection, myoepithelial cells were observed to be in the lumen of the 
duct (Figure 29K). The development of lesions by RCAS-CD8-IGF-IR is highlighted by 
whole mount analysis in which ducts expand and form nodules in ductal branches (Figure 29 
H and L) but not in uninfected mammary gland (Figure 29D). In summary, RCAS-CD8-IGF-
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IR induces hyperplastic lesions in MMTV-TVA mammary glands. This is accompanied by 
expansion of CD8-IGF-IR expression and disruption of myoepithelial cell layer as indicated 
by CK14.    
To date we have not determined whether RCAS-CD8-IGF-IR causes mammary 
tumors in MMTV-TVA mice. Mice didn‘t develop tumors within 6 months after infection. 
Therefore, at the time of writing this dissertation, we have not yet determined whether IGF-IR 
and ErbB2 transform different progenitor cells, although infection of Erbb2 into mammary 
glands doesn‘t result in expansion of CK14, which is highly suggestive of IGF-IR and ErbB2 
having different mechanisms of action.  
 
 
13 week old mice were injected intraductally with RCAS-CD8-IGF-IR virus and harvested 2 
and 6 weeks after infection. Representative H&E staining show hyperplasia in the duct after 
6 weeks of infection. Immunostaining was performed with antibodies against IGF-IR and 
K14. K6 and K8 immunostaining is still under study.  Magnification 40x. Representative 
whole mount pictures were taken at 4x magnification. 
Non infected  
mammary glands
H&E IGF-IR K14
2 weeks           
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6 weeks          
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Whole mount
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Figure 29. RCAS-CD8-IGF-IR is detected 2 weeks and 6 weeks of infection 
9-12 week old female MMTV-TVA mice were injected intraductally with RCAS-CD8-IGF-IR virus and 
harvested 2 and 6 weeks after infection. Histology was analyzed by H&E staining. Representative 
H&E staining show hyperplasia in the duct after 6 weeks of infection. Immunostaining was performed 
with antibodies against IGF-IR and CK14. Pictures were taken at 40x magnification. Representative 
whole mount pictures were taken at 4x magnification.  
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4.2 Summary and Discussion 
In this study, we show that bigenic mice developed tumors significantly faster 
compared to either of the transgenic mice alone. Histological analysis showed that ErBB2 
tumors were predominantly adenocarcinoma, CD8-IGF-IR tumors were mixed 
adenosquamous carcinoma, and interestingly, bigenic tumors showed a phenotype resembling 
both oncogenes. Mammary tumors arising from overexpression of CD8-IGF-IR in transgenic 
as well as in bigenic mice contained CK14 and CK6 positive cells indicating that expression 
of IGF-IR in the mammary gland of transgenic mice may results in expansion of 
myoepithelial cells expressing CK14 and progenitor cells expressing CK6 thus reflecting the 
mixed cell lineage differentiation in the tumor. We hypothesized that the difference in tumor 
histology may relate to the transformation of different progenitor cell types by IGF-IR and 
ErbB2. To investigate this, we have developed a mouse modeling system using avian RCAS 
retrovirus as vehicle to deliver CD8-IGF-IR or ErbB2 into transgenic mice expressing the 
avian receptor TVA under the control of a MMTV promoter. This allows retroviral infection 
of specific mammary cell types in vivo. Mammary intraductal injection of RCAS-CD8-IGF-
IR into mice has shown expression of CD8-IGF-IR. After six weeks, CD8-IGF-IR caused 
hyperplastic lesions in MMTV-TVA mice, however up to date we have not detected tumors 
arising from CD8-IGF-IR overexpression.  
The rapid mammary tumorigenesis in bigenic mice overexpressing CD8-IGF-IR and 
ErbB2 compared to either of the transgenes alone is intriguing, given that IGF-IR and ErbB2 
crosstalk has not previously been observed in vivo in mice overexpressing both oncogenes. 
However, the rapid tumorigenesis in bigenic tumors showed a time-dependent difference in 
tumor histology. Tumors that appeared rapidly were highly differentiated whereas tumors that 
developed with a long latency were undifferentiated. This was accompanied by a time-
dependent expression of IGF-IR and ErbB2. Bigenic differentiated tumors are dominated by 
overexpression of IGF-IR whereas undifferentiated tumor showed a stronger ErbB2 staining. 
It is possible that the lack of co-expression of ErbB2 and IGF-IR in many tumors actually 
reduced the impact of the intercross. If tumors expressing only a single transgene were 
eliminated, the co-expression of both oncogenes would be reflected and that would greatly 
enhance tumorigenesis and may show a cooperative effect. 
 Furthermore, these observations might suggest that IGF-IR and ErbB2 do not 
physically cooperate in the process of tumorigenesis as many tumors arose expressing only on 
oncogene. In contrast to this, studies of crosstalk between IGF-IR and ErbB2 have been 
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mainly studied in vitro in breast cancer cell lines (17, 83, 162) in which IGF-IR and ErbB2 
expression is noted or modulated in a single cell lines. In these systems, IGF-IR signaling has 
been associated with trastuzumab resistance. In trastuzumab resistant cells, IGF-IR and HER2 
physically interact by heterodimerization but not in parental, trastuzumab sensitive cells (81). 
Only one study examined the crosstalk between IGF-IR and ErbB2 in vivo (84). In this study, 
IGF-IR was required to activate ErbB2. Interestingly, blocking of ErbB2 did not alter IGF-IR 
activation suggesting a hierarchical interaction between IGF-IR and ErbB2.  
On the other hand, a faster tumor rate in bigenic mice suggests that crosstalk occurs 
between IGF-IR and ErbB2. IGF-IR and ErbB2 share some of the same downstream signaling 
targets. Both receptors activate downstream signaling intermediates such as PI3K/AKT or 
ERK1/2. In addition, IGFs are able to directly phosphorylate ErbBs (106). In addition, a 
recent study comparing genes regulated by growth factors (IGF-I, insulin, EGF and heregulin) 
in MCF7 cells showed that there was a highly significant overlap (correlation coefficient 0.6) 
(143), consistent with highly redundant nature of growth factor downstream signaling (e.g. 
PI3K, ERK1/2 etc). Further comprehensive studies are required to analyze whether IGF-IR 
and ErbB2 physically interact and which downstream signaling pathways are activated by 
IGF-IR, ErbB2 and in mice overexpressing both IGF-IR and ErbB2.  
 Mouse mammary tumor pathology can be used to classify tumors according to the 
oncogenic pathways that have been activated (168). Tumors arising from ErbB2/ras pathway 
oncogenes form solid nodular tumors lacking myoepithelial cells, whereas Wnt pathway 
oncogenes form tumors with squamous differentiation, myoepithelial components and 
lymphocytic infiltration (177). It has been hypothesized that this difference in tumor 
pathology is caused by oncogenes transforming different progenitor cell types. ErbB2 is 
thought to transform progenitor cells that are committed to the luminal epithelial lineage, 
whereas Wnt transforms early progenitor cells that still contain bipotent differentiation 
capability (173, 175). Therefore, cellular heterogeneity within a tumor can be indicative of 
continual differentiation of transformed stem cells. Characterization of tumors overexpressing 
CD8-IGF-IR revealed similar pathologies to those of Wnt-activated tumors in which tumors 
contain both luminal and myoepithelial cells, squamous differentiation and expansion of CK6 
positive cells. Interestingly, we also reported on the development of mammary tumors in 
transgenic mice that overexpress IRS1 and IRS2 (MMTV-HA-IRS1, MMTV-HA-IRS2) 
which resemble the same phenotype as tumor overexpressing CD8-IGF-IR (178). Consistent 
with our mouse model, mammary tumors arising from an inducible overexpression of wild-
type IGF-IR, in the mouse mammary gland also revealed a propensity for high differentiation, 
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squamous differentiation and keratinization (45). Similar observations were made in tumors 
overexpressing des(1-3)-IGF-I (40) and tumors arising from IGF-II overexpression also 
showed squamous components (179). Together, these data show that hyperactivation of IGF-
IR via overexpression of the receptor, its ligand or the downstream adapter proteins (IRS1 and 
IRS2) cause highly differentiated tumors characterized by frequent squamous differentiation.  
 We showed that overexpression of IGF-IR leads to expansion of progenitor cells in the 
tumor expressing CK6 suggesting a role for IGF-IR in stem or progenitor cells. Several 
signaling pathways are implicated in regulating mammary stem cells. Examples of these are 
Wnt, Notch, Hedgehog and TGF-ß pathways that when deregulated in the mammary glands 
induce mammary tumors (180, 181). Moreover, alterations of Wnt signaling in the mammary 
gland caused an expansion of stem cells (173). In MMTV-Wnt1 and MMTV-ß-catenin 
transgenic mice, numbers of mammary cells expressing CK6 are increased in hyperplastic 
glands and tumors similar to CD8-IGF-IR overexpressing tumors (Figure 24).  This suggests 
that IGF-IR may modulate mammary stem/progenitor cells similar to wnt/b-catenin.  
Supporting this, a recent studies showed a role for IGF-IR in mouse embryonic stem cell self-
renewal. This study showed that retinol activates the IGF-IR/IRS1 axis to activate PI3K for 
promoting self renewal of embryonic stem cells (182). Further indirect evidence implicates 
IGF-IR in mammary stem/progenitor cells. The PTEN/AKT/ß-catenin pathway plays a role in 
regulating mammary stem/progenitor cells (71). In a previous publication, we showed that 
IRS proteins functionally interact with ß-catenin signaling pathways (178). Given that IRSs 
are the main adapter proteins recruited to the activated IGF-IR, implicates IGF-IR in stem cell 
regulation. Indeed, recent in vitro studies have shown that IGF-I can phosphorylate, stabilize 
or cause nuclear translocation of ß-catenin in different cancer tissues including colon, 
melanoma, and prostate cancer cells (170, 183, 184). Further experiments need to definitely 
proof a role of IGF-IR in regulating stem cells in the mammary gland.  
Several reports indicate that IGF signaling impact myoepithelial cell proliferation. 
Myoepithelial specific overexpression of IGF-I enhances mammary tumorigenesis in vivo by 
paracrine stimulation of IGF-I on the adjacent ducal epithelium (185). Transplantation of cells 
with a targeted deletion of IGF-IR showed that IGF-IR is required for proliferation of the 
myoepithelial precursors (58). However, IGF-IR had no effect on growth of luminal 
progenitor cells (58, 60). Furthermore, myoepithelial cells are responsible for luminal 
polarization and have been postulated to inhibit dysregulated luminal cell growth (61, 62). 
Disruption of the normal IGF-signaling by overexpression of the IGF-IR in the normal 
mammary gland of MMTV-TVA mice resulted in disruption of the myoepithelial layer as 
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indicated by CK14 staining after 2 and 6 weeks of infection with RCAS-CD8-IGF-IR. 
Similarly, MMTV-CD8-IGF-IR transgenic mice had fewer or no myoepithelial cells 
surrounding the luminal epithelial cell layer resulting in highly dilated ducts (results not 
shown, (44)). Supporting this, we found that overexpression of CD8-IGF-IR leads to 
expansion of myoepithelial cells in the tumor. Of note, these myoepithelial cells are not 
normal cells recruited to the tumors because they have pleomorphic nuclei and are 
disorganized. 
 It appears that breast cancer arises from both stem/progenitor cells and more 
differentiated cells. Cancers that do arise from stem cells may exhibit cellular heterogeneity; 
on the other hand cancers arising from more differentiated cells are likely more uniform in 
their phenotype. It seems that cells at a specific stage of differentiation are more susceptible to 
transformation effects to certain oncogenes but not others. More specifically, we propose that 
IGF-IR transforms a multi potent stem cell/progenitor cell population whereas ErbB2 
transforms progenitor cells that are already committed to the luminal epithelial cell lineage 
(Figure 30). Therefore, the TVA technology is the ideal system to trace differences in 
transforming ability of IGF-IR and ErbB2. Infection with RCAS virus containing the CD8-
IGF-IR or ErbB2 is TVA dependent and thus restricted to cell lineages that express the tva 
transgene. Since the viruses are replication defective in mammalian cells, the descendants of 
infected and transformed progenitors can be traced during development and cancer 
progression (137, 138, 140). Up to date we cannot make a conclusion whether IGF-IR and 
ErbB2 transform different progenitor cells. Infection of RCAS-CD8-IGF-IR in the mammary 
gland resulted in hyperplastic lesions with disruption of the myoepithelial layer and expansion 
of myoepithelial cells into the lumen.   
 In summary, this in vivo mouse study showed that bigenic mice developed tumors at a 
faster rate compared to either of the transgenic mice alone. Phenotypic and histological 
analysis suggests no cooperative effect between IGF-IR and ErbB2 but rather implies that 
IGF-IR and ErbB2 transform different progenitor cell types. This hypothesis is currently 
under study using the TVA technology.  
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Figure 30. Proposed model of mammary tumorigenesis induced by IGF-IR and ErbB2.  
IGF-IR transforms a multi potent stem/progenitor cell which than gives rise to heterogeneous tumors 
consisting of luminal and myoepithelial tumor cells. ErbB2 transforms progenitor cells that are already 
committed to the luminal epithelial cell lineage thus gives rise to tumors that are more uniform in their 
phenotype.  
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5 Summary and Significance 
 The work reported in this thesis extends our current understanding of IGF-IR and its 
role in TNBC as well as in tumor development and tumor progression. Furthermore, this 
thesis laid the groundwork for anti-IGF-IR therapy as a promising and tolerable treatment of 
patients with TNBC. 
 
5.1 Summary and significance of targeting IGF-IR in breast cancer 
Many advances have been made in understanding estrogen receptor (ER) and HER2-
positive disease, which can be treated with anti-estrogen or anti-HER2 therapy. However, 
approximately 20-25% of all breast tumors are triple-negative breast cancers (TNBC) 
characterized by low to absent expression of ER, progesterone receptor (PR) and HER2 (18, 
20). 60-90% of TNBC consist of basal-like breast cancers expressing genes such as 
cytokeratins CK5 and CK14, which are characteristic of basal epithelial cells (21). TNBC 
currently has no approved targeted therapies, and often responds poorly to chemotherapy (22). 
TNBC preferentially affects younger women and African-American women, and is associated 
with high histological grade and aggressive clinical behavior (23). It is this subtype of breast 
cancer, which has the highest unmet clinical need to develop novel targeted agents. 
IGF-IR is a potent oncogene and plays an important role in cancer promoting 
proliferation, survival and resistance to anti-cancer therapies in many human malignancies 
including breast cancer. Within the last few years several drugs targeting the insulin like 
growth factor receptor (IGF-IR) have entered clinical trials and are showing promising early 
results. One of the goals of this thesis and an important component in the clinical 
development of targeted therapies against cancer is to identify appropriate patient populations 
in which tumors show addiction to a particular pathway for continued survival and 
proliferation, and in which these tumors are susceptible to the drug.  In this study, we first 
used a transciptomic approach to identify which subtype of breast cancer has an active IGF 
pathway. A previous publication showed that an IGF gene expression signature, based upon 
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genes induced or repressed by IGF-I, was present in triple-negative human breast cancers 
(TNBC), and found here similarly present in TNBC cell lines. We identified that an IGF-IR 
tyrosine kinase inhibitor (BMS-754807) was especially active in TNBC cell lines and 
sensitivity was significantly correlated to expression of the IGF gene signature. This finding 
was supported by an unbiased approach using comparative gene expression analysis among 
the most resistant and sensitive cell which identified TNBC as being sensitive. Moreover, we 
chose a human TNBC tumorgraft model based on the highest activation of both IGF pathway 
and IGF-IR expression and could clearly show that human TNBC tumors grown in vivo are 
responsive to BMS-754807 as a single agent and in combination with chemotherapy tumor 
regression occurred until no tumor was palpable. This regression was associated with reduced 
proliferation, increased apoptosis, and mitotic catastrophe. 
As we prepare for an era of targeted and individualized medicine, limited 
understanding of TNBC biology presents a challenge in developing novel therapies. One of 
the exciting areas of future research involves the translation of scientific discoveries into 
clinically relevant treatments. The studies described in this thesis provide a clear biological 
rationale to test anti-IGF-IR therapy in combination with standard therapy (chemotherapy) in 
patients with TNBC. However, currently no clinical trials are testing this approach in patients 
with TNBC. Several other possible targets are being investigated in the clinic for the 
treatment of TNBC. These include the epidermal growth factor receptor (EGFR) (186), and 
vascular endothelial growth factor receptor (VEGFR) (187). Currently, the most promising 
targeted therapy are poly(ADP-ribose) polymerase 1 (PARP1) inhibitors which showed 
selective activity against BRCA-mutated TNBC cancers (188), resulting in disease 
stabilization or anti-tumor responses in patients with BRCA-associated ovarian, breast or 
prostate cancers (189). It is apparent that PARP inhibitors will only be effective in such a 
small percentage of TNBC patients that more effective therapies should precede into clinical 
development.  
Many studies identified ER-positive breast cancer as an important target for anti-IGF-
IR therapy, and the significance of IGF-IR as a target in TNBC has been poorly addressed. 
Interestingly, there is a growing literature indicating a role for IGF-IR in the aggressive 
subtype of breast cancer, which is pointed out in the discussion of Chapter 3. Our data 
presented in this thesis significantly contributed to a role of IGF-IR in TNBC by showing that 
the highest IGF-pathway activation is present in human TNBC as well as in TNBC cell lines.  
In addition, this study clearly shows that successful IGF-IR therapy can only be 
achieved if a patient population is identified that is addicted to the oncogenic pathway and 
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that is sensitive to IGF-IR therapy. Our study is supported by several clinical trials testing 
IGF-IR therapy. Several Phase I studies reported that IGF-IR therapy is especially successful 
in patients Ewing‘s sarcoma (94, 97). A patient with a chemo-refractory Ewing‘s Sarcoma 
who was treated with the monoclonal antibody AMG479 showed complete response anti-IGF-
IR treatment (97). Similarly, two objective responses has been observed with the IGF-IR 
antibodies from Pfizer (94). One explanation for this successful therapy is that Ewing 
Sarcomas are highly dependent on IGF-IR signaling. These sarcomas are characterized by a 
recurrent chromosomal translocation resulting in a fusion gene. This fusion consists of the 
EWS (Ewing Sarcoma) gene on chromosome 22 with one of several genes of the ETS family. 
The most common fusion occurs with the FLI-1 gene and is detected in approximately 85% of 
cases (190). It was shown that EWS-FLI1 fusion can bind the IGFBP3 promoter and repress 
its activity. A loss of IGF-BP3 increases IGF-I and increases IGF-IR activity (191). In 
addition, it was shown that IGF-IR is required for EWS-FLI-1 mediated transformation (192). 
This shows that Ewing sarcomas are highly dependent on IGF-IR, which explains the 
successful response to IGF-IR therapy.  We hope that by identifying breast cancers that have 
an active IGF pathway, as measured by high levels of p-IGF-IR and IGF-IR and high 
activation of the IGF signature, that we will be able to predict breast cancers that will respond 
to anti-IGF-IR therapy. 
A phase II clinical study evaluated the IGF-IR antibody CP-751,871 in combination 
with paclitaxel, carboplatin in first-line treatment of advanced NSCLC (non small cell lung 
cancer) (95). Initial data suggested that the response rate might vary simply according to the 
histopathology with longer progression free survival in squamous cancer than in other lung 
cancer histologies. Further immunohistochemical analysis found that IGF-IR was a weak 
predictor of response in squamous cell NSCLC (153). Despite the initial success of the Phase 
II study, Pfizer recently (December 2009) discontinued the Phase III trial of figitumumab as a 
first-line treatment in patients with advanced NSCLC as the trial was unlikely to meet the 
primary endpoint of improving overall survival compared to paxlitaxel and carboplatin alone. 
In addition, serious adverse events occurred with more events including deaths in patients 
receiving CP-751,871. Pfizer admitted that they did not select any patient population who 
might benefit. This example emphasizes the importance of selecting patients in which the 
tumor has an active IGF-IR pathway for continued survival and proliferation, and in which 
these tumors are susceptible to IGF-IR therapy.  My thesis demonstrates the first use of a gene 
expression signature to predict sensitivity to an IGF-IR inhibitor, and the study provides a 
biologically driven rationale for targeting IGF-IR in TNBC. 
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Our data significantly contributed to further elucidating biomarkers for IGF-IR therapy 
by incorporating a transcriptomic IGF-gene signature with conventional evaluation of protein 
levels by immunohistochemistry. Currently, no validated molecular markers for sensitivity or 
resistance allow restriction of clinical trials to those patients who are most likely to benefit. 
The majority of translational research studies focused on the predictive value of IGF-IR itself, 
its ligands IGF-I and IGF-II, and adjacent adapter proteins IRS1 and IRS2. In this thesis, we 
showed that the IGF-signature alone was a week positive predictor for response. The strength 
of the signature may come when used in combination with IGF-IR protein levels and activity. 
Thus IGF-IR alone, or the IGF signature alone maybe insufficient to indicate an active IGF 
pathway, but the combination may yield better prediction.  
 
5.2 Summary and significance of IGF-IR in modulating ErbB2 
induced tumorigenesis 
 Evidence suggests crosstalk between IGF-IR and ErbB2 in breast cancer cells in vitro, 
but little data exists on the interplay between these growth factor receptors in initiating 
mammary tumorigenesis in vivo. Therefore, we assessed the ability of a dominant active IGF-
IR (CD8-IGF-IR) to promote mammary tumorigenesis of mice that overexpress ErbB2. We 
identified that mice expressing both oncogenes (CD8-IGF-IR and ErbB2) developed tumors 
significantly faster compared to either transgene alone. Interestingly, tumors overexpressing 
CD8-IGF-IR displayed expansion of K14 positive myoepithelial cells and progenitor cells 
expressing K6. Analysis of co-operativity between ErbB2 and IGF-I was complicated by the 
data suggesting that IGF-IR and ErbB2 transform different progenitor cell types. To 
investigate this, I developed a mouse modeling system using avian RCAS retrovirus as a 
vehicle to deliver CD8-IGF-IR or ErbB2 into transgenic mice expressing the avian receptor 
TVA under the control of a MMTV promoter. This allows retroviral infection of specific 
mammary cell types in vivo. Mammary intraductal injection of RCAS-CD8-IGF-IR into mice 
has shown expression of CD8-IGF-IR. After six weeks, CD8-IGF-IR caused hyperplastic 
lesions in MMTV-TVA mice with expansion of myoepithelial cells expressing K14. 
However, up to date we have not detected tumors arising from CD8-IGF-IR overexpression.  
 First, this study shows the potency of the IGF-IR and its oncogenic potential in 
promoting tumors. IGF-IR alone is sufficient to transform mammary epithelial cells. IGF-IR 
also appears to be as effective as ErbB2 at transforming mammary epithelial cells as palpable 
tumors occur at a similar rate.    
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 Second, this is the first study that examines whether IGF-IR modulates ErbB2 induced 
tumorigenesis in vivo. It is important to report that bigenic mice showed a phenotype 
resembling both oncogenes in which tumors that appeared rapidly are CD8-IGF-IR driven and 
highly differentiated, whereas tumors that developed with a long latency are undifferentiated 
and dominated by ErbB2 expression. This is an important observation because IGF-IR and 
ErbB2 might not crosstalk during mammary tumorigenesis because they might transform 
different progenitor cells. So far, crosstalk between IGF-IR and ErbB2 has been mainly 
addressed in breast cancer cell lines (17, 83, 162) in which IGF-IR signaling has been 
associated with trastuzumab resistance. Supporting our finding, immunohistochemical 
heterogeneity of TNBC showed no significant overlap in the staining of IGF-IR and EGFR, 
another member of the epidermal growth factor receptor family (51). Indeed, this study 
pointed out that IGF-IR rarely coincided with other growth factor receptors.  
 This study improves the current knowledge of IGF-IR induced transformation and 
tumor progression. Human breast tumors with a mixed luminal and basal phenotype or a pure 
basal phenotype, have a poorer prognosis than uniform luminal breast tumors (193). In 
addition, breast tumors lacking ER or PR expression are associated with poor histological 
differentiation (194). Thus, tumors overexpressing the CD8-IGF-IR have characteristics of 
aggressive tumors and resemble tumors similar to human triple negative breast carcinoma. 
Supporting this, Lerma et al suggested that IGF-IR might be relevant in the development of 
basal breast carcinomas (51).    
 
5.3 Future directions and unanswered questions  
 Although we have made significant progress in finding a breast cancer subtype that is 
the most responsive to anti-IGF-IR therapy there are still some questions that need to be 
addressed. Future studies that will be carried on in the laboratory will address different 
aspects of the research presented in this thesis. They include comprehensive studies on 
identifying biomarkers for response to anti-IGF-IR therapy and test whether BMS-754807 
reduces tumor-initiating cells. Further studies will examine the molecular mechanism why 
BMS-754807 and docetaxel synergize. In addition, we are still in the progress of determining 
whether IGF-IR and ErbB2 transform different progenitor cells. Lastly, the biological 
consequences of IGF-IR overexpression on stem cell renewal and tumor initiating cells will 
be investigated. 
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5.3.1 Identify biomarkers for response to anti - IGF-IR and subsequent 
sensitivity to anti-IGF-IR therapy 
 To date, the majority of data suggest that IGF-IR may be a relatively strong negative 
predictive factor, similar to the estrogen receptor for hormone therapy and HER2 for anti-
HER2 therapy, but that IGF-IR alone is a weak positive predictive factor. Therefore, we 
proposed in Chapter 3 that the combination of IGF-IR levels and downstream gene transcripts 
is a useful method for identify patients who may respond to anti-IGF-IR therapy.  
 We have developed a transcriptomic signature of IGF action that has identified the 
IGF pathway as being highly active in triple-negative breast cancer (52). Confirming that this 
signature can measure IGF activity, we found that the signature was reversed in three different 
models (cancer cell lines or xenografts) treated with three different anti-IGF-IR therapies. 
However, the overlap of genes that are altered is not perfect, and it is likely that the common 
overlap of these genes may be a better marker of response to an IGF-IR inhibitor. Therefore, 
transcriptomic signatures from BMS-754807-treated tumorgrafts should be generated. In 
addition, meta-analytic methods should be used to integrate changes induced by BMS-
754807, anti-IGF-IR antibody h10H5 treated neuroblastoma xenografts (125) , and anti-IGF-
IR tyrosine kinase inhibitor A-928605  treated NIH3T3-CD8-IGF-IR cells (126) and BMS-
754807 treated GEO colon cancer xenografts. The overlap and integration of the genes 
modulated by three inhibitors would probably be better predictors of response of cells to anti-
IGF-IR therapy than the IGF signature alone. Furthermore, the combined integration of an 
additional proteomic signature may strengthen our ability to predict tumors that may respond 
to an IGF-IR inhibitor. Therefore, proteomic signatures from BMS-754807-treated 
tumorgrafts should be generated. In addition, we already performed protein arrays on 25 
breast cancer cell lines stimulated for various time points with IGF-I. However, at the time of 
this thesis, bioinformatic analysis is still ongoing to identify proteins that are induced and 
repressed by IGF-I. We expect to identify a set of proteins that are induced and repressed by 
IGF-I which represent an IGF proteomic signature. Ultimately, the combination of 
transcriptomic and proteomic analysis would help to develop an assay that may be utilized to 
select patients who may benefit from anti-IGF-IR therapy. 
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5.3.2 Identify the molecular mechanism why BMS-754807 is active in 
combination with Docetaxel  
 In Chapter 3 we found that anti-IGF-IR therapy is especially active in combination 
with an anti-microtubule therapy (docetaxel). We speculated that double blockade of G1 and 
G2/M is especially effective since anti-IGF-IR therapy mainly acts as a G1 block, and 
docetaxel causes a G2/M block. However, as pointed out in Chapter 3 ingenuity pathway 
analysis of the IGF-signature identified G2/M checkpoint as the major IGF regulated process 
after 24 hours, with IGF upregulating numerous genes involved in G2/M transition including 
AURKA, AURKB, BUB1, CCNB, CENPE, CENPA and CDCA8. Further intrigue is 
provided by the finding that BMS-754807 actually inhibits AURKA [112], albeit with lower 
affinity than IGF-IR. It is will be an interesting project to determine if BMS-754807 and 
docetaxel synergize due to a concomitant action on the G2/M checkpoint and if IGF-IR 
regulates directly or indirectly AURKA/B.  
 
5.3.3 To test whether BMS-754807 reduces tumor initiating cell number, 
and blocks an increase in TIC following chemotherapy treatment 
 The last five years has seen resurgence in the notion that solid cancers may arise from 
a subset of tumor initiating cells, also known as cancer stem cells (195).  The MC1 tumorgraft 
contains a small population (3-10%) of tumor initiating cells (TICs) that are aldehyde 
dehydrogenase (ALDH1) positive (145, 196); ALDH1 negative cells are unable to form 
tumors. The ALDH1 positive population overlaps with the previously noted TIC markers 
CD44+/CD24- (145, 197). In addition, TIC number is increased in human breast cancers 
following chemotherapy (198). As several recent studies point to a role for the IGF pathway 
in stem cell renewal, it will be important to examine how blockade of IGF-IR affects TIC 
number. The presence and number of TICs can be determined by using rapid and simple 
indirect assays (mammosphere forming assay and TIC markers ALDH1 and CD44/24) and 
the direct assay of limited dilution transplantation.  
 In Chapter 3 we reported that MC1 tumorgrafts treated with BMS-754807 showed 
growth inhibition and in combination with chemotherapy regressed until no tumor was 
palpable. After 14 days of treatment, we analyzed the tumor curves and the tumor histology. 
We didn‘t report in Chapter 3 that at that time point a small portion of the treated and 
untreated tumorgraft tissues were taken and collagenase-digested to test mammosphere 
forming capability. Mammosphere culture was performed as previously described (68). 
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Briefly, isolated single-cell suspensions were plated in ultralow attachment plates (Corning) at 
a density of 20,000 viable cells/ml in primary culture and 8000 cells/ml in subsequent 
passages. Cells were grown in a serum-free mammary epithelial basic medium (MEBM, 
Lonza) supplemented with B27 (Invitrogen), 20ng/mL EGF and 20ng/mL bFGF (Invitrogen), 
and 4μg/ml heparin (Sigma). Bovine pituitary extract was excluded. MC1 primary 
mammospheres were grown for 14 days and medium was added every 3–4 days. Primary 
mammospheres were counted using a Leica MZ16 F microscope and mammosphere forming 
units (MSFE) were calculated by dividing the number of mammospheres by the number of 
seeded cells. In addition, mammospheres were then collected for serial passages by 
centrifugation (1000rpm) and dissociated enzymatically (5min in 0.05% trypsin, 0.53mM 
EDTA-4Na; Invitrogen). Dissociated cells were sieved through a 40-μm filter and analyzed 
microscopically for single-cells. If too many groups of cells were present at mechanical 
dissociation and filtering were repeated. Single cells were replated on fresh nonadherent 
plastic to form secondary mammospheres, which were counted using a Leica MZ16 F 
microscope after 14 days.  This will test for self-renewal capacity.  
 Primary mammospheres of control cells were generated with an efficiency of 1.59 ± 
0.37%, whereas Docetaxel treated cells generated less spheres with an efficiency of 1.16 ± 0.6 
% (Appendix, Figure 31). BMS-754807 did not change primary mammospheres formation 
with an efficiency of 1.68 ± 0.44%. However, combination treated cells had the least 
capability to form primary mammospheres (MSFE = 0.35 ± 0.2 %). Untreated and BMS-
754807 treated MC1 cells were capable of self-renewal in secondary mammosphere formation 
with an MSFE of 3.57 ± 0.65 % and 4.21 ± 0.27 %, respectively. Docetaxel treated cells 
reduced the ability to self renew with an efficiency of 0.78 ± 0.24 %. Interestingly, the 
combination of BMS-754807 and Docetaxel dramatically reduced the ability of cells to self-
renew (MSFE = 0.21 ± 0.18).  
 Although we did not observe an effect on TICs by treatment with BMS-754807 alone 
these preliminary data are intriguing. However, the presence and number of TICs should be 
reanalyzed in combination with TIC markers ALDH1 and CD44/24 and the direct assay of 
limited dilution transplantation. 
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5.3.4 Test whether IGF-IR is involved in stem cell renewal of a normal 
mammary gland and whether IGF-IR increases TICs in the tumor 
 The existence of stem cells in the mammary gland was established decades ago that 
showed that epithelial cells isolated from different regions were able to generate a normal 
mammary gland consisting of ductal, alveolar and myoepithelial cells (199). Limiting dilution 
experiments with mouse mammary epithelial cells suggest that 1 per 1000 to 1 per 2000 
mammary epithelial cells are progenitor cells that are capable of generating a complete 
mammary outgrowth (200-202). Therefore, limiting dilution experiments with mammary 
epithelial cells from MMTV-CD8-IGF-IR mice should be performed to identify the 
proportion of progenitor cells that are able to form a complete mammary gland. If IGF-IR 
increases the stem cell proportion, we would expect that more than 1 per 1000 cells are 
capable of generating ductal outgrowth. In addition, CD24, β1 (CD29) and α6 (CD49f) 
integrins (203, 204), have been recently used to isolate and characterize stem/progenitor cell 
populations from the mouse mammary gland and can be used to analyze the number of 
stem/progenitor cells in the mammary gland. Similarly, it has been speculated that solid 
cancers may arise from a subset of tumor initiating cells/cancer stem cells (195). As several 
recent studies point to a role of the IGF pathway in stem cells it would be interesting to 
examine how overexpression of the IGF-IR (CD8-IGF-IR) affects the TIC number.   
 
5.3.5 Determine whether CD8-IGF-IR and ErbB2 transform different 
progenitor cell types 
 We have successfully created an RCAS-CD8-IGF-IR virus, which infects mammary 
glands of MMTV-TVA mice in vivo. This resulted in hyperplastic lesions after 6 weeks of 
infection that is accompanied with an increase of myoepithelial cells in the lumen of the duct. 
To date, RCAS-CD8-IGF-IR was not able to form tumors (mice have been injected with virus 
6 months ago). Once we have generated tumors with RCAS-CD8-IGF-IR we will then be able 
to compare the histology of CD8-IGF-IR induced lesions and tumors to ErbB2 lesions and 
tumors at the same time points after infection. As shown in Figure 30 we proposed that IGF-
IR transforms a stem cells which gives rise to tumors that exhibit cellular heterogeneity; 
whereas ErbB2 transforms a progenitor cell that is already committed to the luminal epithelial 
lineage thus tumors are likely more uniform in their phenotype. 
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5.4 Final Conclusions 
Since recent molecular classification of breast cancer identified breast cancer subtypes 
with divergent histopathological features and clinical outcomes, therapeutic approaches 
moved to personalize medicine according to each subtype of breast cancer. For the early use 
of hormonal therapy to trastuzumab, targeted therapies have clearly found a place in the 
treatment of breast cancer. TNBC is associated with high histological grade and aggressive 
clinical behavior. Currently, no FDA approved targeted therapy is available for the treatment 
for TNBC. In addition, these tumors often respond poorly to chemotherapy. Studies 
performed in this thesis endeavor hope for patients with TNBC as IGF-IR therapy is effective 
and tolerable treatment for this subtype of breast cancer. Therefore, the future of targeted 
therapies in TNBC is more promising than currently envisioned.  
This study shows the potency of the IGF-IR and its oncogenic potential in promoting 
tumors and furthermore improves our current knowledge of IGF-IR induced transformation 
and tumor progression. Identification that IGF-IR might rarely coincided with other growth 
factor receptors such as the ErbB2 receptor in tumor progression provides valuable 
information of mammary tumor progression.  
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6.1 Supplementary Figures 
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Figure 31. BMS-754807 in combination with Docetaxel reduces mammosphere formation 
A. Isolated MC1 single cell suspension were plated in ultralow attachment plates at a density of 
20,000 viable cells/ml. Mammospheres were grown for 14 days and medium was added every 3–4 
days. Primary mammospheres were counted using a Leica MZ16 F microscope and mammosphere 
forming units (MSFE) were calculated by dividing the number of mammospheres by the number of 
seeded cells. B. Primary mammospheres were collected for serial passages by centrifugation, 
dissociated enzymatically for a single cell suspension. Cells were plated at a density of 8,000 viable 
cells/ml. Secondary mammospheres were counted using a Leica MZ16 F microscope after 14 days 
and MSFE were calculated as described above. Values represent the means ± SE of 12 replicates per 
treatment group. 
 
Chapter 6 – Appendix 
 
118 
 
6.2 Supplementary Materials  
4x denaturing sample loading buffer:  
0.5 M Tris-HCl, pH6.8 
8% sodium dodecyl sulfate 
0.2% bromophenol blue  
30% glycerol 
20% mercaptoethanol 
 
4x Resolving Gel Buffer (4x Tris-HCL pH 8.8): 
300 ml H2O 
91 g Tris base 
Adjust pH to 8.8 with 1N HCL 
fill up to 500 ml with H2O, autoclave or filter solution 
add 2g SDS, store at 4ºC 
0.5 M Tris-Base pH 8.8 
0.4 % SDS 
 
4x Stacking Gel Buffer (4x Tris-HCL pH 6.8): 
40 ml H2O 
6.05g Tris base 
Adjust pH to 6.8 with 1N HCL 
fill up to 100 ml with H2O, autoclave or filter solution 
add 2g SDS, store at 4ºC 
 
1x Electrophoresis (Running) Buffer: 
For 20 liter: 
Dissolve the following in 2 liters H2O: 
60.4g Tris Base 
288g glycine 
20g SDS    
bring up to 20 liters and store at room temperature 
 
Transfer buffer: 
20% methanol (100%) 
20mM Tris 
150mM glycine 
pH 7.5 – 8.3, store at 4ºC 
 
8% Acryl Amid Gel: 
 Resolving gel:  Stacking gel:  
40% Acrylamid (Biorad) (39:1)/[ml] 1.6    200 µl 
4x resolving gel buffer/[ml]   2    0.5  
water [ml]     4.4   1.3 
10% APS [µl]     80   20 
Temed [µl]     8   2 
Total volume [ml]    8.1   2 
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Washing buffer: PBST 
PBS 
(0.05%) Tween-20  
 
Blocking buffer: 
PBS 
5% Carnation dried milk or bovine serum albumine (Sigma) 
0.05% Tween-20 
 
PBS:  
1.56g sodium phosphate, monobasic 
4.08g sodium phosphate, dibasic (anhydrous) 
8.78g NaCl 
In 1 l H20, pH 7.2 with NaOH 
 
LB Media/Agar: 
The media was prepared as described on LB-bottle. Per 1 l LB-Media 100μg/ml Ampicilin 
was added. The plates and the LB media was stored at 4°C. 
 
50 x TAE buffer: 
For 1 l of TAE buffer the following ingredients were added: 
242 g Tris Base 
57.1 ml Glacial acedic acid 
100 ml 0.5 M EDTA 
 
Agarose Gel- 1%: 
1 g Agarose  
100 ml 1x TAE 
2 μl Ethidium Bromid (EtBr) 
 
Loading dye: 
25%     Ficoll   
0.25%  Xylene Cyanol 
0.25%  Bromo Phenol Blue 
A 10 ml stock solution was diluted 1:1 in 1x TAE before use. 
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6.3 List of Abbreviations  
 
Most of the abbreviations are explained in the text. 
APS       ammonium persulphate 
ATP       adenosine triphosphate 
ATCC      American Type Culture Collection 
BMS      Bristol Myers Squibb 
bp       base pair 
BSA       bovine serum albumin 
CaCl2       calcium chloride 
°C       degrees Celsius 
cDNA      complementary DNA 
C-Terminus     Carboxyl-Termius 
DMEM     Dulbecco‘s Modified Eagle‘s Medium 
DMSO     dimethyl sulphoxide 
DNA      deoxyribonucleic acid 
dNTP      Desoxynuclosid triphosphate 
DTT       dithiothreitol 
ddH2O      double distilled water 
EDTA      ethylenediamine tetra-acetic acid 
EGF       epidermal growth factor 
EGFR       epidermal growth factor receptor 
ER      Estrogen Receptor 
Hrs       hours 
H2O       water 
IGF-IR      Type I insulin like growth factor receptor 
InsR       Insulin receptor 
kB       kilo base pair(s) 
kDa       kilo dalton 
KCl       potassium chloride 
L      Liter 
LB      Luria Broth 
NaH2PO4     sodium di-hrydogen orthophosphate 
Na2HPO4      Di-sodium hydrogen phosphate 
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NaN3      sodium azide 
M       molar 
µ      micro- 
m      milli- 
MgCl2      magnesium chloride 
MgSO4      magnesium sulphate 
min       minutes 
ml       milliliter 
μg       microgram 
μl      microliter 
mM       millimolar 
mRNA      messenger RNA 
NaCl      sodium chloride 
Na2HPO4      di-sodium hydrogen orthophosphate 
nm       nanometer 
PAGE      polyacrylamide gel electrophoresis 
PI3K      Phosphatidylinositol-(3,4,5)-tri phosphate kinase 
PBS       phosphate buffered saline 
RNA       ribonucleic acid 
rpm       revolutions per minute\ 
RT      room temperature 
SDS       sodium docecyl sulphate 
sec       second 
siRNA      small interfering RNA 
SV40       simian virus 40 
TEMED   N,N,N‘,N‘-tetramethylene-ethylenediamine Tris  
(hydroxymethyl) aminomethane 
Tween20      polyoxyethylenesorbitan monolaurate 
V       volts 
Wt      wild type 
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6.4 Curriculum Vitae 
 
Persönliche Informationen  
 
Name:   Litzenburger 
Vorname:   Beate Christiane 
Geburtsdatum: 14.05.1980 
Geburtsort:  Hattingen 
Nationalität:  Deutsch  
 
 
Ausbildung 
 
1990 – 1999  Theodor Körner Gymnasium, Bochum 
   Abschluss: Abitur, 1999 
 
1999 – 2000  Butler County Community College, El Dorado, KS, USA 
 
2000 – 2006  Rheinisch Westfälische Technische Hochschule Aachen  
   Studium der Biologie  
   Abschluss: Diplom Biologin, 2006 
 
2004-2005  Rheinisch Westfälische Technische Hochschule Aachen 
   Wirtschaftswissenschaften für Ingenieure und Naturwissenschaftler
   Abschluss: Zertifikat ―Unternehmerisches Denken und Handeln―: 
   12/2005 
 
Seit 10/2006  Rheinisch Westfälische Technische Hochschule Aachen in  
   Zusammenarbeit mit Baylor College of Medicine, Lester and Sue Smith 
   Breast Center, Houston, TX, USA 
   Promotionsstudium 
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6.5 Publications 
 
6.5.1 Publications 
 
1. Beate C. Litzenburger, Chad J. Creighton, Anna Tsimelzon, Bonita T. Chan, Susan G. 
Hilsenbeck, Wang T.
 
, Joan M. Carboni, Marco M. Gottardis, Jenny C. Chang, Michael T. 
Lewis, Fei Huang, and Adrian V. Lee. High IGF-IR activity in triple-negative breast 
cancer correlates with sensitivity to anti-IGF-IR therapy (JCI, submitted) 
 
2. Litzenburger BC, Kim HJ, Kuiatse I, Carboni, J. M., Attar, R. M., Gottardis, M. M., 
Fairchild, C. R., Lee, A. V. BMS-536924 reverses IGF-IR-induced transformation of 
mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. 
Clin Cancer Res 2009; 15(1): 226-37  
 
3. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, 
Gottardis MM, Wong TW, Attar RM, Carboni JM, Lee AV. Constitutively active type I 
insulin-like growth factor receptor causes transformation and xenograft growth of 
immortalized mammary epithelial cells and is accompanied by an epithelial-to-
mesenchymal transition mediated by NF-kappaB and snail. Molecular and Cellular 
Biology, April 2007, p. 3165-3175, Vol. 27, No. 8 
 
6.5.2 Review 
 
4. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth 
factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers in 
Bioscience 13, 3273-3287, May 1, 2008 
 
6.5.3 Book Chapter 
 
5. Casa, A., Litzenburger, B., Dearth, R., and Lee A.V. Insulin-like growth factor signaling 
in normal mammary gland development and breast cancer progression. Breast Cancer: 
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Prognosis, Treatment, and Prevention. 2nd Ed. Editor: Jorge R. Pasqualini. New York, 
NY, 2008. 303-321. 
6.5.4 Poster presentations 
 
1. Beate C. Litzenburger, Chad J. Creighton, Anna Tsimelzon, Bonita T. Chan, Susan G. 
Hilsenbeck, Fei Huang, Joan M. Carboni, Marco M. Gottardis, Jenny C. Chang, Michael 
T. Lewis, and Adrian V. Lee. High IGF-IR activity in triple-negative breast cancer cell 
lines correlates with sensitivity to IGF-IR inhibitor BMS-754807. (32nd Annual CTRC-
AACR San Antonio Breast Cancer Symposium, #1132, 2009, SABCS Basic Science 
Scholarship)  
 
2. Wang Y-F, Litzenburger B, Kuiatse I, Dearth RK, Casa AJ, Tsimelzon A, Hilsenbeck 
SG, Li J, Hennessey BT, Mills GB, Lee AV. Expression and activity of both IGF and 
Insulin signaling pathways in a large panel of breast cancer cell lines. (32nd Annual 
CTRC-AACR San Antonio Breast Cancer Symposium, #4168, 2009) 
 
3. Litzenburger B.C., Michael J. Toneff, Robert K. Dearth, Hyun-Jung Kim, Isere Kuiatse, 
Ora Britton, Yi Li, Adrian V. Lee. Constitutive activation of the insulin-like growth factor 
receptor accelerates ErbB2-induced mammary tumorigenesis (Gordon Research 
Conference, Insulin-like growth factors in physiology and disease, 2009) 
 
4. Litzenburger B.C., Kim H.J., Carboni J, Fairchild C.R., Gottardis M.M., Wong T.W., 
Attar R.M, Lee A.V. IGF-IR inhibitor BMS-536924 causes growth inhibition and 
polarization of MCF7 breast cancer cells in 3D culture (Department of Medicine Research 
Symposium, 2008) 
 
5. Litzenburger B.C., Kim H.J., Carboni J, Gottardis M.M., Wong T.W., Attar R.M., Cui 
X., Lee A.V. Small molecule inhibitor BMS-536924 completely reverses IGF-IR-
mediated transformation of immortalized mammary epithelial cells (Gordon Research 
Conference, Insulin-like growth factors in physiology and disease, 2007) 
 
6. Litzenburger B.C., Kim H.J., Carboni J, Gottardis M.M., Wong T.W., Attar R.M., Cui 
X., Lee A.V. Small molecule inhibitor BMS-536924 completely reverses IGF-IR-
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mediated transformation of immortalized mammary epithelial cells (29th Annual San 
Antonio Breast Cancer Symposium, #4113, 2006) 
 
7. Litzenburger B.C., Kim H.J., Carboni J, Gottardis M.M., Wong T.W., Attar R.M., Cui 
X., Lee A.V. Small molecule inhibitor BMS-536924 completely reverses IGF-IR-
mediated transformation of immortalized mammary epithelial cells (NCI-AACR-EORTC, 
Prague, #564, 2006) 
 
8. Litzenburger B.C., Kim H.J., Carboni J, Gottardis M.M., Wong T.W., Attar R.M., Cui 
X., Lee A.V. Small molecule inhibitor BMS-536924 completely reverses IGF-IR-
mediated transformation of immortalized mammary epithelial cells (Second Annual 
Breast Center Retreat, #11, 2006, 1st place poster prize) 
 
6.5.5 Honors and Awards  
 
2009  San Antonio Breast Cancer Symposium Basic Science Scholars scholarship 
 
2008-present Department of Defense Predoctoral Traineeship Award  
 
2007-2008 Fellowship of the German Academic Exchange Service (DAAD)  
 
2007  1st place oral presentation award winner at the Breast Center Retreat,   
  Baylor College of Medicine, Houston, TX 
 
2006  1st place poster award winner at the Breast Center Retreat,   
  Baylor College of Medicine, Houston, TX 
 
1999-2000  President‘s Honor Roll. Butler County Community College, Kansas, USA 
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